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Abstract 
Introduction: Preterm labour occurs in 76,000 women in England and Wales each year and 
accounts for 75% of neonatal mortality. Infection and inflammation are key triggers of preterm 
labour. The transcription factor NF-ĸB plays a key regulatory role in the expression of the 
labour associated genes such as COX-2, prostaglandins and MMPs, as well as pro-inflammatory 
cytokines such as IL-8, IL-1β, IFN-γ and TNF-α. The anti-inflammatory prostaglandin 15-deoxyΔ-
12,14 Prostaglandin J2, a CRTH2 agonist can inhibit NF-ĸB and delay preterm labour in a murine 
model of inflammation induced preterm labour. It is well recognised that the immunology of 
pregnancy is biased towards a Th2 rather than Th1 response. CRTH2 agonists induce the 
production of the anti-inflammatory cytokines IL-4 and IL-10 in T-helper 2 cells in vitro, thus 
have potential to further alter the Th1:Th2 ratio in favour of the Th2 bias. Aims: This thesis 
examines the role of the CRTH2 receptor and its agonists in pregnancy and parturition, and its 
potential as a therapeutic target for the prevention of preterm labour. Methods: PCR, western 
analysis and flow cytometry were used for CRTH2 expression studies. To examine the effect of 
CRTH2 agonists on NF-ĸB activation, western analysis of p65 and phospho-p65 was performed. 
The effect of the agonists on interleukin profiles was demonstrated by flow cytometry. 
Myometrial contractility response to agonists was measured using a myograph. To determine 
the in vivo effect of a small molecule CRTH2 agonist on inflammation induced preterm labour, 
CD1 mice were given an intrauterine injection of LPS and the CRTH2 agonist. Delivery outcome 
and the effect on labour associated genes and interleukins were determined by PCR, western 
analysis and ELISA. Results: Amniocytes and myocytes show low CRTH2 mRNA levels however 
do not express the protein at detectable levels. The small molecule CRTH2 agonist Pyl A does 
not inhibit NF-ĸB in amniocytes and myocytes, indicating that the inhibition of NF-ĸB by 
15dPGJ2 is independent of CRTH2. Although 15dPGJ2 was able to inhibit the production of pro-
inflammatory cytokines in peripheral blood mononuclear cells, Pyl A was unable to alter the 
Th2 cytokine profile. Pyl A inhibits myometrial contractility, although in a mechanism 
independent of CRTH2. In the murine model of inflammation induced preterm labour fetal 
viability was significantly increased by Pyl A, however, preterm labour was augmented rather 
than prevented. Conclusion: 15dPGJ2 inhibits NF-ĸB and inflammation induced preterm labour 
in the mouse in a mechanism independent of CRTH2. Contrary to anticipated, Pyl A does not 
modulate the Th1:Th2 bias or delay preterm labour in vivo. However, 15dPGJ2 suppresses the 
Th1 response in vitro, thus represents a potential anti-inflammatory therapeutic target for 
both the prevention of preterm labour and inflammation induced brain injury.  
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1.1 Preterm labour  
Incidence 
Preterm labour is defined as labour occurring between the 24th and the 37th week of 
pregnancy. It can be further classified as extremely preterm (24-27 completed weeks), 
very preterm (28-31 completed weeks) and late preterm (32-36 completed weeks) [1]. 
Its incidence in the western world remains between 6-15% depending on the 
geography and demographics of the population [2]. The singleton preterm delivery 
rate in England over the last decade has been between 5.7 and 6.7%, with a transient 
increase to 7.5% between 2005 and 2006 (Figure 1.1)[3]. The incidence of extreme 
prematurity is around 3%, which equates to roughly 2600 of the 76,000 premature 
births per year in England and Wales [4].  
 
 
Figure 1.1 Singleton preterm delivery rates in the UK (Sykes et al 2011) [3] 
Examination of singleton preterm delivery rates in the UK for the last 15 years reveal that 
while increasing efforts have been placed into understanding preterm labour, little, if any 
clinical impact has been made. Recent reviews have described an increasing rate of PTL 
particularly < 32 weeks. However, analysis of the latest data suggests a transient increase in 
the past 6 years, the cause of which is unclear.  
(Data available online from NHS, http://www.ic.nhs.uk/statistics-and-data-collections, 
http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/index.htm).  
 
Preterm labour is a heterogeneous condition [5], which contributes to the challenge of 
finding a universal preventative strategy. Despite increased research in preterm labour 
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(Figure 1.2), the incidence has remained unchanged over the last 2 decades, reflecting 
the lack of any major advances in its prevention. 
 
Figure 1.2 PubMed literature search for causes of preterm labour over the last 2 decades 
 A blast search using “preterm labour” or “preterm labor” and “causes” or “mechanisms” 
highlights the increasing efforts in the field to better understand the mechanisms underlying 
preterm labour. A search was performed from 1991-2010 in five-year intervals. 
  
 
Neonatal morbidity and mortality 
Around 75% of neonatal deaths can be accounted for by preterm birth [6]. 77% of 
neonatal deaths reported in the UK in 2006 were of babies that were born preterm [7]. 
Survival rates sharply decrease from 99% at 32 weeks to 1% at 23 weeks, and this is 
associated with a reciprocal increase in the risk of handicap [8]. 70% of long term 
health problems, such as neurodevelopmental impairment and respiratory disease [6] 
can be accounted for by preterm birth. Short-term complications of prematurity 
include necrotising enterocolitis, sepsis, respiratory distress, periventricular 
haemorrhage, and long-term sequale include chronic lung disease and 
neurodevelopmental impairment. As reported in the EPICure study, of those babies 
born before 25 weeks who survive to discharge, 23% developed severe disability by 30 
months of corrected age [9]. Improvements in neonatal survival over the last few 
decades can be attributed to improvements in the provision of neonatal care and 
antenatal corticosteroids, rather than any major advances in the prevention of 
preterm labour.  
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Economic cost  
 
The financial cost to the NHS is increased the earlier the gestation of delivery. The 
estimated cost of hospitalisation for a term infant is £584 compared with £317,166 for 
an extremely preterm neonate. The projected financial burden for all babies born 
preterm per year is estimated at £2.946 billion for the subsequent 18 years [10]. 
 
1.2 Physiology of term labour 
 
During pregnancy the myometrium remains quiescent and the cervix remains long and 
closed. The mechanisms controlling the final signal for the onset of labour have been 
extensively researched; however the single final trigger is still debatable. In 
preparation for and during labour the myometrium, fetal membranes and cervix 
undergo significant biochemical and physiological changes which lead to uterine 
contractility, membrane rupture and cervical dilation. 
 
 
Figure 1.3 Components of the common terminal pathway of human parturition (Romero et 
al 1994) [11] 
Labour involves many physiological changes to the myometrium, fetal membranes and the 
cervix which lead to uterine contractility, membrane activation and rupture, and cervical 
dilatation.  
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Membrane activation 
Human amnion consists of a single layer of epithelial cells and a sub-epithelial layer of 
mesenchymal cells which is the major site of prostaglandin production. The final 
trigger for membrane rupture is likely to be controlled by different proteins to uterine 
contractility [12-14], since contractions do not always ensue following either natural or 
artificial membrane rupture. However, there is likely to be significant overlap in the 
biochemical events leading to membrane activation and rupture; for example, the 
expression of COX-2 and the production of PGE2 both increase in the amnion at term 
[15-19].  Prior to the rupture of amnion, activation and weakening of the membranes 
occur. Collagen type I is the predominant collagen providing strength to the amnion, 
along with collagen IV which is a component of the basement membrane and the 
connection between the epithelial and mesenchymal layers [20]. Matrix 
metalloproteinases (MMP’s) degrade collagen, with MMP-1, MMP-2, MMP-3, MMP-8 
and MMP-9 readily detected in amniochorion [21]. There is significant evidence that 
particularly MMP-9 is involved in remodelling of the amnion leading to weakness and 
susceptibility to membrane rupture [22-24]. Inflammatory cytokines also contribute to 
membrane activation even in term labour not complicated by chorioamnionitis. The 
pro-inflammatory cytokines IL-1β and IL-8 are up-regulated during labour in the 
amnion as are IL-6 and IL-8 in the choriodecidua [25]. Pro-inflammatory cytokines 
including IL-1β and IL-6 drive the production of COX-2 and PGE2 in amnion [26-29].  
 
Cervical ripening and dilatation 
Similar to the remodelling that occurs during membrane activation prior to membrane 
rupture; the cervix undergoes significant remodelling in order to efface and dilate. As 
with the biochemical changes seen in the amnion, the cervix also remodels with the 
combination of both structural and inflammatory components. A reduction in collagen 
synthesis, along with an increase in collagenase and MMP activity contributes to 
cervical ripening at term [30-32]. The predominant collagen components are type I 
and type II, and as the cervix ripens, the concentration of collagen decreases by as 
much as 30-50% [33-35]. The cervix becomes infiltrated with leukocytes as part of a 
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physiological inflammatory reaction, which contributes to the production of pro-
inflammatory cytokines [25, 36]. Cervical prostaglandins also play a key role in 
effacement and dilation of the cervix through several mechanisms.  PGE2 decreases the 
concentration of collagen [37], increases the synthesis of proteoglycans [38],  
enhances migration of leukocytes towards the cervix the [35] and augments the 
potency of pro-inflammatory chemokines [39]. 
 
Uterine contractility 
The myometrium is the muscular portion of the uterus which is responsible for uterine 
contractility. Human myometrium is composed of smooth muscle cells arranged into 
bundles which are delineated by connective tissue and interspersed with 
microvasculature [40]. Interaction between actin and myosin in the smooth muscle 
cell leads to myocyte contractility [41]. This interaction is regulated by the enzyme 
myosin light chain kinase (MLCK) [42], which phosphorylates myosin, and can be 
inhibited by myosin phosphatase (MLCP). MLCK is activated by intracellular calcium 
and calmodulin [43]. The sources of calcium include extracellular calcium which enters 
through calcium channels after depolarisation of the myocyte, and the intracellular 
calcium stores [44]. The control of contractility is proportional to the activity ratio of 
the MLCK and MLCP which determine the phosphorylation status of myosin regulatory 
light chain [40]. Oxytocin and prostaglandin F2 alpha (PGF2α) alter the activity ratio of 
MLCK and MLCP which leads to the increase in sensitivity of the contractile unit to 
calcium [45-47].  The connexins, which are a family of gap junction proteins, also 
regulate contractility by controlling the interaction between cells for the propagation 
of action potentials. The main connexins present in term myometrium are connexin-
43, connexin-40 and connexin-45 [48, 49].  
 
Oxytocin 
Oxytocin is a physiological agonist of uterine contractility. It is a nonapeptide released 
from the posterior pituitary and the choriodecidua [50, 51]. Oxytocin exerts its action 
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through the G protein coupled oxytocin receptor (OTR). Upon stimulation of the 
receptor, Gαq/II and Gβγ (from Gαi) G-protein subunits are released leading to activation 
of the phospholipase C (PLC) isoforms β1, β3 and β2, β3 respectively [52]. In turn, this 
leads to release of calcium stores, which leads to depolarisation of the myocyte and 
ultimately to myometrial contractility [40]. 
 
Prostaglandins; Prostaglandin E2 (PGE2) and Prostaglandin F2α (PGF2α)  
Prostaglandins play a key role in parturition by aiding cervical ripening and myometrial 
contractility. Although the majority of prostaglandins are derived from the amnion, 
the source of prostaglandins involved in myometrial contractility is likely to be the 
decidua and myometrium [53]. Prostaglandins are derived from arachidonic acid from 
cell membrane phospholipids by the action of the phospholipase enzymes PLA2, PLC 
and PLD [54]. The cyclo-oxygenase enzymes lead to the production of the intermediate 
PGH2, which can be converted into PGE2, PGF2α and also PGI2 and PGD2. COX-2 is the 
rate limiting step for prostaglandin synthesis and is the primary regulator of 
prostaglandin synthesis in labour [55]. Figure 1.4 summarises the pathway of 
prostaglandin synthesis [56].     
 
 
Figure 1.4 The biosynthesis of prostaglandins (Black et al 2008) [56] 
This diagram shows the pathway of prostaglandin production from arachidonic acid.  
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The main prostaglandins contributing to uterine contractility are PGE2 and PGF2α. PGE2 
has 4 receptors with the EP1 (Gαq) and EP3 (Gαi) being pro- contractile and EP2 and EP4 
(both Gαs) being considered as relaxatory [57-60]. Upon stimulation of the EP1 and EP3 
receptors, PGE2 leads to calcium release via inositol triphosphate (InsP3) and inhibition 
of adenylate cyclase and cAMP respectively [40]. Recent data suggests however, that 
spontaneous and PGE2-induced myometrial contractility is via the EP3 rather than the 
EP1 receptor [61].  PGF2α stimulates myometrial contractility via the FP receptor, which 
is likely to be via an increase in intracellular calcium mobilisation [62].  
 
1.3 Pathophysiology of preterm labour 
 
Approximately 30% of preterm births are due to elective deliveries for reasons such as 
pre-eclampsia and intrauterine growth retardation [63]. The remainder are 
spontaneous labours. Preterm labour is a heterogeneous condition, which results from 
many contributing factors and is often referred to as the “preterm labour syndrome”. 
The main aetiological factors involved in the pathophysiology of preterm labour are 
vascular disorders, structural factors such as stretch or cervical or uterine disorders, 
but most commonly infection and inflammation. However, a clinical spectrum exists 
that covers all, and women can present with all or one of the following manifestations 
as shown in Figure 1.5.  
 
Figure 1.5 Components of the clinical manifestations of premature activation of the terminal 
pathways involved in human parturition (Romero et al 1994) [11] 
Premature activation of membranes leads to preterm rupture of membranes, whereas early 
and asymptomatic dilatation of the cervix is seen in women with cervical insufficiency. 
Premature uterine contractility is present in many women who present in threatened preterm, 
labour.  
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Vascular disorders 
Uteroplacental ischaemia and placental abruption 
The most common pathological features in the placenta of women who show no signs 
of inflammation who deliver preterm are maternal and fetal vascular lesions [5]. 
Vascular lesions in the decidual vessels attached to the placenta are associated with a 
mean odds ratio of 3.8 for delivering preterm with intact membranes, and an odds 
ratio of 4 with premature rupture of membranes [64]. Placental abruption is also more 
commonly seen in women delivering preterm than at term [65-67]. The rennin-
angiotensin system is a possible mechanism of ischemia induced preterm labour [68, 
69] since angiotensin II can induce myometrial contractility both directly [70] and 
indirectly via the production of prostaglandins [71]. The presence of release of 
thrombin with decidual necrosis and haemorrhage can also activate labour, with in 
vitro studies showing a thrombin induced dose-dependent increase in myometrial 
contractility [72]. Thrombin is also capable of inducing an inflammatory response by 
activating neutrophils, chemoattraction of monocytes and by aiding lymphocyte 
proliferation [73].  
 
Structural factors 
Cervical insufficiency 
Cervical insufficiency is defined by the inability to retain a pregnancy as a result of 
painless dilatation of the cervix. The incidence of true cervical insufficiency is 1% [74]. 
The cause of an inherently insufficient cervix is unknown, and is usually diagnosed 
retrospectively after a mid trimester loss or early preterm delivery in the absence of 
painful contractions. However, a weakened cervix can also be a result of direct cervical 
trauma from multiple dilations following several surgical terminations or cone 
biopsies/LETZs [75, 76]. Exposure to diethylstilbestrol in utero is also thought to result 
in a weakened cervix [77]. Inflammation and infection are also associated with cervical 
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insufficiency since a shortened cervix fails to effectively maintain the barrier to 
ascending infection [74].  
 
Uterine anomalies 
The presence of a uterine anomaly has an incidence of 0.5% [78] and is a recognized 
risk factor for preterm birth. Uterine didelphys [79], a unicornuate uterus[80] and a 
septate uterus [81] can lead to an increased rate of preterm labour, although the 
mechanism for this is not fully understood. 
 
Uterine stretch 
Women with multiple pregnancies or polyhydramnios have a higher rate of preterm 
delivery. This has directed many studies to investigate a role of uterine over distension 
and stretch in preterm labour. In vitro studies have confirmed that stretch of both 
amniocytes and myocytes can lead to the expression of labour associated genes such 
as prostaglandin E2, COX-2, and the oxytocin receptor [82-84]. 
 
Infection and Inflammation 
 
A long recognised correlation between intrauterine infection and preterm birth exists. 
Goldenburg et al discovered that 80% of women delivering before 30 weeks had 
evidence of infection in the amniotic fluid and/or fetal membranes compared with 
only 30% of women delivering after 37 weeks [63]. Specifically in the amniotic fluid 
microbial invasion occurs in only 1% of women not in labour at term [85]. In 
comparison,  12.8% of women with intact membranes in labour have evidence of 
microbial invasion [86], and as many as 75% of women in labour with preterm 
premature rupture of membranes [87]. The most common microorganisms found in 
amniotic fluid are the genital mycoplasmas including Ureaplasma urealyticum, 
Mycoplasma hominis, Streptococcus agalactiae, Escherichia coli, and Gardnerella 
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vaginalis [88, 89]. It is likely that ascending infection from the vaginal and cervix is the 
most common source of intrauterine infection. Other routes include haematogenous 
spread via the placenta, retrograde seeding from the peritoneal cavity via the fallopian 
tubes and introduction via invasive procedures such as amniocentesis, as shown in 
Figure 1.6.  
 
Figure 1.6 The proposed routes of transmission of microbes causing intrauterine infection. 
Adapted from Romero et al 1988 [90] 
I: ascending from the vagina and cervix, II: transplacental, III: retrograde seeding from the 
peritoneum, IV: invasive procedures. 
 
The presence of microorganisms results in the recruitment of leukocytes leading to an 
inflammatory response. Gram negative bacteria contain endotoxins, whereas gram 
positive bacteria contain peptidoglycans and lipoteichoic acid, and mycoplasmas 
contain lipoglycans [73]. These components are recognised by pattern recognition 
receptors (PRRs) which further enhance the inflammatory response upon activation. 
As part of the inflammatory response, pro-inflammatory cytokines are produced and 
this leads to activation of a biochemical cascade; including the production of pro-
labour proteins such as prostaglandins [91] required for uterine contractility and 
cervical ripening and MMP’s [92, 93] which are important in membrane rupture.     
 
As revealed by an interrogation of the Pubmed literature, increasing research efforts 
are being expended on deducing the role that inflammation plays in preterm birth (see 
Figure 1.7) [3].  Evidence has emerged that inflammation in the absence of infection 
can be sufficient to cause preterm labour [94]. There is also significant evidence that 
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inflammation leads to an increase in neonatal morbidity regardless of an absence of 
intrauterine infection [95, 96].  
 
 
Figure 1.7 PubMed literature search for causes of preterm labour over the last 2 decades 
(Sykes et al 2011) [3] 
A blast search using “preterm labour” or “preterm labor” and “inflammation” highlights the 
increasing increased awareness and efforts to better understand the role of inflammation in 
preterm labour.  The search was performed from 1991-2010 in five-year intervals. 
 
The fetal inflammatory response syndrome refers to the fetal response to the 
presence of maternal inflammation/infection [97]. The fetus mounts an inflammatory 
response, which was first classified as an elevated plasma IL-6 and CRP [98, 99]. 
Subsequently it has also been found to be associated with activation of neutrophils 
and monocytes [100], and a polarised Th1 response characterised by an increase in 
IFN-γ producing cells [101]. The fetal inflammatory response syndrome is an 
independent risk factor for severe neonatal morbidity due to the potential 
involvement of several target organs [97], as summarised by Figure 1.8.  
 
 
Figure 1.8 Target organs of the fetal inflammatory response syndrome (Gotsch et al 2007) 
[97] 
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1.4 The management of preterm labour 
 
Presentation and risk factors 
 
Preterm labour can present with preterm rupture of membranes, cervical dilation 
and/or uterine contractions. Symptoms of threatened preterm labour increases the 
risk of early delivery, yet in 70% of cases the pregnancy continues until term [102]. 
Women in established preterm labour present with cervical dilation in the presence of 
regular contractions, (with the exception of women with cervical incompetence, 
where cervical dilation is painless).  Known risk factors for preterm labour include a 
history of prior mid trimester loss or preterm labour [103], women with multiple 
pregnancies [104], previous cervical treatment [105] and uterine anomalies [80].  
 
Screening  
 
Cervical length screening can be adopted in women at high risk of preterm labour. The 
shorter the cervix, the higher the risk is of preterm labour. A cervical length of <25mm 
in asymptomatic high risk women has a positive predictive value of 70% for delivery 
<35 weeks if detected at 14-18 weeks, and 40% if detected at 18-22 weeks [106]. In 
women presenting with threatened preterm labour a recent meta analysis concluded a 
cut off of 15mm gives a positive predictive value 60% and negative predictive value of 
96% of delivery within 1 week if presenting under 34 weeks of gestation [107]. 
 
Collection of fetal fibronectin from the posterior fornix is also commonly used as a 
screening tool both in asymptomatic and symptomatic women. Fetal fibronectin is an 
extracellular matrix glycoprotein secreted by the chorion. If any biochemical disruption 
to the fetal membranes occurs, this glycoprotein will be detected in the high vagina. A 
negative result places both asymptomatic and symptomatic women at low risk of 
preterm labour. A systematic review of 26,876 cases revealed a likelihood ratio for 
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positive results of 4.01 (95% CI 2.39-5.49) for predicting birth before 34 weeks in 
asymptomatic women, with a corresponding LR for negative results of 0.78 (0.72 to 
0.84). In symptomatic women the LR for a positive result was 5.42 (95% CI 4.36-6.74) 
for delivery within 7-10 days, and 0.25 (95% CI 0.2-0.31 ) for a negative result [108]. 
Cost savings are seen with the introduction of fetal fibronectin testing into clinical 
practice as a result of a reduction in hospitalisation, administration of corticosteroids 
and the reduction of in utero transfers to tertiary referral centres in women with a 
negative result [109]. 
 
Prevention 
Cerclage 
Cervical cerclage for cervical insufficiency was first described by Shirodkar in 1955 
[110], and later by McDonald in 1957 [111]. Both techniques provide structural 
support for a weakened cervix, but may also improve the cervical immunological 
barrier by improving retention of the mucous plug, and preventing ascending infection 
by maintaining cervical length.   Cervical cerclage can be placed electively in women 
with a strong history suggestive of cervical insufficiency, or can be placed if the cervix 
becomes short as detected by ultrasound. A multicentre randomized trial of history-
indicated cervical cerclage in women with 3 or more mid-trimester losses of preterm 
births showed a reduction in the risk of PTB before 33 weeks from 32 to 15% [112]. A 
meta-analysis of 208 women at high risk of preterm labour with a short cervix 
(<25mm), concluded a statistically significant reduction in rate of preterm delivery <35 
weeks with cerclage placement (relative risk 0.61; 95 % CI 0.4-0.92) [113]. There is also 
some evidence that cervical cerclage in women at high risk results in a statistically 
significant reduction of a composite of perinatal mortality and morbidity [114]. 
 
Progesterone  
There have been several large trials looking at the potential benefits of vaginal 
progesterone to reduce the rates of preterm delivery using gestational age of delivery 
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as a primary outcome [115-118]. A large multicentre randomised controlled trial 
including mainly women without a prior history of preterm birth has shown a 45% 
reduction in preterm labour at <33 weeks using 90mg of vaginal progesterone in 
women with a short cervix of 10-20mm [118]. A composite of neonatal indices were 
also reduced, including a 60% reduction in respiratory distress syndrome. The 
multicentre trial OPPTIMUM, a randomised controlled trial of women at high risk or 
preterm labour is specifically powered for long-term neonatal outcome, and therefore 
should provide robust evidence of the effect of progesterone on neonatal morbidity 
and mortality.   
 
Tocolytics 
Tocolytics are aimed at suppressing uterine contractility. They include NSAIDS, beta 
agonists, calcium channel blockers and oxytocin receptor antagonists. Although 
tocolytics have been shown to increase the delay to delivery at 48 hours and 7 days 
[119], there is no evidence of a clear reduction in perinatal mortality or neonatal 
morbidity [120]. However, a short course of tocolysis for women with threatened 
preterm labour is given to allow time for the administration of corticosteroids to 
stimulate fetal maturation. It is likely that the inability of tocolytics to prevent preterm 
labour is partly because most women in threatened preterm labour are not destined 
to labour; and conversely for those women that really did need tocolysis, once uterine 
contractility is established it is likely that the multiple biochemical pathways involved 
are too advanced to be overcome by transient inhibition of the contractions. 
Nifedipine, (a calcium channel blocker) and Atosiban (an oxytocin antagonist) are the 
most commonly used tocolytics in the UK.  Although there have been no direct 
randomised controlled trials comparing Atosiban with Nifedipine, using adjusted 
indirect comparisons  there is a non-significant trend to an increased delay in delivery 
by 48 hours with Nifedipine [121], with a trend also towards an improvement in 
perinatal morbidity, lower side effect profile and a lower cost [122]. A recent meta-
analysis reviewed 95 randomised controlled trials of tocolytic therapies including 
prostaglandin inhibitors, calcium channel blockers, oxytocin receptor antagonists, 
magnesium sulphate and beta mimetics on [123]. Maternal outcomes included a 48 hr 
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delay in delivery and side effects, whereas neonatal outcomes of respiratory distress 
syndrome and mortality were reported on. The meta-analysis concluded that 
concluded that prostaglandin inhibitors and calcium channel blockers had the highest 
probability of delaying delivery and improving neonatal and maternal outcomes. 
 
 
1.5 The immunology of pregnancy, term and preterm labour  
The immunology of pregnancy 
The immunology of pregnancy is a complex phenomenon that involves a balance 
between maternal immune tolerance and suppression, often referred to as the 
“immune paradox of pregnancy”. The fetus has been described as a semi-allogeneic 
graft, being a product of two histoincompatable individuals [124, 125]. This poses a 
challenge to the mother; to both tolerate the expression of paternal antigens, whilst 
maintaining the ability to reject in the case of overwhelming infection [126]. This 
challenge is undertaken in part by the immune system. It was first proposed by 
Medawar that the fetus essentially acts as an allograft that avoids rejection due to a 
physical separation from the mother, its own antigenic immaturity and the 
immunological inertness of the mother (i.e. maternal immune suppression) [127]. 
Highly regulated responses from both the innate and adaptive immune systems 
facilitate immune tolerance and immune activation when needed.  
 
The immune system has two main defence systems which coordinate the immune 
response: the innate and the adaptive system. The innate immune response is a non-
specific reaction towards foreign antigens, whereas the adaptive response forms an 
antigen specific reaction [128]. Although different immune components are involved 
in these systems, much overlap and cross talk exist between the two. Figure 1.9 is a 
pictorial representation of the key components of these systems during pregnancy. 
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Figure 1.9 The key components of the adaptive and innate immune system in pregnancy 
(Sykes et al 2012) [129] Mediators of the adaptive and innate immune system work in parallel 
to facilitate a balance between immune tolerance of the fetus whilst maintaining the ability to 
mount a response against invading pathogens. PWBC: Peripheral white blood cells. 
 
 
Innate immune system in pregnancy 
 
The innate immune system the most primitive form and is the first line in the host’s 
ability to defend against pathogens. Although it is non-specific, it is critical for the 
prevention of microbial invasion. The innate immune system includes physical and 
biochemical barriers to non-self.  For example, the amnion acts as a membrane barrier 
to the mother throughout gestation. Also, immunologically active secretions such as 
lysozymes and defensins serve as biochemical barriers to invasive pathogens. Cellular 
components of the innate immune system include neutrophils, monocytes and 
macrophages, which protect against pathogens by phagocytosis. The innate immune 
system has also evolved to recognize non-self utilising pattern recognition receptors 
(PRRs) [85] that recognise molecular signatures of pathogens [130]. PRRs are also 
capable of recognising non-infections endogenous proteins , such as Hsp70 [131].  
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Toll like receptors (TLRs) are a major component of pattern recognition receptors. To 
date 11 members have been discovered in mammals [132]. The Toll like receptors 
(TLRs) TLR 2 and TLR 4 are pattern recognition receptors stimulated by gram positive 
and gram negative bacteria respectively [133]. TLR 2 and TLR 4 are of particular 
interest in relation to pregnancy and preterm labour. Both receptors are expressed on 
gestational tissues including trophoblasts [134], amnion epithelial cells, [135] and the 
myometrium [136]. The expression of these receptors is increased in term labour in 
amnion and in myometrium [135, 136]. An important activator downstream of TLRs is 
NF-κB which leads to the production of immune response proteins such as cytokines 
and chemokines [137]. 
 
Adaptive immune system in pregnancy 
 
In contrast to the innate immune response, the adaptive immune response is a more 
specific response. The adaptive immune system relies upon B and T lymphocytes, 
which are responsible for the humoral and cellular responses respectively [138]. B cells 
differentiate into plasma cells which then secrete antibodies. Antibodies work in 
concert with the rest of the immune system by activating complement and immune 
cells including macrophages and neutrophils to target pathogens [139]. T cells (CD3+) 
can be subdivided into T helper cells (Th cells) (CD4+) and cytotoxic T cells (Tc cells) 
(CD8+), with Th cells being subdivided further into Th1 and Th2 cells depending on the 
cytokines they produce.  The cytokines produced by T helper cells play a central role in 
the protection against pathogens, but also play a role in allergy and autoimmune 
conditions. The cytotoxic T cells generally target virally infected cells resulting in cell 
death [139]. 
 
The hypothesis of immune suppression during pregnancy, proposed originally by 
Medawar [140] has been superseded by a more complex hypothesis where a change 
in the ratio and function of maternal leukocytes occurs rather than complete 
suppression. For example there is an increase in the total peripheral white cell count 
from the early stages of pregnancy with no change in the CD4 and CD8 counts (T 
                                                                                                          Chapter 1: Introduction 
37 
 
helper and cytotoxic T cells respectively) [141]. However, within the T helper CD4 
positive population an increase in T regulatory cells is seen in pregnancy [142].  
 
An important component of the adaptation of the immune system in pregnancy is the 
regulation of specific cytokine production [143]. Pregnancy is largely represented by a 
shift towards Th2 activity [143] [128] [144, 145]. During pregnancy, peripheral blood 
lymphocytes show an increase in mRNA of the prototypical Th2 interleukin IL-4 and 
lower mRNA levels of the prototypical Th1 interleukin interferon gamma (IFN-γ) [146]. 
Also, in vitro stimulation of peripheral lymphocytes in pregnant women display 
increased production of IL-4 and reduced production of IFN-γ compared with non 
pregnant controls [147]. The Th2 cytokine bias is likely to be more pronounced at the 
maternal fetal interface [148]. Decidual leukocytes produce IL-4 and IL-10 [149], with 
Th2 cytokines also being produced by non-immune cells including trophoblasts and 
decidual cells to contribute to the Th2 cytokine predominance [150] [151]. Th2 
interleukins are capable of suppressing the Th1 interleukins as a form of regulating the 
Th1:Th2 ratio [152],  and can also suppress the production of IL-8 and prostaglandins 
[153]. In turn this offers a mechanism by which the Th1:Th2 ratio can contribute to 
pregnancy maintenance along with immune tolerance of the fetus as an allograft.  
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The immunology of term labour 
 
Term labour is seen as an inflammatory event with physiological activation of the 
immune system. Local inflammation in the fetal membranes, cervix and uterus plays a 
key role in the cascades leading to both term and preterm birth [73]. 
 
Immune activation in the decidua and fetal membranes at the maternal fetal interface 
In preparation for delivery, the fetal membranes and decidua undergo complex 
biochemical events leading to the physical separation of the membranes from the 
decidua and their rupture. The decidua forms the interface between the maternal and 
fetal tissues, and it was proposed by Casey and MacDonald that it may also regulate 
maternal-fetal immuno-tolerance during pregnancy [154]. In the amnion, the pro-
inflammatory cytokines IL-1β and IL-8 are up regulated during labour as are IL-6 and IL-
8 in the choriodecidua [25]. IL-1β stimulates COX-2 production, which in turn leads to 
the production of PGE2 in the amnion. The amnion is a major source of prostaglandins 
which are required for uterine contractility and cervical ripening [26].  
 
Immune activation in the cervix  
At the beginning of parturition, the cervix undergoes a major remodelling process 
referred to as “ripening”. This occurs independently, yet concurrently with the 
activation of the fetal membranes and myometrium. Cervical ripening involves 
activation of an inflammatory cascade that involves the release of pro-inflammatory 
cytokines and the infiltration of leukocytes [25, 155]. IL-8 is a chemokine produced by 
many immune cells but primarily macrophages and monocytes [156] and is increased 
in the cervix with the onset of labour [157]. The invading inflammatory cells contribute 
to the release matrix metalloproteinases (MMPs) that, along with activated 
collagenases, degrade the structural connective tissue and collagen fibres of the cervix 
[32].  
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Immune activation in the uterus 
During term labour, there is a significant influx of inflammatory cells including 
lymphocytes, macrophages and neutrophils [155]. These infiltrating leukocytes 
contribute to the source of pro-inflammatory interleukins and prostaglandins which 
are involved in term labour. Immunohistochemistry demonstrates that the immune 
cells are the likely origin of the majority of pro-inflammatory cytokines within the 
myometrium during labour [158]. From this study IL-1β was predominantly located in 
leukocytes, with weak staining in myocytes, whereas IL-6 and TNF-α were restricted to 
leukocytes. A number of studies have also identified increases of IL-8 in the 
myometrium with the onset of labour [157-159]. 
 
There has been some debate as to whether the activation of inflammatory pathways 
in the myometrium is a cause or consequence of labour. Recent work by Bisits and 
colleagues used mathematical modelling to distinguish which pathway of myometrial 
activation was most likely to occur first [160]. Of the three pathways investigated; 
inflammatory stimulation, functional progesterone withdrawal or oxytocin receptor 
activation, data provided from quantitative RT-PCR on key genes of each pathway 
strongly supported inflammation as the primary driver for activation of the 
myometrium. 
 
The immunology of preterm labour 
Although the initial triggers of preterm and term labour may well differ, with term 
labour seen as physiological and preterm labour seen as a pathological condition, the 
terminal events leading to delivery of the fetus are common to both [161]. The 
inflammatory response present in term labour also exists in preterm labour, except 
with a greater rate of association with infection, with approximately 30% of preterm 
deliveries being associated with an infective process [162]. The earlier the gestation of 
preterm labour, the higher the association with infection is. 80-85% of women in 
preterm labour < 28 weeks show evidence of intrauterine infection, with >90% around 
24 weeks, compared with 15% of women delivering late preterm at 34-36 weeks [163].  
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The mechanism by which infection is able to trigger the parturition cascade is 
undoubtedly linked to an integrated network of interactions between the pro 
inflammatory cytokines and prostaglandins. In response to intrauterine infection, 
infiltrating leukocytes and decidual cells are capable of secreting the proinflammatory 
cytokines IL-1, IL-6, IL-8 and TNF-α [90, 154, 164] These act in concert to stimulate 
uterine contractions, and remodel both the cervix and the fetal membranes leading to 
cervical dilation and rupture of membranes respectively [162, 163]. 
 
Although microbial infection is a common cause of inflammation, the presence of 
infection is not essential for inflammation driven preterm labour. There is a causal role 
for cytokines in labour even in the absence of infection [165]. We have previously 
shown that pregnancies without clinical overt signs of infection still show increased 
levels of IL-8 in the myometrium [166]. Moreover, a recent genomic study of amnion 
tissues from women in spontaneous labor without histological chorioamnionitis 
revealed that these tissues present an acute inflammation gene expression signature 
[167]. 
 
Immune activation in the decidua and fetal membranes at the maternal fetal interface 
In response to intrauterine infection, infiltrating leukocytes and decidual cells are 
capable of secreting the pro-inflammatory cytokines IL-1, IL-6, IL-8 and TNF-α [90, 154, 
164]. These cytokines induce prostaglandin production in the fetal membranes and 
decidua leading to initiation of parturition [168, 169]. IL-6 is a pro-inflammatory 
cytokine and a major mediator of host response to inflammation and infection [170]. 
IL-6 is significantly increased in amnion and choriodecidua in women with preterm 
delivery compared with term delivery [171] and is the most sensitive and specific 
indicator of infection-associated preterm labour [11, 172]. Detection of increased in IL-
6 in amniotic fluid and cervicovaginal fluid is an independent risk factor for preterm 
labour and neonatal morbidity [173], including cerebral palsy [174] and 
bronchopulmonary dysplasia [175]. IL-8 mRNA expression is also increased in preterm 
labour by more than 50-fold and more than 1000-fold in preterm labour with evidence 
of chorioamnionitis [176]. 
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Immune activation in the cervix  
Premature ripening of the cervix usually occurs in conjunction with uterine 
contraction, but in the case of cervical insufficiency is classically painless. The cervix 
plays not only a mechanical role but also a biochemical role in the prevention of 
ascending infection as demonstrated by the higher incidence of microbial invasion of 
the amniotic fluid in women with a shorter cervix [177, 178]. Consistent with the 
protective role of the immune response within the cervix, women who are destined to 
deliver preterm have a lower number of macrophages antenatally compared with 
women delivering at term [179]. In contrast, an exaggerated immune response in the 
cervix is also associated with preterm labour. Both IL-6 and IL-8 levels are significantly 
higher in cervical secretions of women destined to deliver preterm [180]. Although the 
specific role of IL-6 in inducing preterm birth is not fully understood, the function of IL-
8 is by chemoattracting leukocytes such as neutrophils that contribute to cervical 
ripening by producing MMPs [181].  
 
Immune activation in the uterus 
Preterm labour as well as term labour is characterised by marked leukocyte invasion 
into the myometrium [155]. Pro-inflammatory cytokines such as IL-8 and IL-1β are 
increased in the myometrium in women in preterm labour compared to women not in 
labour [182]. As well as pro-inflammatory cytokines there is also increased expression 
of chemokines including CCL5, CXCL5, and CCL20 [183]. As with term labour, pro- 
inflammatory cytokines lead to the increased production of prostaglandins in the 
myometrium. IL-1β and TNF-α stimulate arachidonic acid release thereby activating 
phospholipid metabolism [184] and increasing the production of prostaglandins [185, 
186]. IL-1β up regulates COX-2 expression [187] stimulating the production of PGE2 
[188] and increases oxytocin secretion both of which contribute to uterine contractility 
[189]. 
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1.6 The Th1 and Th2 interleukins in pregnancy, term and preterm labour  
 
The Th1/Th2 cytokines  
Th1 and Th2 cells originate from undifferentiated Th0 cells under the influence of their 
prototypical cytokines IFN-γ and IL-4 respectively. Th1 and Th2 cells differ in the 
cytokines that they produce and their function. Th1 cells produce pro-inflammatory 
cytokines; IFN-γ [190], IL-2 [191], and TNF-α [192], and are the major effectors of 
phagocyte-mediated host defence which protect against intracellular pathogens [191, 
193, 194]. Th2 cells produce a mixture of pro- and anti-inflammatory cytokines; IL-4, 
IL-5, IL-13, IL-10 [190] and IL-6. IL-4 and IL-10 are considered to be anti-inflammatory 
cytokines [195] and IL-6 is considered to be pro-inflammatory [196]. Although IL-10 
and IL-6 are typically classed as Th2 cytokines [144, 197-201], IL-10 is also produced by  
Th1 cells, macrophages and B cells [202, 203], whereas IL-6 is also produced by 
macrophages, fibroblasts and B cells [204].  
 
The Th2 cytokines have several functions and are commonly associated with 
facilitating antibody responses [205]. IL-4 stimulates IgE and IgG1 antibody production 
[206]. IL-5 promotes the growth and differentiation of eosinophils whereas IL-13 and 
IL-10 inhibit the activity of macrophages [206]. Transcriptional regulation of the Th1 
cell cytokine production is mainly by T-bet and STAT-4 [148], whereas the 
predominant Th2 cytokine IL-4 is regulated by STAT-6, c-maf, GATA-3 and NFAT [207]. 
Although the Th1 and Th2 responses may be described as discrete responses, there is 
considerable cross talk and overlap between the functions of the T helper cells. For 
example the Th1 cytokines can promote the production of complement-fixing 
antibodies involved in antibody dependent cell cytotoxicity [208]. A balance between 
Th1 and Th2 exists rather than complete suppression of one over the other.  Figure 
1.10 (from O’Garra et al) summarises the cytokines secreted by the Th1 and Th2 cells, 
their function, and the internal regulation that exists to maintain the Th1/Th2 
interleukin profile [194].  
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Figure 1.10 The regulation of T helper cell responses (O’Garra et al 2000) 
Th1 development is dependent on IL-12 and IFN-γ and is required mainly for cell-mediated 
immunity of the adaptive immune system. Th1 development is antagonised directly by IL-4 
and indirectly by IL-10. Th1 development is dependent on IL-4 and is important for immune 
tolerance, allergy and atopy.  
 
 
The Th1/Th2 cytokines and pregnancy maintenance 
Recognition of a bias towards the Th2 cytokine profile during pregnancy has been well 
documented. Wegmann and colleagues were the first group to hypothesise that Th2 
predominance together with downregulation of the Th1 response is important for 
pregnancy maintenance [209]. This has subsequently been supported by both murine 
studies and the clinical course of Th2 and Th1 based conditions in pregnancy. For 
example, IL-2, IFN-γ and TNF-α induce miscarriage in mice, which can be reversed by 
inhibitors of the Th1 cytokines, or by administering the anti-inflammatory Th2 cytokine 
IL-10 [210, 211]. Th1 mediated autoimmune conditions like rheumatoid arthritis 
generally improve in pregnancy [212], whereas the Th2 autoimmune spectrum tend to 
worsen, for example systemic lupus erythematosus [213]. The Th2:Th1 bias and thus 
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diminished cell-mediated immunity may be responsible for the increased susceptibility 
in pregnancy of conditions caused by intracellular pathogenesis such as influenza, and 
listeria monocytogenes [145]. Pregnancy hormones such as progesterone [214], 
leukaemic inhibitory factor [215], estradiol [216] and prostaglandin D2 (PGD2) [217] 
promote the Th2 cell profile, and are likely to be in part responsible for the Th2 bias 
associated with pregnancy.  
 
Peripheral blood 
 
Several studies have reported on a Th2 bias in peripheral blood leukocytes in 
pregnancy. Marzi and colleagues stimulated peripheral blood mononuclear cells 
(PBMCs) with phytohaemagglutinin (PHA), and measured interleukin secretion by 
ELISA showing  an increase in IL-4 and IL-10 with a reduction in IFN-γ and IL-2 in 
pregnancy compared with non-pregnant controls [147]. These results were 
reproduced by using flow cytometry by Reinhard et al in phorbol myristate acetate 
(PMA) stimulated cells, demonstrating an increase in intracellular IL-4 production and 
a reduction in intracellular IFN-γ and IL-2 in pregnancy compared with non-pregnant 
controls [218]. In vivo confirmation of this bias has since been demonstrated by PCR 
showing decreasing mRNA of IFN-γ through pregnancy along with a concurrent 
increase in IL-4 mRNA which peaks in the 7th month compared with non-pregnant 
controls [146]. Whilst the majority of studies support this bias, there are some studies 
that do not consistently reproduce this bias. Shimoaka et al., reported a reduction in 
PMA-stimulated IL-4 during pregnancy [219] while Matthiesen and colleagues 
presented data suggesting an increase in both IL-4 and IFN-γ secreting cells in 
pregnancy compared with  non-pregnant controls [220, 221]. Such discrepancies may 
be due to characterisation of cytokine profiles in either isolated cell populations or 
whole blood, the gestational stage at time of blood collection, or the undiagnosed 
presence of infection or inflammation, confounding results. 
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Maternal fetal interface and non-immune cells 
Local cytokine production at the maternal interface may be of greater significance 
than measurements obtained in the peripheral blood [193], however, access to tissue 
makes researching this challenging. Despite this, a number of studies have successfully 
shown a bias towards the Th2 cytokine profile during pregnancy. IL-4 and  IL-10 
production by T cells at the maternal fetal interface is associated with successful 
pregnancy [193]. Decidual CD4+ cells from women undergoing unexplained recurrent 
pregnancy loss typically exhibit reduced IL-4 and IL-10 production [149]. Trophoblast, 
decidua and amnion all contribute to the Th2 cytokine environment by production of 
IL-13 [222], IL-10 [223], IL-4 and IL-6 [224, 225].  
 
Local regulation of the Th1/Th2 to promote the Th2 bias at the maternal fetal interface 
is likely to occur in a number of ways. Local production of IL-4 and IL-10 inhibits the 
function of both Th1 cells and macrophages [226]. Co–culture of trophoblasts and T 
cells results in an increase in the transcription factors GATA-3 and STAT-6 (which 
regulate Th2 cytokine production), and a reduction in the Th1 transcription factor 
STAT-4 and subsequently decreased production of IFN-γ and TNF-α [227]. In vitro 
studies also show Th2 interleukins can modulate labour associated genes by inhibiting 
the production of the Th1 cytokine TNF-α [152], and TNF-α-induced COX-2 and/or 
PGE2 synthesis in amnion-derived wish cells. Similar effects are also observed in 
decidual and placental cells [153, 228-230]. 
 
The Th1/Th2 cytokines and term labour 
Peripheral blood 
Labour is often seen as a pro-inflammatory state marking the end of the pregnancy 
and thus it would be anticipated that a Th1 bias exists during labour, however, there 
are limited studies looking at the Th1:Th2 ratio in peripheral blood cells in labour. One 
study has reported a reduction in serum IL-4 in the later part of labour with a peak in 
the cytokine TNF-α in early labour consistent with a Th1 bias over Th2 [231]. 
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Consistent with this, an increase in IFN-γ and IL-1β in women in active labour has also 
been reported [232]. 
 
Maternal fetal interface and non-immune cells 
There is substantial evidence that the Th1 cytokines play a role in the initiation of 
labour at term [192]. The importance of local rather than peripheral production of the 
cytokines is highlighted by their direct input into the biochemical pathways involved in 
parturition. TNF-α and IL-1β are both increased in amnion, amniotic fluid and decidua 
at term [233] and can induce PGE2 production in amniocytes and decidual cells in vitro 
[234, 235]. Therefore, despite the pro-inflammatory nature of the Th1 cytokines they 
are required for successful pregnancy contributing to the physiology of term labour.  
 
The Th1/Th2 cytokines and preterm labour 
 
Immune and non-immune cells contribute to a cytokine-rich environment in the 
presence of infection and inflammation. Since preterm labour is associated with both 
infection and inflammation, the increase in the Th1 pro-inflammatory cytokines seen 
in preterm labour is not surprising. Pro-inflammatory cytokines, (typically of Th1 type), 
ultimately result in the production of prostaglandins and MMPs  [236]. This triggers a 
cascade of pro-labour events including uterine contractility and fetal membrane 
rupture. If this cascade is activated too early in pregnancy then preterm labour can 
ensue.  
 
Peripheral blood 
Several studies support the hypothesis of an altered bias towards the pro-
inflammatory Th1 cytokines in peripheral blood during preterm labour. Serum taken 
from women with preterm pre-labour rupture of membranes (pPROM) compared to 
women who deliver at term exhibit a higher concentration of IFN-γ, with undetectable 
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levels of IL-4 and IL-5 in both groups [237]. In a study of 30 women in preterm labour, 
mitogen and antigen stimulated PBMCs show a higher production of the pro-
inflammatory cytokines IFN-γ and IL-2 favouring a Th1 response compared with 
controls who delivered at term [238]. Activation of the Th1 cytokines also occurs as a 
specific response to infection caused by intracellular bacteria, parasites and viruses 
[239], and thus a prominent Th1 response would be expected in infection mediated 
preterm labour. While the Th1 cytokine response may be suppressed by both the 
maternal and fetal immune system during pregnancy [240], it still maintains the 
capacity to mount a defensive response in the context of infection. Activated T cells 
drive both local and systemic cytokine production [239]. This is evident for example in 
neonates exposed to intrauterine infection in that there is an increased percentage of 
IFN-γ-producing peripheral leukocytes [241].  
 
Maternal fetal interface and non-immune cells 
The inflammatory response at the maternal fetal interface is likely to reflect the most 
pronounced aberrant Th1 biased profile in preterm labour. A recent meta-analysis 
concluded that pro-inflammatory cytokines at the maternal fetal interface play a role 
in the events leading to spontaneous preterm labour, while systemic inflammation 
does not appear to be present in asymptomatic women early on in pregnancy who 
then go on to deliver preterm [242].  
 
Placentas from women following preterm delivery compared with term delivery show 
a bias towards the Th1 profile with significantly higher levels of IFN-γ and IL-2 as well 
as the Th1 inducing cytokine IL-12 [243]. Also, placentas from women delivering 
preterm have lower levels of the Th2 cytokines IL-4 and IL-10 than placentas from 
term deliveries. The Th1 cytokine TNF-α is increased in choriodecidual tissues [171] 
and amniotic fluid [244] in preterm labour. TNF-α is known to stimulate prostaglandin 
production through the TNF receptor 2, leading to uterine contractions, and is also 
likely to contribute to MMP-9 production leading to PROM via activation of its 
receptor TNF Receptor 1 (TNFR1) [92].  
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The source of pro-inflammatory cytokines at the maternal fetal interface in preterm 
labour may be from both non-immune cells and infiltrating leukocytes.  Cytokine levels 
in placentas and fetal membranes from preterm deliveries (with and without 
intrauterine infection) correlate with the extent of leukocyte infiltration in fetal 
membranes [233]. This supports the suggestion that in the presence of infection, the 
primary cellular source of cytokine production in fetal membranes is likely to be 
infiltrating leukocytes rather than amniocytes or choriodecidual cells  [233].  
 
1.7 The role of Nuclear Factor-κB in pregnancy, term and preterm labour  
 
Nuclear factor Kappa B (NF-κB) is a transcription factor that plays a central role in 
controlling the inflammatory response [161]. The NF-κB signaling pathway also plays 
an important role in the process of human labour [245]. Therefore targeting the 
inhibition of this transcription factor is an attractive therapeutic strategy for the 
prevention of both preterm labour and inflammation induced neurological damage 
associated with inflammation induced preterm labour.  
 
The NF-ĸB family consists of 5 members; NF-ĸB1 (p105/p50), NF-ĸB2 (p100/52), Rel A 
(p65), Rel B and c-Rel [245]. They play a central role in controlling the inflammatory 
response, apoptosis, tissue remodelling and cell proliferation [161]. Pro-inflammatory 
cytokines such as IL-1β and TNF-α are both regulated by and can activate NF-κB giving 
rise to a positive feed forward loop and thus further activating the NF-κB regulated 
genes [246]. The following labour associated genes; phospholipase A2 isoenzymes 
(cPLA2) [247], COX-2, IL-8, IL-6, and MMPs [245] are also transcriptionally regulated by 
NF-κB.  
 
NF-κB signalling 
NF-ĸB transcription factor activity is inducible by the release of its inactive subunits in 
the cytoplasm for nuclear translocation. The inactive subunits of the NF-ĸB family are 
localised as homo or hetero dimers in the cytoplasm together with the NF-ĸB inhibitor 
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IκB. The IκB family has several members; IκB α, IκBβ, IκBε, IκB-γ, IkB-z, p105, p100, and 
Bcl3. The IκB proteins contain multiple ankyrin repeat motifs important for the 
maintenance of NF-ĸB in the cytoplasm [248], by mediating binding to the NF-ĸB rel 
homology domain (RHD) [245]. IκB degradation and the subsequent release of the NF-
ĸB subunits is regulated by the IκB kinases (IKK). The first IKK complex identified 
consists of two subunits IKK-α (IKK-1) and IKK-β (IKK-2), and the regulatory component 
IKK-γ (also known as NEMO) [247]. IKK-β phosphorylates IκB in response to 
proinflammatory stimuli and stress [249]. Recently another IKK complex was been 
identified containing IKK- ε, which mediates activation of NF-ĸB by Phorbol ester [250].  
Upstream kinases mediate the phosphorylation of the IKK complexes including; MAP 
Kinase, NF-ĸB-inducing kinase (NIK), NF-ĸB-activating kinase, (NAK), receptor activator 
for NF-ĸB and its ligand (RANK and RANKL), mitogen activated protein kinase/ERK 
kinase kinase 1, 2 and 3 (MEKK1,2,3) [251, 252]. Once activated the IKK proteins 
phosphorylate IκB at specific serine residues [253] which result in the attachment of 
ubiquitin residues [254]. Ubiquitated IκB is then cleaved by the 26S prosteosome [255] 
which allows the NF-ĸB subunit to translocate into the nucleus to bind specifically to 
DNA response elements. 
 
Three signalling pathways are involved in NF-ĸB activation; the atypical, non-canonical 
and the canonical pathways. DNA damage activates the atypical pathway and results in 
phosphorylation of IĸBα by p38 induced casein kinase-2 (CK-2). The non-canonical 
pathway is activated by lymphotoxin β or B-cell activating factor (BAFF) and upon 
activation IKKα phosphorylates p100 generating p52, releasing RelB/p52 dimers for 
translocation into the nucleus. More relevant to the work in this thesis is the canonical 
pathway, which is activated by lipopolysaccharide, TNF-α and IL-1β. IĸBα is 
phosphorylated by IĸB kinase (IKK) and is degraded to release p50/p65 dimers for 
translocation into the nucleus where it functions as a transcriptional activator of 
labour associated genes and pro-inflammatory cytokines. Figure 1.11 summarises the 
pathways involved in NF-ĸB activation from Lindstrom et al [245].  
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Figure 1.11 Schematic illustration of the three signalling pathways of NF-ĸB activation. 
(Lindstrom et al 2005) [245] 
The canonical pathway is activated by pro-inflammatory cytokines, the atypical pathway by 
DNA damage, and the non-canonical pathway by lymphotoxin β and BAFF. Inactive subunits 
reside in the cytoplasm attached to the IKB inhibitory proteins. Once phosphorylated the 
active subunits translocate into the nucleus. 
 
 
Peripheral blood 
 
NF-κB is known to play a key regulatory role in controlling the Th1 immune response 
by modulating the expression of Th1 cytokines [256]. NF-κB activity in PBMCs has been 
shown to be suppressed in pregnancy compared with non-pregnant controls [257]. 
The reduction in Th1 cytokine production in PBMCs and specifically T cells during 
pregnancy is likely to be as a result of this down regulation of the NF-κB/IκB signalling 
[240, 258]. It is not known whether NF-κB activity is increased in PBMCs in term or 
preterm labour. 
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Amnion 
 
NF-ĸB plays a key role in the regulation of prostaglandin synthesis in labour through 
more than one mechanism. NF-ĸB regulates the production of cytosolic 
phospholipases A2 isoenzymes (cPLA2) in human gestational tissues. These enzymes 
generate arachidonic acid from glycerophospholipids [247]. Secondly NF-ĸB is a 
transcriptional regulator of COX-2 in amnion epithelial cells. COX-2 contains two NF-ĸB 
response elements in its promoter region, and site directed mutagenesis of these 
regions represses the activity of the COX-2 promoter reporter construct in amnion 
epithelial cells [259]. 
 
NF-κB activity is increased in amnion during labour [259], with term pre-labour 
samples showing varying degrees of p65 expression at different time points, which is 
likely to reflect the physiological transition that precedes parturition [260]. Pro-
inflammatory cytokines such as IL-1β, IL-8 and IL-6 are elevated in the amnion and 
choriodecidua of women in term and preterm labour choriodecidua [233]. These 
interleukins are regulated by NF-ĸB [161]. Inhibition NF-κB can result in the inhibition 
of LPS induced pro-inflammatory cytokines including IL-8 and TNF-α in amnion and 
choriodecidua [261]. 
 
Myometrium 
 
Chapman and colleagues have previously reported the presence of all subunits except 
Rel B and p52 in the myometrium. Although total p65 was found to be reduced in 
lower segment myometrium in labouring women, DNA binding activity was actually 
increased [262]. In contrast expression of the p65 subunit shows a marked increase in 
the fundal myometrium during labour [263]. This is consistent with the concept that 
the fundal myometrium is more important than the lower segment for the 
propagation of uterine contractility.  These findings are consistent in animal studies 
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with NF-ĸB activity increased in the pregnant mouse uterus [264] and the fundal 
myometrium in baboons at term [265]. 
 
NF-κB plays a key role in the transcriptional regulation of contractile associated genes 
in the myometrium at the time of labour. The oxytocin receptor (OTR) [266] and COX-2 
[259] genes contain NF-κB response elements in their promoter regions. OTR mediates 
oxytocin induced myometrial contractions through activation of phospholipase C and 
downstream calcium release from intracellular stores [267]. The COX-2 enzyme is the 
rate-limiting step for prostaglandin synthesis, which is responsible for uterine 
contractions. COX-2 is elevated in lower segment myometrium towards term [268], 
and in labour verses non labour samples [269], as is IL-1β at the onset of labour [270].  
NF-κB is required for IL-1β induced expression of COX-2 in myocytes [271], 
representing another mechanism of NF-κB mediated inhibition of COX-2.  
 
NF-κB also regulates the pro-inflammatory cytokines IL-8 and IL-6 in the myometrium, 
both of which contain NF-κB recognition elements within their promoter regions [245]. 
IL-8 is dramatically increased in labouring myometrium [272], and is detected in the 
supernatant of non-stimulated and IL-1β stimulated myocytes in vitro [273]. 
Microarray analysis on myocytes overexpressing p65 shows that NF-κB regulates genes 
principally related to immunity and inflammation in these “non-immune” cells [274]. 
This provides evidence that the myometrium is capable of functioning as a distinct 
immune organ and that inflammatory pathways are critical components during 
parturition [159].  
 
Cervix 
 
NF-κB is also involved in transcriptional regulation of matrix metalloproteinases 
(MMPs), including MMP-9, which are required for remodelling of the extracellular 
matrix [269], leading to  both cervical ripening and fetal membrane rupture. 
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NF-κB activity in preterm labour  
 
As already highlighted, the terminal biochemical pathways that are activated in term 
labour are also activated in preterm labour. Premature enhanced activation of NF-κB 
can be triggered by the presence of infection and inflammation. For example, a 
positive feed forward loop also exists from the activation of NF-κB by the pro-
inflammatory cytokines such as TNF-α and IL-1β and subsequently leading to their own 
transcriptional activation [187, 245, 275].  
 
NF-κB inhibition is therefore an attractive target for the prevention of preterm labour 
since, as well as inhibiting labor-associated genes involved in uterine contractility, 
cervical ripening and fetal membrane rupture, it would also inhibit the pro-
inflammatory cytokine production. The outcome of which would be to both inhibit 
preterm labour and the neurological damage associated with inflammation induced 
preterm labour. 
 
 
1.8 15-deoxy ∆ 12,14 Prostaglandin J2 (15dPGJ2) 
 
15-deoxy-Δ 12,14-Prostaglandin J2 (15dPGJ2) is an anti-inflammatory cyclopentenone 
prostaglandin. It exerts anti-inflammatory effects through inhibiting the activation of 
NF-ĸB [276]. 15dPGJ2 inhibits NF-κB and COX-2 in both in human myocytes and 
amniocytes in vitro [271]. It is also capable of delaying inflammation induced preterm 
labour in the mouse in vivo [277]. In addition it reduces pup mortality from 75% to 5% 
and inhibits pup brain NF-κB and JNK activation. 15dPGJ2 is an endogenous 
prostaglandin, and is a product of PGD2 via a series of dehydration reactions, [278] as 
summarised in Figure 1.4. It can accumulate intracellularly, and is detected in amniotic 
fluid [279], placenta [280]   and urine [281]. 
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15dPGJ2 has multiple cellular targets. It is a ligand with high affinity to the peroxisome 
proliferator receptors for example PPAR-γ [247, 282]. 15dPGJ2 can also act 
independently of the PPARγ through inhibition of different transcription factors such 
as NF-ĸB [283] AP-1 [284] and NF-AT [285, 286]. Additionally, 15dPGJ2 is a ligand for 
chemoattractant receptor-homologous molecule 2 (CRTH2) that is present on Th2 
cells, eosinophils and basophils [287]. The mechanism by which 15dPGJ2 inhibits NF-κB 
in amniocytes and myocytes is not yet fully understood. It is plausible that CRTH2 may 
play a role in the inhibition, which warrants further investigation.  
 
 
1.9 Chemoattractant receptor-homologous molecule expressed on T 
helper 2 cells  
 
Chemoattractant receptor-homologous molecule expressed on T helper 2 cells 
(CRTH2) was first discovered by Nagata et al [287] in 1999 as a second receptor to 
Prostaglandin D2 (PGD2). Other names for CRTH2 include DP2, GPR44 and CD294. The 
human CRTH2 gene is located at chromosome 11q12, its transcript length is 2.9kb and 
it has two exons and one intron [288]. As a typical G Protein coupled receptor it has 
seven putative transmembrane domains [289], with two glycosylation sites at its N 
terminus, and a long cytoplasmic tail with multiple phosphorylation sites [287]. CRTH2 
is coupled to the Gi type G proteins enabling it to inhibit adenylate cyclase and thus 
decrease cAMP production. 
 
Distribution of CRTH2 expression 
 
CRTH2 is expressed on Th2 cells, eosinophils, basophils, monocytes and dendritic cells 
[289, 290]. The T cells that express CRTH2 secrete interleukins typical of Th2 cells; IL-4, 
IL-5, IL-13 [291]. These T cells include Th2 cells and Th2-type CD8+ T cells (Tc2). In 
cultured CD4+ T cells CRTH2 expression is increased by IL-4, and inhibited by the Th1 
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cytokine IL-12 [291, 292]. CRTH2 is not expressed on human Th1 cells, and this has led 
to CRTH2 becoming a cell differentiation marker of Th2 cells [291]. 
 
Studies of the expression of CRTH2 on non-immune cells are limited, probably due to 
the lack of antibodies available for detection using techniques other than FACS. 
Human bronchial epithelial cells express CRTH2 as demonstrated by FACS analysis by 
Chiba et al [293]. Other cell types reported to express CRTH2 include chondrocytes 
[294], osteoblasts [295] and keratinocytes [296]. Nagata et al have demonstrated 
CRTH2 mRNA in many human tissues; with high expression in heart, brain, stomach, 
small intestine, liver, thymus, and placenta and moderate expression in the colon, 
uterus, pancreas, prostate and peripheral blood leukocytes [287]. Although, it is 
possible that the expression demonstrated in these tissues is through the presence of 
infiltrating leukocytes.  
 
Function of CRTH2 
 
As alluded to by its name, upon stimulation CRTH2 leads to chemotaxis of leukocytes 
including Th2 cells, basophils and eosinophils [291, 297, 298] . Up regulation of cell 
adhesion molecules such as CD11b in eosinophils and basophils are likely to aid 
migration of the cells to target locations [298]. CRTH2 stimulation also leads to up 
regulation of CD40 in Th2 cells which is needed for T cell to B cell interaction, thus 
implying a functional role in aiding leukocyte effector response [287]. It is likely that 
CRTH2 plays a functional role in maintaining a Th2 cytokine bias since CRTH2 agonists 
result in a dose dependent increase in the production of IL-4, IL-5, IL-13 and IL-10 in 
cultured Th2 cells [217, 299]. CRTH2+ T cells are increased at the maternal fetal 
interface during pregnancy in women undergoing elective termination compared to 
women with recurrent miscarriage, suggesting a protective role of CRTH2 in the 
maintenance of pregnancy [300]. PGD2 production from the placenta is likely to be 
responsible for chemoattracting the CRTH2 positive cells and maintaining a pro-
pregnancy Th2 cytokine predominance at the maternal fetal interface [301].  
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CRTH2 agonists and their downstream effects 
 
Endogenous CRTH2 agonists include PGD2 and 15dPGJ2. In response to PGD2, CRTH2 
induces intracellular calcium mobilization and chemotaxis in Th2 cells, eosinophils and 
basophils in a Gα/i dependent manner [297].
 PGD2 induces cytokine production via the 
calcineurin and PI3K pathways as demonstrated by inhibition with calcineurin 
inhibitors and the PI3K inhibitor Wartmannin [302]. 15dPGJ2 induces calcium 
mobilisation, actin polymerisation and up regulation of CD11b eosinophils via CRTH2 
[303]. Up regulation of CD11b via CRTH2 may be mediated via Gq class proteins 
leading to activation of p38 MAP kinase and phosphoinositol-3-kinase (PI3K), as these 
responses are resistant to the pertussin toxin [304]. The non-steroidal anti-
inflammatory agent Indomethacin is also an agonist of CRTH2. Indomethacin induces 
Ca2+ mobilization and cell migration via CRTH2 in Th2 cells, which is sensitive to the 
pertussin toxin indicating a Gα/i dependent mechanism [305]. Indomethacin also 
induces Th2 cytokines in vitro [299]. The potential role of CRTH2 and CRTH2 agonists 
for the immuno-modulation during pregnancy has not previously been examined.  
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1.10 Summary and Aims  
 
Preterm labour and long-term neonatal morbidity is associated with infection and 
inflammation. NF-κB is a transcription factor that regulates both inflammatory and 
labour associated gene expression. Preterm labour is associated with a switch from a 
Th2 bias to a proinflammatory Th1 bias. Our group have previously shown that the 
CRTH2 agonist 15dPGJ2 inhibits NF-κB in cultured human amniocytes and myocytes, 
and delays inflammation induced preterm labour in the mouse.  
 
This study aims establish if a small molecule CRTH2 agonist can replicate the effects of 
15dPGJ2 with the potential of delaying preterm labour and reducing the adverse 
effects on the neonate which are associated with inflammation induced preterm 
labour.  
 
In this thesis the following questions will be answered:  
 
1. Is CRTH2 expressed in human amniocytes and myocytes? 
 
2. Does a small molecule CRTH2 agonist inhibit NF-κB?  
 
3. Do CRTH2 agonists modulate the Th1/Th2 cytokine profile in peripheral blood 
mononuclear cells in pregnancy and labour?  
 
4. Is uterine contractility inhibited by CRTH2 agonists? 
 
5. Can a small molecule CRTH2 agonist delay inflammation induced preterm labour?
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CHAPTER 2 
 
 
Materials and Methods  
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2.1 Materials 
2.1.1 Chemicals, Reagents and Solvents 
 
Acrylamide (Biorad) 
Acetic Acid (VWR) 
Agarose (VWR) 
Ampicillin (Sigma) 
Bovine Serum Albumin (Sigma) 
Brefeldin (Sigma) 
Ca Cl2 (Sigma) 
Chloroform (Sigma) 
Coomassie Brilliant Blue (Biorad) 
15-deoxy-Δ 12,14-Prostaglandin J2 (15dPGJ2) (Cayman Chemicals) 
DEPC treated water (Ambion) 
Dextran (Fluka) 
13, 14 dihydro 15 keto Prostaglandin D2 (Cayman Chemicals) 
Dimethyl Sulfoxide (DMSO) (Sigma) 
Ethanol (VWR) 
Ethylenediaminetetraacetic acid (EDTA)  
Ficoll Paque Plus (GE healthcare) 
Fugene Transfection reagent (Promega) 
GeneJuice Transfection reagent (Novagem) 
Glucose (Sigma) 
Glycerol (BDH Chemicals) 
Indomethacin (Sigma) 
Interleukin-1β (R&D systems) 
Ionomycin (Sigma) 
Isopropanol (Sigma) 
LPS 0111:B4 (Sigma) 
LPS 055:B5 (Sigma) 
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LPS 0128:B12 (Sigma) 
LPS 0127:B8 (Sigma) 
LPS Salmonella Smooth Form (Alexis) 
Methanol (VWR) 
MgCl2 (Sigma) 
NaCl2 (Sigma 
NP-Alternative (Calbiochem) 
Optilyse (Beckman Coulter) 
Paraformaldehyde (VWR) 
Phorbol 12 myristate 13 acetate (PMA) (Sigma) 
Prostaglandin D2 (Cayman Chemicals)  
Protein ladder (Promega) 
Pyl A and Pyl B (Oxygen Healthcare) 
Rat Serum (Sigma) 
Robosep (Stem Cell Technologies) 
Saponin (Sigma) 
SDS 20% (National Diagnostics) 
Skimmed Milk (Sigma) 
S.O.C Media (Invitrogen) 
Sodium Azide (BDH Chemicals) 
Sybr green (Applied Biosystems) 
Sybr safe DNA gel stain (Invitrogen) 
TEMED (Sigma) 
Tetraethyl ammonium chloride (Sigma) 
Tris (Sigma) 
Trypan Blue (Sigma) 
Tween 20 (BDH) 
Versalyse (Beckman Coulter) 
X481 (Glaxo Smith Kline) 
 
 
 
                                                                                     Chapter 2: Materials and Methods  
 
61 
 
2.1.2 Antibodies 
Primary Antibodies 
β-actin   Cat no. A 2228, Sigma 
CD4-APC Cat no. 551980, BD Pharminogen 
CD11b- PE Cat no. 555388, BD Pharminogen 
COX-2 (C-20) Cat no. 1745, Santa Cruz 
CRTH2-PE Cat no. A07413, Beckman Coulter 
CRTH2 Cat no. PR- 4029, ProScience 
CRTH2 Cat no. PR- 4027, ProScience 
CRTH2 Cat no. 23092, Santa Cruz 
CRTH2 Cat no. 2178, Santa Cruz 
p-65 Cat no 8008, Santa Cruz 
Phospho-p65 (Ser 536) Cat 3033s, Cell signalling 
CD49d-APC cat no 130-093-281, Miltenyi Biotec 
IFN-γ-FITC Cat No. 554700, BD Pharminogen 
IL-4- PECy7 Cat no. 500824, BioLegend 
TNF-α–FITC 
 
Secondary antibodies 
Anti Rabbit IgG HRP Cat no. 7074, Cell Signalling  
Anti Rat HRP Cat 61-9520, Invitrogen 
Donkey anti Goat-HRP Cat no. SC 2020 Santa Cruz 
Goat anti Mouse-HRP Cat no. SC 2005 Santa Cruz 
 
Isotype controls 
APC Mouse IgG1 κ isotype Control Cat no. 550854, BD Pharminogen 
APC mouse IgG2b isotype control Cat no. 130-092-217, Miltenyi Biotec 
FITC Mouse IgG1 κ isotype control Cat no. 554679, BD Pharminogen 
PE Rat IgG2a isotype control (matched to CRTH2-PE) Cat no. 731666 Beckman Coulter 
PE/Cy7 Rat IgG1 κ isotype control antibody Cat no. 400416, BioLegend 
PE Mouse IgG1 κ isotype control Cat 555749, BD Pharminogen 
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2.1.3 Cell culture materials 
Collagenase XI or IA (Sigma) 
Dispase (Gibco) 
Dulbecco’s Modified Eagles Medium (Sigma) 
Fetal calf serum (Sigma) 
L-glutamine (Sigma) 
Penicillin Streptomycin (Sigma) 
RPMI medium (Invitrogen) 
Trypsin/EDTA (Sigma) 
Plastic ware (from Appleton woods): T25 cell culture flask, 24 well plates cell strainer, 
filter unit, 50 and 15 ml falcons, conical flasks.  
2.1.4 Buffers 
Buffer A (Cytosolic) 
10 mM HEPES 
10 mM KCL 
0.1 mM EDTA 
0.1 mM EGTA 
2 mM DTT 
1% v/v NP-40 and Complete protease inhibitor (Roche) 
 
Buffer B (Nuclear) 
10 mM HEPES 
10 mM KCL 
0.1 mM EDTA 
0.1 mM EGTA 
2 mM DTT 
400 mM NaCl2 
1% v/v NP- 40 and Complete protease inhibitor (Roche) 
 
Whole cell lysis buffer 10X (Cell Signalling) 
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2.1.5 RNA and DNA synthesis  
DNAse Buffer 10x (Invitrogen) 
DNAse Grade 1 (Invitrogen) 
DNA ladder (Invitrogen and Bioline) 
DNA loading dye (Invitrogen) 
dNTP 10 mM (Invitrogen/Novogem) 
DTT 0.1mM (Invitrogen) 
EDTA 25 mM 
Oligo DT (Invitrogen) 
Primers (Thermo Scientific) 
Random Hexamer (Invitrogen) 
RNA later (Sigma) 
RNAse Out (Invitrogen) 
Solution Q 5x (Qiagen) 
Superscript III (Invitrogen) 
Taq Pol (Qiagen) 
Trizol (Invitrogen) 
Qiagen PCR buffer 10x (Qiagen) 
 
2.1.6 Cloning, sequencing, transfection and in vitro transcription translation  
AMAXA Basic Nucleofector Smooth Muscle Cell Kit (Lonza) 
AMAXA Basic Nucleofector Primary Mammalian Epithelial Cell kit (Lonza) 
DNA Maxiprep/Miniprep kit (Qiagen) 
Endonuclease (New England Biolabs) 
Escherichia coli TOP 10 (Invitrogen) 
Geneclean Column kit (Qiagen) 
Geneclean Spin Kit (Qbiogene)  
Gen Elute Gel Extraction Kit (Qiagen) 
Methionine 1mM/35S (Perkin Elmer), 
pSG5 Vector (Agilent Technologies) 
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pCR® -BluntII-TOPO® (Invitrogen)  
T4 DNA ligase (Invitrogen) 
T7 TNT Coupled Reticulocyte Lysate System (Promega) 
TOPO cloning kit (Invitrogen) 
 
2.1.7 Western and ELISA  
High Performance chemiluminescence film (GE healthcare) 
Laemelli buffer x4 
0.2 M Tris pH 6.8 
8% SDS 
40% Glycerol 
0.4M DTT 
0.4% Bromophenol Blue 
 
Polyacrylamide 10% Resolving gel 
10% Acrylamide 
Tris HCl pH 8.8 
0.1% SDS 
0.1% Ammonium Persulfate 
0.04% TEMED 
 
Polyacrylamide 5% Stacking gel 
5% Acrylamide 
Tris HCl pH 6.8 
1% SDS 
1% Ammonium Persulfate 
0.1% TEMED 
 
Phosphate Buffered Saline (PBS) (In house) 
PVDF membrane (Millipore) 
Running Buffer 1x SDS (In house) 
1x TBS (In house) 
1x TBS-T (In house) 
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Transfer Buffer 
100 mls TB buffer 10x 
200 mls Methanol 
700 mls Distilled Water 
3.75 mls 10% SDS  
 
TH1/Th2 Multiplex ELISA kit, Meso scale Discovery 
 
2.1.8 Contractility  
Gas 95% 02 5% CO2, BOC 
 
Krebs henseleit buffer pH 7.4 
Glucose 2.0g/L 
MgSO4 0.141g/L 
KH2PO4 0.16g/L  
KCl 0.35 g/L 
NaCl2 6.9g/L 
CaCl2 0.373g/L 
NaHO3 2.1g/L 
  
Muscle Strip Myograph 800MS, DMT 
Powerlab software, ADInstruments 
 
2.1.9 Murine study  
 
Morphine 
Isofluorane 
CD1 Outbred Mice (Charles River) 
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2.2 Primary Cell culture 
2.2.1 Amnion epithelial cells (Human) 
Amnion was collected from women on the Labour ward at Queen Charlotte’s hospital 
in accordance with the Ethical approval Ref 2002/6283. Pre-labour amnion was taken 
from women undergoing elective caesarean section at term.  
 
Amnion was separated from the choriodecidua, cut into strips and washed in 
phosphate buffered saline (PBS). It was then incubated in 0.5 mM of EDTA-PBS for 15 
minutes at room temperature, followed by a PBS rinse. The intracellular matrix was 
digested in pre-warmed dispase at 2g/L in PBS for 45 minutes at 37°C. The epithelial 
cells were then isolated by shaking the amnion strips vigorously in Dulbecco’s modified 
Eagle’s medium, DMEM for 3 minutes, then pelleted by centrifugation for 10 minutes 
at 2000rpm. Cells were resuspended in DMEM containing 10% fetal calf serum, 2 
mM/L L-glutamine, 100U/ml Penicillin and 100 μg/ml of Streptomycin and grown to 
confluence in T25 flasks at 5% CO2. 
 
2.2.2 Myometrial Smooth Muscle cells (Human) 
Myometrial biopsies were collected from women on the Labour ward at Queen 
Charlotte’s hospital in accordance with Ethical approval (Ref 3358). Pre-labour 
myometrium was collected at time of elective caesarean section.  
 
Myometrial biopsies were taken from the upper margin of lower segment incisions 
during elective caesarean sections. Tissue was washed in PBS, and mechanically 
dissected with two sterile blades to form a paste-like texture. Cells were isolated by 
incubating with 15 mg of Collagenase 1A, 15 mg of Collagenase X and 50 mg of BSA in 
30 mls of PBS for 45 mins at 37°C. The suspension was filtered through a cell strainer 
and centrifuged at 400 g for 5 minutes. The cells were resuspended and cultured in 
DMEM as described in above. 
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2.2.3 Peripheral Blood Mononuclear cells (Human) 
Blood from pregnant and non-pregnant women was collected in accordance with the 
South East London Ethics approval Ref: 10/H0805/54. 4mls of blood was collected in 
sodium citrate vacutainers. Two methods were used for leukocyte isolation, 
depending on the leukocyte fraction of interest. For isolating granulocytes, dextran 
was used, and for isolating lymphocytes Ficoll was used.  
 
a) Dextran  
The white cell fraction was isolated by incubating 4 mls of blood with 4mls of 4.5% 
Dextran (Fluka Analytical) in PBS for 45 minutes at 4°C. The leukocyte fraction was 
centrifuged at 500g for 10minutes, and the pellet was resuspended in PBS. 
 
b) Ficoll 
For lymphocyte isolation, 4 mls of blood was mixed with 4 mls of PBS. 4 mls of 
blood/PBS was layered over 3 mls of Ficoll (GE healthcare), and centrifuged at RT for 
40mins at 400g. The supernatant was  discarded and the Lymphocyte halo was washed 
in PBS and resuspended in RPMI 1604 medium with 10% fetal calf serum and 2 mM/L 
L-glutamine, 100U/ml Penicillin and 100 μg/ml of Streptomycin and plated in 24-well 
plates.  
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2.3 Protein extraction 
2.3.1 Whole cell lysate preparation 
Adherent cultured cells (amniocytes and myocytes) were collected using a cell scraper 
and placed in whole cell lysis buffer (Cell Signalling) with 5 µl/ml of protease inhibitor 
(Sigma). Cells were incubated on ice for 20 minutes and centrifuged at 13,000rpm for 
10 minutes at 4°C. Whole cell lysates from tissue were prepared by homogenising in 
lysis buffer, centrifugation and collection of supernatant. Leukocytes were collected 
using a 1ml pipette and incubated on ice in lysis buffer for 5 minutes and centrifuged 
for 20 minutes at 13,000rpm at 4°C. The supernatant was stored at -80°C until use.  
 
2.3.2 Nuclear and Cytosolic protein extraction 
Cells were collected as described in 2.2.1 and lysed in Buffer A (10 mM HEPES, 10 mM 
KCL, 0.1 mM EGTA, 0.1 mM EDTA, 1mM DTT, 1%(v) NP-40 with protease inhibitor), 
with the cytosolic fraction collected following centrifugation at 13,000rpm for 60s at 
4°C. The pellet was then resuspended in Buffer B (10 mM HEPES, 10 mM KCL, 0.1 mM 
EGTA, 0.1 mM EDTA, 2MM DTT, 400 mM NaCl2 and 1% v/v NP-40 and protease 
inhibitors), incubated on a shaker for 15 minutes at 4°C, and then centrifuged at 
13,000 rpm for 5 minutes at 4°C . The supernatants were stored at -80°C until analysis. 
 
2.3.3 MSD protein extraction buffer for Multispot Elisa  
Murine brain and myometrium was collected and snap frozen on dry ice and stored at 
-80 until use. For protein extraction, tissue was grinded with a pestle and mortar in 
liquid nitrogen and homogenised in MSD lysis buffer (150mM NaCl2, 20mM Tris pH 7.5, 
1mM EDTA, 1mM EGTA, 1% Triton X-100, with Phosphatase Inhibitor (Sigma) and 
Protease inhibitor (Roche)).  
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2.3.4 Protein quantification 
Protein quantification was performed using the BIORAD assay, measuring absorbance 
at 655 nm.  
 
2.4 RNA extraction 
Total RNA was isolated from tissue, primary cell cultures and Peripheral blood 
mononuclear cells using Trizol© according to the manufacturer’s instructions. Briefly, 
tissue was washed in PBS and homogenised using the power homogeniser in 1ml of 
Trizol© per 100 mg of tissue. For primary cell cultures 1 ml of Trizol© was added to 
each T25 flask or 200ul per well of a 6 well plate and cells were collected using a cell 
scraper. Prior to RNA extraction from white blood cells, the white cell fraction was 
prepared from blood by incubation with 4.5% Dextran in PBS for 45 minutes at 4°C. 
This fraction was then centrifuged for 10 minutes at 200g and the resulting pellet was 
resuspended in 1 ml of Trizol© per 1 ml of white cell fraction. 
 
 
2.5 cDNA synthesis 
RNA was treated with DNase to remove contaminating DNA. 1 μg of RNA was 
incubated with 1 μl DNase and 1 μl of DNase buffer made up to 10 μl volume with 
DEPC treated water for 15 minutes at room temperature. The reaction was terminated 
by the addition of 1 µl of 25mM EDTA for 10 minutes at 65°C. 8 µl of the DNAse 
treated mix was incubated with 1 µl of 10 mM dNTP and 1 µl of Oligo DT (12-18 
0.5ug/ml) for 5 minutes at 65°C.  To this mix 2 µl of 10x RT buffer, 4 µl of 25 mM 
MgCl2, 2 µl of 0.1m DTT, 1 µl of RNAse Out and 1µl of Superscript III was added.  (In 
the reverse transcriptase controls no Superscript III was added). The mix was 
incubated at 42°C for 10 minutes and the reaction was terminated at 70°C for 15 
minutes. 0.5 µl of RNAse H was added and mix was incubated at 37°C for 20 minutes. 
Samples were stored at -20°c until further use. 
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2.6 Polymerase Chain Reaction (PCR) 
 
PCR is used to amplify specific DNA sequences from a small amount of template and 
provides information on gene expression as it amplifies cDNA reverse transcribed from 
messenger RNA. Paired oligonucleotide primers for amplification of genes of interest 
were either designed by Primer 3 software or were based on publications. Primers 
were checked against sequences of the genes of interest using GenBank sequences. 
The primer sets produced amplicons where the intron/exon boundary was crossed 
wherever possible. Non-template reverse transcriptase controls were used. 
 
2.6.1 Reverse Transcriptase Polymerase Chain Reaction 
 
The PCR programmes varied depending on the primers and the gene of interest. All 
reactions included a denaturing step to denature the primers and DNA template. 
Cooling then allowed for annealing of the primers to the target sequence. The DNA 
polymerase (Taq Po or PFU Turbo) extends the primers at the 3 prime end.  Repeated 
cycling results in exponential production of the target sequence.  
 
For detection of human CRTH2 in Amniocytes, Amnion, Myocytes, Myometrial, 
Choriodecidual and Placental tissue a 309bp CRTH2 transcript was amplified using PCR 
mix A, PCR program A, and Primers A, Tables 1-3. In preparation for cloning human 
CRTH2 white blood cell cDNA was used and a 1.188kb transcript was amplified using 
PCR mix C, Program C, and Primers C, Tables 1-3. 
A 344bp CRTH2 transcript was amplified from murine myometrial tissue cDNA using 
PCR mix A, Primers E, with the following programme: 94°C for 3 minutes, and 34 cycles 
of 94°C for 1 minute to denature, 63°C for 1 minute to anneal, and 72°C for 3 minutes 
to extend, followed by a 10 minute holding step at 72 °C.  (See Tables 1-4) 
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2.6.2 Quantitative Polymerase Chain Reaction 
 
Quantitative PCR was performed with SYBR Green PCR mix. The cycle at which the 
fluorescence reaches a preset cycle threshold (non-template control threshold) was 
used for quantification. The ΔΔCT method was used for comparative analysis, with 
data normalised relative to two endogenous housekeeping genes, B actin and L19 or 
GAPDH to serve as endogenous controls.   
 
For quantification of human amniocyte and myocyte CRTH2 a 114bp transcript was 
amplified using PCR mix B, TAQMAN program B, and Primers B, Tables 1-3. Myometrial 
murine tissue was used to quantify the Th1 and Th2 cytokines using PCR mix B, 
TAQMAN program B and the relevant primers in Table 4. 
 
2.6.3 Agarose gel electrophoresis 
 
PCR products were detected using 1-1.5% Agarose gels to confirm product sizes. 
Agarose was microwaved in 1x TBE buffer until dissolved. On cooling 1:10000 Sybr 
Safe gel stain was added, and the gel was allowed to set.   Once set the PCR product 
was diluted with 6x loading buffer and loaded onto the gel. The gel electrophoresed at 
100 V for 20-40 minutes. The gel was transilluminated and photographed under UV 
light. 
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Table 1 PCR Mix 
 
PCR  Mix A B C 
Enzyme Taq Po 0.5 µl Sybergreen 12.5ul PFU turbo 0.5 µl 
CRTH2 Forward 
Primer 
0.5 µl (3.2 pmol 
stock) 
0.06 µl (20um stock) 0.5 µl (3.2 pmol 
stock) 
CRTH2 Reverse 
Primer 
0.5 µl (3.2 pmol 
stock) 
0.06 µl (20um stock) 0.5 µl (3.2 pmol 
stock) 
cDNA 2 µl (600ng/ µl) 1 µl 1 µl 
Water 17 µl 11.38 µl 11 µl 
Buffer 2.5 µl X10 Qiagen 
buffer 
n/a 2.5 µl 10% buffer 
PFU 
dNTP mix (2mM 
Novagem) 
2.5 µl n/a 2.5 µl 
5x Solution Q 5 µl n/a 5 µl 
25mM MgCl2 1.5 µl n/a 1.5 µl 
Volume of mix 25 µl 25 µl 25 µl 
 
Table 2 PCR Program 
 
Program A B C 
Polymerase 
activation 
95°C  3 min 50°C 2 min 95°C 3min 
Denature 94°C 1 min 95°C 10 min 94°C 1 min 
Anneal 67°C for 1 min 95°C 15s 75°C 1 min 
Extend 72°C for 2 mins 60°C 1min 72°C 2 min 
Hold 72°C for 10mins Hold 72°C 10min 
Cycles 35 40 36 
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Table 3 Primers (Human) 
 
  Forward Reverse (Anti sense) Size 
A CRTH2 CCTCTGTGCCCAGAGCCCCACGATGTCGGC CACGGCCAAGAAGTAGGTGAAGAAG 309bp 
B CRTH2 CCTCTGTGCCCAGAGCCCCACGATGTCGGC ATGTAGCGGATGCTGGTGTTG 114bp 
C CRTH2 GGC ACTCACACGCGAAAGTAT ACCAGGGTGCCGCGGTTC 209bp 
D CRTH2 CTGCCCTTCTTCACCTACTTCTTGGC GTGTCCCGGAACACGAAATAGGGCAC 265bp 
E CRTH2 GGATCCATGTCGGCCAACGCCACACTGAAGCC 
BamH I site 
AGATCTCTAACTCGAGGTGCTGCTCAGCGCCC 
Bgl II site 
1188bp 
F CRTH2 T7 TAATACGACTCACTATAGG 
For CRTH2 insert TCACCAGCCTGGCCTTCTTC 
SG5 GAAATTTGTGATGCTATTGC 
CRTH2 insert TGCAGTTTGCAGAAGGTGGTG 
n/a 
G GAPDH TGATGACATCAAGAAGGTGGTGAAG TCCTTGGAGGCCATGTAGGCCAT 240bp 
 
 
Table 4 Primers (Murine) 
 
  Forward Reverse  Size 
H M CRTH2 CGTAGCCGTGAGCCTGCGACTG GGCGATTGCGGAGCCCACCACT 344bp 
I M IFN γ AGCGGCTGACTGAACTCAGATTGTAG GTGTAGTCAGTTTTCAGCTGTATAGG 252bp 
J M TNF α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 175bp 
K M IL-10 ACCTGGTAGAAGTGATGCCCCAGGCA ACCTGGTAGAAGTGATGCCCCAGGCA 237bp 
L M IL-4 CGAAGAACACCACAGAGAGTGAGCT GACTCATTCATGGTGCAGCTTATCG 181 bp 
M M B Actin AGGCTGTGCTGTCCCTGTAT GCTGTGGTGGTGAAGCTGT 201 bp 
N M GAPDH CTCCACTCACGGCAAATTC TCTCCATGGTGGTGAAGACA 170bp 
O M L-19 GAAAAAGAAGGTCTGGTTGGA TGATCTGCTGACGGGAGTTG 72 bp 
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2.7 Cloning and sequencing of CRTH2 
 
In order to achieve a good positive control for determining the presence of CRTH2 at 
the protein level I cloned CRTH2. Human peripheral leukocytes were used to extract 
mRNA and to reverse transcribe to cDNA in order to amplify the whole length of 
CRTH2 for cloning.  
 
2.7.1 cDNA synthesis 
 
Peripheral blood leukocytes were isolated using Dextran 4.5% and mRNA was 
extracted with Trizol© as described in section 2.4. 1µg of DNAse treated RNA was 
incubated with 1 µl of 10 mM dNTP and 3 µl of Random hexamer for 5 minutes at 
65°C.  To this mix 1µl of 10x RT buffer, 4 µl of 25 mM MgCl2, 2 µl of 0.1mDTT, 1 µl of 
RNAse Out and 1 µl of Superscript III was added. The mix was incubated at 25°C for 10 
minutes 50°C for 50 minutes and 85°C for 5 minutes. The mix was chilled on ice and 1 
µl of RNAse H was added and incubated at 37°C for 20 minutes. 
 
2.7.2 CRTH2 amplification 
A 1.18kb transcript was amplified from white cell cDNA with primers from Table 3 (C). 
The reaction mix was as described in Table 1 (C). The reaction protocol was as 
described in Table 2 (C).  The primers introduced a BamH 1 digest sequence upstream 
of the CRTH2 coding sequence and a Bgl II restriction digest sequence downstream. 
The fragment was then separated on a 1% Agarose DNA gel.  
 
2.7.3 Purification of DNA from agarose gel 
The whole length of CRTH2 was cut out of the gel under UV light vision and the Gene 
Clean Spin Kit was used according the manufacturer’s instructions. The gel was melted 
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in 400 µl of GC SPIN GLASSMILK in the Geneclean spin filter at 55°C for 5 minutes. The 
liquid was spun at 12,000g into a catch tube.  The filter was washed with 500 µl of GC 
SPIN NEW Wash, and spun for 30 seconds, a repeat wash step was performed and 
then a repeat spin for 1 minute was performed to dry the DNA pellet.  The DNA was 
eluted with 50 µl of GC SPIN Elution Solution, and the spin filter was transferred to a 
fresh catch tube and spun for 30 seconds at 12,000 x g to collect the eluted DNA. 
 
2.7.4 Cloning into intermediate vector; pCR® -BluntII-TOPO® 
 
The PCR product (gel elute) was cloned into a TOPO Vector according to 
manufacturer’s instructions. Briefly, ligation was performed with 1 µl of PCR product, 1 
µl of TOPO salt solution, 3 µl of Nuclease free water H20 and 1 µl of TOPO–II vector for 
30 minutes at room temperature. Top10 E.coli cells were transformed with 1 µl of 
cloning reaction by heat shock at 42°C for 45 seconds and cooled on ice for 2 minutes. 
150 µl of S.O.C medium was added to the transformed cells and incubated at 37 °C for 
1 hour, and then plated onto ampicillin plates and incubated overnight at 37°C. 
Colonies were then selected the next day and 3mls of L-Medium was inoculated and 
incubated overnight at 37°C on a shaker set at 200rpm. The next day the medium was 
centrifuged at 3800rpm at 4°C and the DNA pellet was isolated using the QIAprep 
Miniprep Spin Kit. Briefly the pellet was resuspended in 250 µl of Buffer P1, 250 µl of 
Buffer P2, 350 µl of Buffer N3 and centrifuged at 13000 rpm for 10 minutes.  The 
supernatant was transferred to the Miniprep spin column and centrifuged for 15 
seconds. The column was washed with Buffer PE and centrifuged dry. DNA was eluted 
with 50 µl of dH20 and quantified by Nanodrop.  
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The plasmid was digested at the BamH 1 and Bgl II sites using 2 µl of Buffer 3 (New 
England Biolabs), 0.5 µl BSA, BamH 1 and Bgl II digestion enzymes and 2 µg of Plasmid 
DNA for 90 minutes at 37 °C.  The products were then run on a 1% DNA Agarose gel, 
cut and purified using the Geneclean kit for insertion into the pSG5 vector. The map of 
the pCR Blunt TOPO is shown in Figure 2.1 showing the insertion point of the PCR 
product. 
 
2.7.5 Cloning into the pSG5 Vector 
 
Ligation was performed with 1 µl of T4 ligation enzyme, 2 µl of T4 buffer, 1 µl of pSG5 
vector, 1.5 µl of insert, and 4.5 µl of water overnight at 16°C.  E.coli Top 10 competent 
cells were transformed as above. Colonies were grown overnight on ampicillin plates 
at 37°C, all colonies were picked and L medium was inoculated and incubated 
overnight at 37°C.  All colonies were purified using the QuickLyse Miniprep kit. Plasmid 
DNA for each colony was digested at the BamH 1 and Bgl II sites, as shown in Figure 
2.2, and run out on a 1% Agarose gel to confirm product insertion and the correct size 
of product. 8 colonies of 24 were selected based on correct size of product insertion to 
transform and place into the pSG5 vector, plated out, and isolated again with the 
QIAprep Miniprep spin kit for good quality DNA. Plates were stored at 4°C. Plasmids 
were digested the insert purified for sequencing.  
Figure 2.1 Map of the pCR Blunt Topo 
Vector 
This map shows insertion and ligation 
sites from the Invitrogen data sheet. 
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2.7.6 DNA sequencing 
 
Sequencing of the plasmid DNA was performed by the MRC Clinical Sciences Centre at 
Imperial College. The sequencing reaction contained the 1 μl of T7 Forward or pSG5 
Reverse primer with 600ng of DNA in a 10 μl volume. See Table 3 for primers 
sequence.  
 
2.7.7 Plasmid DNA preparation for transfection  
 
Once sequences were confirmed to be correct and inserted in the correct orientation, 
the stored plates with the colonies of transformed cells were re-picked, and 5mls of 
LB-Broth was inoculated and incubated at 37°C on the shaker at 200rpm for 8 hours. 
1ml of the LB- Broth starter culture was placed into 250mls of LB-Broth on the shaker 
overnight ay 37°C. The following day the medium was transferred into a conical 
centrifuge tube and centrifuged for 20 minutes at 3600 rpm at 4°C. The supernatant 
was discarded and the bacterial pellet was purified with the QIAprep Maxiprep kit. 
10mls of Buffer P1 and 10mls of Buffer P2 were added and incubated for 5 minutes at 
Figure 2.2  Map of the pSG5 Vector 
This map shows insertion and ligation sites. 
From the Agilent Technologies data sheet 
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room temperature. 10mls of Buffer P3 was added and incubated for 10minutes in a 
filter cartridge. The lysate passed through the cartridge into a HiSpeed Maxi tip and 
entered a resin and was then washed with 60mls of Buffer QC. 15mls of Buffer QC was 
used to collect the DNA elutant which was then precipitated with Isopropanol. The 
elutant was passed though the QIAprecipitator and was dried with flushing of air. 
1.5mls of Buffer TE was passed through the precipitator to collect the DNA into a 
microcentrifuge tube.  
 
2.8 Transfection of CRTH2 
 
Myocytes 
 
Myometrial smooth muscle cells were cultured in six well plates until they reached 90-
95% confluence. The AMAXA Basic Nucleofector Smooth Muscle Cell Kit was used to 
transfect the cells. GFP was used as a positive control for the transfection efficiency. 
On the day of transfection cells were Trypsinised and centrifuged at 100 x g for 10 
mins at room temperature. Approximately 1x10 6 cells were then resuspended in 100 
μl of the Nucleofector solution with either 2μg of CRTH2 expression vector or 2 μg of 
GFP. The cell suspension was transferred into the cuvette and placed into the 
Nucleofector Program and electroporated on Program A-033. 500 μl of prewarmed 
medium was added and cells were gently plated into fresh six well plates.  Cells were 
incubated at 37 °C in humidified 5% CO2. Medium was changed 18 hours post 
transfection. Gene expression of GFP was determined by fluorescent microscope on 
day 1, day 2 and day 3-post transfection. Gene expression of CRTH2 was determined 
by Flow cytometry on day 1, day 2 and day 3.  
 
Amniocytes 
 
For transfection of CRTH2 into amniocytes; primary amnion epithelial cells were 
cultured until 80% confluence. GeneJuice® (Novogem) or Fugene (Promega) 
transfection reagent was used according to manufacturer’s guidance with 1 µg of DNA 
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per well. Cells were grown in 6 well plates and at the time of confluence the 
transfection reagent was added to the wells together with 1μg of CRTH2 expression 
vector. Cells were harvested for analysis after 24 hours. GFP was used as a positive 
control for the transfection efficiency. 
 
2.9 In vitro transcription translation 
 
CRTH2 expression in a cell free system was examined with the T7 TNT Coupled 
Reticulocyte Lysate System. This was in order to produce high quantities of CRTH2, and 
to demonstrate CRTH2 at the protein level without the need for antibodies. The TNT 
mix and cold Methionine 1mM were incubated with 0.2 μg of the CRTH2 expression 
vector 30°C for 90 minutes.  The product underwent gel electrophoresis and western 
blotting as described in section 2.10.  The membrane was probed with antibodies 1, 2 
and 3 from Table 5 and detection was with chemilluminescent substrate of 
horseradish peroxidase. In order to demonstrate CRTH2 without the use of antibodies 
cold Methionine was substituted with radioactive 35S Methionine. The product 
underwent gel electrophoresis and was transferred onto a membrane. Detection was 
by x-ray film.  
 
2.10 Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel 
electrophoresis and Western blotting  
 
2.10.1 SDS polyacrylamide gel electrophoresis 
 
The SDS polyacrylamide gel was prepared as the stacking gel and then the resolving 
gel. TEMED and Ammonium persulphate polymerise both stacking and resolving gels. 
Once the stacking gel was set, the resolving gel was layered on top, and the 10 well 
comb added. As the gel was setting, protein was denatured at 100°C with 4x loading 
dye for 5 minutes. Once set, the gels were mounted in the BIORAD tanks and combs 
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were removed and wells were rinsed with running buffer prior to loading protein. 
Protein ladder and protein of interest were loaded and gels electrophoresed in 1x SDS 
Running buffer at 100V until passage into the stacking gel, and then 140V until the dye 
front had migrated to the bottom of the gel.  
 
2.10.2 Western blotting 
 
PVDF membrane was activated with methanol for 1 minute and distilled water for 3 
minutes prior to transfer. Resolved gels were allowed to equilibrate in Transfer buffer 
prior to transfer. The BIORAD wet transfer technique was used. The layers consisted of 
(from bottom to top): sponge; two layers of Whatman paper; the gel; the membrane; 
two layers of Whatman paper and sponge. 
 
The sandwiched unit was then enclosed in the BIORAD transfer tank with the 
membrane towards the anode and the gel towards the cathode. Transfer was for 90 
minutes at 100V at 4°C. Following transfer, the membrane was re-activated in 
methanol for 1 minute and distilled water for 3 minutes. The membrane was then 
blocked in 5% milk in 1x TBS-T for 1 hour. Primary antibodies were used at varying 
concentrations and incubated at varying times. (See Table 5) After primary and 
secondary antibody incubations membranes were washed in 1x TBS-T for 10, 10 and 
10 minutes. Detection was achieved using chemilluminescent substrate of horseradish 
peroxidase. 
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Table 5 Antibodies 
 
Primary 
Antibody 
Catalogue 
No 
Dilution Incubation Secondary Antibody  1 
hour at room temp 
1 CRTH2 goat Sc- 23092 1:200 TBS 
1% milk 
Overnight, 
4°C 
1:2000 TBS 1% milk 
donkey anti goat 
2 CRTH2 rat Sc-21798 1:500 TBS 
1% milk 
Overnight, 
4°C 
1:3000 TBS 1% milk goat 
anti rat 
3 CRTH2 rabbit PR-4029 1:500 TBS 
1% milk 
Overnight, 
4°C 
1:2000 TBS 1% milk 
mouse anti rabbit 
4 CRTH2 rabbit PR-4027 1:500 TBS 
1% milk 
Overnight, 
4°C 
1:2000 TBS 1% milk 
mouse anti rabbit 
5 P65 mouse SC8008 1:1000 
TBS 1% 
milk 
1 hour Room 
temp 
1:2000 TBS 1% milk goat 
anti mouse 
6 Phospho-p65 
rabbit 
3031S 1:1000 in 
TBS 
Overnight, 
4°C 
1:2000 TBS 1% milk  anti 
rabbit 
7 Progesterone  
mouse 
N/a 1:1000 
TBS 1% 
milk 
Overnight, 
4°C 
1: 2000  TBS  1% milk goat 
anti mouse 
 
 
2.10.3 Protein Sequencing 
 
Whole cell lysates were prepared from positive controls (human heart and white cells), 
amnion and myometrial samples, and underwent electrophoresis. Membranes were 
stained with Coomassie blue (BIORAD) and bands cut at relevant sizes according to 
ladder and corresponding western blots. Membranes and bands were sent to 
Cambridge University Department of Biochemistry for N terminal sequencing using the 
Edman technique, carried out by Cambridge University Department of Biochemistry. 
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2.11 Flow cytometry 
2.11.1 Cell surface staining (CD11b and CD49D) 
Blood was collected from non-pregnant patients in vacutainers containing the 
anticoagulant citrate. The white cell fraction was isolated by incubating with 4.5% 
Dextran for 45 minutes at 4°C. Following centrifugation of the fraction the cells were 
resuspended with PBS containing CaCl2 (0.9mM) and MgCl2 (0.5mM) and counted. 
Cells were then pre-incubated at 37°C, followed by treatment with the CRTH2 agonists 
at 0.1 µm, 1 µm and 10 µm for 15 minutes. The reaction was terminated by the 
addition of 1 ml of ice cold FACSFlow. In experiments with the CRTH2 antagonist, pre 
incubation with x481 was performed for 10 minutes at 37°C. The cells were then 
centrifuged at 400g for 5 minutes at 4°C and resuspended in Robosep for labelling with 
PE anti-CD11b and APC anti-CD49D for 10 minutes at 4°C in the dark. The red cells 
were then lysed by the addition of Optilyse-C for 10 minutes in the dark at room 
temperature. Cells were then washed and resuspended in PBS and 1% FBS for analysis. 
Eosinophils and basophils were identified as CD49D positive and by high side and 
forward scatter, as shown in Figure 2.3. Flow cytometry settings were as follows: 
Forward scatter E0 Voltage, 1.00 Amp gain Lin, and Side scatter of 329 Voltage, 1.00 
Amp gain Lin. 
 
 
Figure 2.3  Forward and Side scatter profile of Peripheral Blood cells isolated using Dextran  
Granulocytes have the highest forward and side scatter. Lymphocytes have a lower forward 
and side scatter than granulocytes and monocytes. Monocytes have a high forward scatter but 
low side scatter 
Granulocyte population 
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2.11.2 Cell surface staining (CRTH2 and CD4) 
Blood was collected in vacutainers containing the anticoagulant citrate and diluted 1:1 
in PBS. 4mls of blood/PBS was carefully layered over 4 mls of Ficoll-PaqueTM PLUS and 
centrifuged at 400 x g for 40 minutes at room temperature. The peripheral blood 
mononuclear cells formed a halo and was collected gently and washed twice in PBS. 
During the second wash, 10ul of the PBMC suspension was added to 10ul of Trypan 
Blue for a cell count with the Neubauer haemocytometer.  
 
The PBMC pellet was resuspended to obtain roughly 3.5 x 106 per eppendorph in 30ul 
of staining buffer (1% Fetal Calf Serum, 0.09% Sodium Azide in PBS). 20ul of CRTH2-PE 
and 3ul of CD4-APC was added and cells were incubated for 1 hour at 37°C. 3ul of 
Mouse IgG1 κ –APC and 1ul of Rat IgG2a- PE Isotype controls were added to relevant 
tubes. Cells were washed and resuspended in PBS for analysis. Flow cytometry settings 
were as follows: Forward scatter E0 Voltage, 1.00 Amp gain Lin, and Side scatter of 329 
Voltage, 1.00 Amp gain Lin. 50,000 cells were counted and gating was on lymphocytes 
based on the forward and side scatter. Lymphocytes were identified according to 
forward and side scatter, as shown in Figure 2.4.  
 
 
Figure 2.4  Forward and Side scatter profile of Peripheral Blood cells isolated using Ficoll 
Paque. Lymphocytes are the most abundant leukocytes isolated with this technique.  
 
 
Lymphocyte population 
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2.11.3 Cell surface staining of Amniocytes and Myocytes 
Amniocytes 
Amnion epithelial cells were prepared as described in section 2.2.1. Cell surface 
staining with the CRTH2-PE antibody was performed on cells before culturing and on 
day 1 of culture. Cultured cells were trypsinised and washed and resuspended in 
Robosep for staining. Cells were incubated with either 20 µl of CRTH2-PE or Isotype 
control 1 hour at 37 oC. The following settings were used for analysis: Forward Scatter 
E1; Voltage 4.77; Amp gain Lin; Side scatter of 320; Voltage 1.00; Amp gain Lin; FL2 347 
log.  A discrete population of amniocytes is shown in Figure 2.5. 
 
Myocytes 
Myometrial smooth muscle cells were prepared as described in section 2.2.2. Cells 
were grown to 100% confluence and harvested by trypsinisation. Cells were washed 
and resuspended in PBS with 2% FCS for staining. Cells were incubated with 20 µl of 
CRTH2-PE or isotype control for 1 hour at 37oC. Cells were washed with PBS and 
resuspended in 250 µl of PBS for analysis. The following settings were used for 
analysis: Forward Scatter E1; Voltage 4.37; Amp gain Lin; Side scatter of 197; Voltage 
log; FL2 350 log. Two discrete populations of myocytes are shown in Figure 2.6, which 
is likely to reflect the different spindle and more rounded cells, or the different 
responses seen to trypsinisation.  
 
Figure 2.5 Forward and Side scatter profile of 
amniocytes 
A discrete population of amniocytes are seen. 
Figure 2.6  Forward and side scatter profile of 
myocytes The discrete population of myocytes are 
gated in Region 1. Myocytes appear as two 
populations, one is likely to reflect the spindle shaped 
myocytes and the other is likely to represent the more 
rounded myocytes.  
It is also possible that these populations may reflect 
the recovery of the shape of the myocytes post 
trypsinisation.  
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2.11.4 Intracellular interleukin staining of PBMCs (IL-4, IFN-γ, TNF-α)  
 
The PBMCs were isolated as described earlier. The pellet was then resuspended in 
11ml of pre-warmed at 37oC RPMI-1640 medium with 10% FCS and 
Penicillin/Streptomycin. 1ml was plated per well of a 24 well plate and incubated 
overnight at 37oC in 5% CO2 and 21 % O2. 18 hours after collection 10 µg of Brefeldin A 
was added to each well to plug the interleukins in the Golgi Apparatus. For Interleukin 
4 analysis 0.5 ul of Phorbol myristate acetate (PMA) to make (50ng/ml) and 1ul of 
Ionomycin to make (0.5µg/ml) were added to the appropriate wells for 5 hours of 
stimulation. For IFN-γ and TNF-α analysis 4 hours of PMA and Ionomycin stimulation 
was performed at the same concentrations as for Interleukin 4 analysis. PMA is a 
protein kinase C activator and Ionomycin is a Ca2+ ionophore and are standard in vitro 
stimuli of T cell cytokines and are used to reflect the responsiveness of T cells in vivo. 
Pre incubation with CRTH2 agonists or vehicle prior to stimulation was at 6 hours prior 
to harvest at the time of addition of Brefeldin A. 
 
Prior to intracellular staining, cell surface staining was performed as described above.  
Directly after the wash step post cell surface staining cells were resuspended in 250µl 
of 2% paraformaldehyde (PFA) and incubated at 37 oC for 15minutes in the dark to fix 
the cell surface antibodies to their receptors. Cells were centrifuged at 1000xg at room 
temperature for 10 minutes and resuspended in 500 µl of 0.5% Saponin and incubated 
for 30 minutes on ice in the dark to permeabilize the cells. After incubation, cells were 
centrifuged at 1000 x g for 10 minutes and resuspended in 0.5% Saponin to make up a 
volume of 50 µl with the relevant antibody (20ul of IL-4 PE/Cy7, 1 µl of IFN-γ -FITC and 
0.5µl of TNF-α-FITC). Relevant isotype controls were used; 0.25 µl of PE/Cy7 Rat IgG1, 
κ or FITC Mouse IgG1 κ.  Cells were incubated for 1 hour at room temperature for IL-4 
or 20 minutes on ice for IFN-γ and TNF-α in the dark. The cell suspensions were then 
washed with 500 µl of 0.5% Saponin and centrifuged at 1000 x g for 10 mins at 4oC. 
The pellets were then resuspended in 250 µl of PBS for FACS analysis. Flow cytometry 
settings were as follows: Forward scatter E0; Voltage 1.00; Amp gain Lin; and Side 
scatter of 329; Voltage 1.00; Amp gain Lin. 
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2.11.5 Compensation adjustments for FACS analysis 
 
Fluorochromes do not emit light at just a single discrete wavelength, but over a range 
of wavelengths. As a result, there may be overlap of spectral emission into the 
specified laser channel selected for analysis creating false positive emissions. This can 
be overcome through compensation. Single fluorophores for positive and negative 
controls were run to set the compensation percentages between channels prior to 
double and triple colours.  
 
The populations of singly labeled cells should not appear in other channels and 
discrete populations should be clearly seen. Under-compensation occurs when signals 
from the singly labeled cells are being detected in the other channels. Over-
compensation can also occur, resulting in the singly labeled cells off-scale on the low 
end in a correlated dot plot. Examples of each are shown below in Figure 2.7. 
     
 
 
Figure 2.7 Examples of different spectral compensation 
(a) Under compensation occurs when the signals detected in other channels, e.g. FL2. 
(b) Over compensation occurs when the signals are off the scale.  
(c) Correct compensation occurs when positive cells occur in the correct channel only. 
 
 
Compensation was required for IL-4 (FL3) and CRTH2 (FL2) and CD4 (FL4) experiments.  
Settings required were as follows: “FL2- 20% - FL3”, “FL3 - 2.5% - FL2”, FL1= 430, FL2= 
460, FL3= 465 and FL4 = 716.  
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2.12 Multi-spot Enzyme linked immunosorbant assay   
 
2.12.1 Tissue preparation 
 
For analysis of Th1:Th2 interleukins in LPS and CRTH2 agonist treated mice, maternal 
myometrium and pup brain was collected at 4 hours post injection and snap frozen in 
dry ice until processing. Whole cell lysate was prepared with the whole cell extraction 
buffer recommended by meso scale discovery. 100mg of tissue per 1 ml of extraction 
buffer was used.  Following grinding of tissue with liquid nitrogen tissue was 
homogenised in ice-cold extraction buffer, and centrifuged for 10 minutes at 
13,000rpm. Protein concentration was determined by Bradford assay (BIORAD).  
 
2.12.2 Meso scale discovery protocol  
 
The mesoscale discovery kit contained standards, detection antibodies, and read 
buffer. Standards were serially diluted and a range was pre determined with a test run 
of sample tissue from the tissue which was anticipated to have the lowest and highest 
concentration of interleukins. The 8-point standard curve ranged from 0-2500 pg/ml. 
While standards were being prepared the 96 well plate was blocked in 1% BSA in PBS 
for 1 hour on the shaker. The plate was washed in PBS-T three times, and then 40 µg 
of murine myometrium or 100µg of pup brain protein lysate was added in a volume of 
25 µl. The plate was gently rocked for 2 hours.  The plate was then washed three times 
with 150 µl of PBS-T and a 25 µl mix of detection antibody, Blocker B and Diluent 100 
was added and gently rocked for 2 hours at room temperature. Following this the 
plate was washed three times in PBS-T and 150 µl of read buffer was added. The plate 
was read with the Sanger analyser. 
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2.12.3 Analysis  
The multi spot Elisa plate is read by the Sanger 2400 imager using 
electrochemiluminescence detection techniques. The quantities of interleukins were 
determined against the standard curve and transferred into an excel spreadsheet.  
 
2.13 Myometrial Contractility 
 
2.13.1 Tissue preparation and mounting 
 
Human tissue  
Myometrium was dissected on a petri dish on ice into 8 strips of approximately 5mm x 
10mm and mounted onto the DMT myograph shown below in Figure 2.8. The tissue 
was stretched to 4g and was allowed to equilibrate for 90 minutes in 4 mls of modified 
Krebs solution (Glucose 2.0g/L, Magnesium sulphate 0.141g/L, Potassium phosphate 
0.16g/L, Potassium Chloride 0.35 g/L, Sodium Chloride 6.9g/L, Calcium Chloride 
dehydrate 0.373g/L, Sodium bicarbonate 2.1g/L, pH 7.4) and gassed with 95% O2 and 
5% CO2. 
 
Murine tissue 
Mice where sacrificed by cervical dislocation at E16 of gestation under general 
anaesthetic. A midline laparotomy was performed to obtain the uterus.  The uterus 
was transported from the animal house to the laboratory in PBS on ice and was used 
within 5 hours of harvesting. Myometrial strips (5mm x 10mm) were mounted on the 
DMT myograph along the circular or longitudinal muscle orientation, and stretched to 
3g of tension. Each organ bath contained 4 mls of Krebs solution (Glucose 2.0g/L, 
Magnesium sulphate 0.141g/L, Potassium phosphate 0.16g/L, Potassium Chloride 0.35 
g/L, Sodium Chloride 6.9g/L, Calcium Chloride dehydrate 0.373g/L, Sodium 
bicarbonate 2.1g/L, pH 7.4) and was gassed with 95% O2 and 5% CO2. Tissue was 
allowed to equilibrate for 30 minutes.  
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Figure 2.8 Image of contractility machine (800MS DMT) 
8 channel organ bath contractility machine.  
 
2.13.2 Dose response to CRTH2 agonists 
 
Cumulative dose responses were performed after 30 minutes of spontaneous 
contractions were recorded to serve as baseline contractility. At the end of the 
experiment 10 -7 M of Oxytocin was added to demonstrate strip viability. 0.1-100 um 
concentrations were added every 20-30minutes at the time of organ bath wash out. In 
some experiments a preincubation step with the CRTH2 antagonist x481 was 
performed.  
 
2.13.3 Analysis of contractility  
 
Contractility was analysed using the Powerlab software V 5.5.6 (ADI instruments) using 
the Peak parameters extension. Parameters analysed were area under the curve (work 
done by the tissue), peak amplitude (peak tissue tension), duration of contractions and 
rate of contractility as shown in Figure 2.9. Data were transferred from the datapad of 
the Powerlab software into an excel spreadsheet and statistical analysis was 
performed with Graph-Pad Prism (v5.0; GraphPad Software, San Diego, CA). Response 
to treatment was measured by normalising to baseline spontaneous contractility and 
divided by the relevant timepoint for the vehicle control.  
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Figure 2.9 Image of a myometrial contraction   
Area under the curve represents the work done by the tissue, the peak of the contraction 
represents the peak tension and the width of the base of the contraction represents the 
duration of the contraction. 
 
 
2.14 Murine model of preterm labour 
 
2.14.1 Husbandry  
 
CD1 mice (Charles River) were housed in conditions compliant with Home Office 
regulations.  All of the animal experiments were performed under the Home Office 
Project Licence (Ref 70/6906). A personal licence was obtained from the Home Office 
for my work, and was adhered to at all times (Ref 70/22094).  
 
2.14.2 Surgery 
 
Mice were time mated such that plug day was day 0. On day 16 mice were 
anaesthetised with Isofluorane briefly and given an intramuscular injection of 
Morphine 2.5mg/kg. Mice were allowed to recover, and the morphine was given 15 
minutes to work. The mice were re-anaesthetised and a midline mini laparotomy was 
performed under aseptic conditions, the uterus was exteriorised, and an intrauterine 
injection of Lipopolysaccharide in a total volume of 25 μl was delivered to the right 
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horn between the two most distal pups. The peritoneum was closed with continuous 
non-locking sutures with 2/0 vicryl, and the skin was sutured with interrupted 2/0 
vicryl. The mice were recovered in a warm incubator until active and were then 
housed separately. Mice were either sacrificed at 4.5 hours post injection for 
harvesting myometrium and pup brain, or allowed to deliver spontaneously. 
Continuous monitoring was achieved via infrared CCTV system that was viewed 
remotely. 
 
 
 
Figure 2.10 CD1 mouse anaesthetised at time of intrauterine injection at laparotomy    
The uterus is exteriorised briefly and the LPS is administered between the two most distal 
pups of the right horn by Hamilton syringe.   
 
 
2.14.3 Dose response  
 
A dose response for the Lipopolysaccharide was first performed to obtain the lowest 
dose at which preterm delivery was consistently obtained. Control mice were given 
PBS alone. A dose of 20 μg was chosen for the model of infection induced preterm 
labour.  
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2.14.4 CRTH2 agonist administration 
 
In experiments where the CRTH2 agonist Pyl A was used, a separate Hamilton syringe 
was used first to administer the 250 μg of Pyl A between the second and third most 
distal pups. In those mice which received LPS also, another syringe was used to 
administer the LPS between the two most distal pups of the right horn.  
 
 
Figure 2.11 Murine bicornuate uterus demonstrating site of intrauterine injection  
LPS is administered between the two most distal pups of the right horn at site 1. Site 2 is used 
for administration of the CRTH2 agonist. 
 
2.14.5 Tissue harvesting  
For tissue harvesting, mice were anaesthetised and sacrificed by cervical dislocation. A 
laparotomy was performed immediately and pups were sacrificed by decapitation in 
accordance with Schedule 1. Myometrium and pup brain were snap frozen and stored 
at -80 oC until processing.  
 
2.15 Statistical analysis  
All data was processed firstly with Microsoft Excel 2007. Statistical analysis was 
performed with Graph-Pad Prism v5 (GraphPad Software, San Diego, CA).  The correct 
statistical test was carried out depending on normality and the number of groups 
analysed. The flow diagram below was used as an aid to determining the correct 
statistical test.  More detail on statistical analysis will be given in each results section.  
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A. Flow diagram to determine statistical test for data with normal distribution 
  
 
 
 
 
 
 
 
 
 
 
 
 
Unpaired T test*       Paired T test     One way ANOVA     One way repeated AVOVA 
* For Catagorical dependant variable and continuous outcome variable the difference in means 
between groups needs to be normal rather than the sample distribution itself  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NORMAL 
1 -2 groups > 2 groups 
Independent Independent Dependent/related Dependent/related 
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B. Flow diagram to determine statistical test for data with non-parametric 
distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mann Whitney          Wilcoxon                      Kruskall Wallis          Friedman ANOVA 
 
Figures 2.12 A and B. Flow diagrams to aid in determining the correct statistical test to be 
used The flow diagram in A was used for normally distributed data, and the flow diagram in B 
was used if the data was not normally distributed. 
 
 
NOT NORMAL 
1-2 groups > 2 groups 
Independent Independent Dependent/related Dependent/related 
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CHAPTER 3 
 
CRTH2 expression 
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Chapter summary 
Hypothesis:  
15dPGJ2 is a CRTH2 agonist. Our group has previously shown that it inhibits NF-κB in 
human amniocytes and myocytes, and also delays preterm labour in the murine model 
of inflammation induced preterm labour. It is possible that CRTH2 plays a role in these 
effects seen with 15dPGJ2.  
 
Aims:  
Firstly, data presented in this chapter aims to determine if the CRTH2 receptor is 
expressed in gestational tissues including amnion, choriodecidua, placenta and 
myometrium, and at the cellular level in amniocytes and myocytes. Secondly, the 
expression profile of CRTH2 in T helper cells was examined at different stages of 
pregnancy and in labour, to determine if there is a potential up regulation of CRTH2 in 
pregnancy, consistent with the Th2 bias that exists in pregnancy.  
 
Methods:  
mRNA expression was determined by PCR. Protein expression was explored using 
western analysis and flow cytometry. 
 
Results:  
CRTH2 is not present at the protein level in amniocytes and myocytes. There is no 
statistically significant increase in CRTH2 expression in lymphocytes during pregnancy, 
and no difference in expression prior to the onset of labour compared with during 
labour. 
 
Conclusion:  
It is unlikely that CRTH2 plays a role in 15dPGJ2-mediated inhibition of NF-κB since 
CRTH2 is not expressed in amniocytes and myocytes, although it may still play a role in 
the delay in preterm labour and increased pup survival in the murine model.  Despite 
not seeing a significant increase in CRTH2 expression on Th2 cells during pregnancy, an 
increase in the functional activity of the receptor during pregnancy is still possible.  
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Introduction 
 
15dPGJ2 inhibits NF-κB in cultured human amniocytes and myocytes in a mechanism 
that remains to be fully explained [271]. 15dPGJ2 also delays preterm labour and 
increases pup survival in the murine model of inflammation induced preterm labour 
[277]. 15dPGJ2 is an agonist of the CRTH2 receptor and therefore this receptor could 
play a role in NF-κB inhibition. CRTH2 is the second prostaglandin D2 receptor, first 
discovered by Nagata et al in a search to find a specific marker expressed in Th2 cells 
but not Th1 cells [291]. It has been shown to be expressed on Th2 cells, eosinophils, 
basophils and monocytes at the protein level [289].  However, there are limited data 
on the expression profile of CRTH2 non-immune cells, gestational tissues and 
myometrium. 
 
The function of CRTH2 appears to be important in maintaining a Th2 type interleukin 
rich environment, with PGD2 inducing IL-4, IL-5 and IL-10 production in vitro [217]. 
Since endogenous PGD2 and 15dPGJ2 are found in the amniotic fluid, it is plausible that 
CRTH2 is expressed in the amnion. Tsuda et al have shown a higher percentage of 
CRTH2 positive decidual T cells in women undergoing elective termination compared 
to women with spontaneous miscarriage [300]. They suggested a role for CRTH2 in the 
maintenance of pregnancy, by providing a Th2 rich cytokine environment at the 
maternal-fetal interface [198].  It is possible that CRTH2 expression in peripheral blood 
also aids in the maintenance of a bias in the Th1:Th2 cytokine ratio in favour of Th2 
profile. 
 
In this chapter, the expression profile of CRTH2 in fetal membranes, placental and 
myometrial tissue along with expression at the cellular level in amniocytes and 
myocytes was explored. The trend in expression of CRTH2 in Th2 cells through 
gestational time points was examined, with a comparison of the expression between 
pre-labour and in labour samples, and between term labour and preterm labour 
samples. 
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Results 
 
3.1 CRTH2 mRNA  
 
CRTH2 mRNA expression pattern was analysed by PCR. Standard PCR was run with 35 
cycle replications and RT-PCR was run at up to 40 cycles. mRNA from peripheral blood 
mononuclear cells (PBMCs) isolated from non-pregnant human blood was used as a 
positive control, and non-template water controls or non reverse transcriptase 
samples used as negative controls. Four primer sets were used (see Table 3). 
 
Initial experiments revealed detectable levels of CRTH2 mRNA in amniocytes, 
choriodecidua, myocytes and placenta with two primer sets (Figure 3.1.1A and B). 
Water control samples were introduced along with a third primer set (Figure 3.1.2A 
and B). Experiments were then tailored to specific tissue/cell types using primer set A 
and B.  
 
mRNA from fetal membranes and myometrium was examined using primer set A 
(n=5). Amnion, myometrium, choriodecidua and placenta were collected from women 
at the time of pre-labour caesarean section. CRTH2 mRNA was detected in all five 
samples of amnion (A), myometrium (B), choriodecidua (C) and placenta (D) using 
PBMCs as a positive control and water non-template water negative control (Figure 
3.1.3 A-D). Although the aim of this was qualitative rather than quantitative, very faint 
bands were seen in both choriodecidual and amnion samples, suggesting low 
expression. 
 
CRTH2 mRNA levels at the cellular level were next investigated. CRTH2 was amplified 
by standard PCR with primer set A and by RT-PCR which primer set B, and products 
were subjected to agarose gel electrophoresis. Detectable levels where seen in 4 of 6 
amniocyte samples (Figure 3.1.4A) and all 6 myocyte samples (Figure 3.1.4B). PBMCs 
were used as a positive control, with reverse transcriptase negative controls.  
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Figure 3.1.1 CRTH2 mRNA initial detection 
mRNA was isolated from cultured amniocytes, myocytes, choriodecidual and placental 
biopsies and converted to cDNA. Qualitative PCR was used with two primer sets to amplify 
CRTH2 showing product sizes of 309bp (A) and 209bp (B). A&B: amniocytes (lane 1), 
choriodecidua (lane 2), myocytes (lane 3), placenta (lane 4). (A= amniocytes, D= 
choriodecidua, M= myocytes, P= placenta) 
 
 
 
 
 
 
Figure 3.1.2 CRTH2 mRNA with controls 
The same cDNA samples from figure 3.1.1 were used, along with a negative control (non-
template) and amplified by PCR using two primer sets showing correct product sizes of 309bp 
(A) and 265bp (B). A&B: non-template control (lane 1), amniocytes (lane 2), choriodecidua 
(lane 3), myocytes (lane 4), placenta (lane 5). (C= control, A= amniocytes, D= choriodecidua, 
M= myocytes, P= placenta) 
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Figure 3.1.3 CRTH2 mRNA in tissue of fetal membranes, myometrium and placenta 
mRNA was isolated from tissue biopsies of fetal membranes, placenta and myometrium and 
converted to cDNA (n=5). Qualitative PCR was used to amplify CRTH2 showing the correct 
product size of 309bp in amnion (A), myometrium (B), choriodecidua (C) and placenta (D). 
Non-template negative controls were used and peripheral blood mononuclear cells (PBMCs) 
were used as a positive control. A-D: Non-template control (lane 1), tissue samples (lanes 2-6), 
PBMCs (lane 7).  
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Figure 3.1.4 CRTH2 mRNA in amniocytes and myocytes 
mRNA was isolated from cultured amniocytes and myocytes and converted to cDNA (n=6). 
Qualitative PCR was used to amplify CRTH2 showing the correct product size of 309bp in 
amniocytes (A) and myocytes (B) (n=6 samples each) using non-template negative controls and 
PBMCs as a positive control. Products from RT-PCR using another primer set were run out on a 
gel showing the correct size of 114bp for amniocytes and myocytes (n=2 samples each) using 
reverse transcriptase negative controls and PBMCs as a positive control. A&B: Non-template 
control (lane 1), cell samples (lanes 2-7), PBMCs (lane 8). C: Reverse transcriptase controls 
(lanes 1,3,5,7,9), PBMCs (lane 2), amniocytes (lanes 4,6), myocytes (lanes 8,10). 
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3.2 Identification of endogenous CRTH2 protein by western analysis  
 
Western analysis was used for the detection of CRTH2 in myometrium and fetal 
membranes, performed as described in section 2.10. The Sc 23092 antibody was used 
for detection and its data sheet demonstrates CRTH2 at a molecular weight of 34kDA. 
Human heart (kindly donated by Dr Grisha Pirianov) and peripheral blood 
mononuclear cell protein lysates were used as positive controls.  Amnion, 
choriodecidua, placenta and myometrium gave strong bands at 55 correlating with the 
positive controls, with no bands seen at 34kDa, Figure 3.2.1 A, B, C and D respectively. 
A second antibody was also used (ProSci 4027) as shown in Figure 3.2.1 E, F, G, H. 
However, a non-specific band was detected at 70kDA which did not show up in the 
human heart and peripheral blood mononuclear cell control samples.  
 
CRTH2 protein expression was also investigated at the cellular level in amniocytes and 
myocytes.  A faint band at 55 was seen in amniocyte cell lysate, however this band was 
as strong as many other bands seen on the blot which is suggestive of being non-
specific (Figure 3.2.2A). No band was detected with myocyte protein lysate (Figure 
3.2.2B).  
 
The presence of the band at 55 could represent the glycosylated from of CRTH2. Since 
no band was detected at the cellular level, (and if this in the correct band), it is 
possible that infiltrating leukocytes account for the expression seen in the tissue. 
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Figure 3.2.1 Detection of CRTH2 in gestational tissues and myometrium  
Protein lysate from gestational tissues and myometrium were subjected to western analysis. 
A-D; Immunoblots were probed with the SC-23092 CRTH2 antibody. Blot A represents amnion, 
blot B choriodecidua, blot C placenta, blot D myometrium. Lanes 1-3 of blots A-C represent 
labour minus samples, and lanes 4-6 of blots A-C represent labour plus samples. Lane 7 of 
blots A-C contains protein lysate from human heart as a positive control. Lanes 2-4 of blot D 
represent labour minus myometrium, lanes 5,6 and 7 are positive controls; human heart, 
PBMCs sample 1 and PBMCs sample 2 respectively. A single band appeared on the 
immunoblot at 55kDa. No band was seen at 34kDa. E-H; Immunoblots were probed with the 
ProScience 4027 antibody. Blot E represents amnion in lanes 1-6, lane 7 human heart, lane 8 
white blood cells. Blot F represents choriodecidua in lanes 1-6, lane 7 human heart, lane 8 
mouse heart. Blot G represents placenta in lanes 1-6, lane 7 human heart, lane 8 white blood 
cells. Blot H represents myometrium in lanes 1-3, lane 4 human heart, lane 5 mouse heart, 
lanes 6-8 white blood cells.   
 
 
 
 
 
 
Figure 3.2.2 Detection of CRTH2 in amniocyte and myocyte whole cell lysate 
Protein lysate from cultured amniocytes and myocytes were subjected to western analysis. 
Immunoblots were probed with the SC-23092 CRTH2 antibody. Blot A represents amniocytes 
(n=8) and blot B represents myocytes (n=8). Human heart was used as a positive control in 
blot A and B in lane 1. A strong single band appeared on the immunoblot at 55kDa with the 
positive control only. No significant band was seen at 34kDa in either amniocytes, myocytes or 
positive control.   
                                                                                                    Chapter 3: CRTH2 expression                                                                                                                                                                                                                                                                                                                    
 
104 
 
3.3 Sequencing the band 
 
In an attempt to confirm that the band persistently seen at 55 was CRTH2, N-terminal 
protein sequencing of the band on these immunoblots was carried out by the 
Biochemistry department at Cambridge University. Figure 3.3A shows an example of 
the protein bands that were sequenced, from PBMCs, myometrium, human heart and 
amnion protein lysate. The bands were cut off from the immunoblot shown in Figure 
3.3B for sequencing. CRTH2 was not identified from these bands at 55kDa. Keratin and 
Immunoglobulin heavy chain proteins were seen, possibly through contamination 
which is a recognised limitation of this technique. If CRTH2 was present, it was masked 
by other proteins of far greater concentration. 
 
 
 
 
 
 
Figure 3.3 Sequencing of the band at 55kDa by N-terminal sequencing  
Protein lysate from PBMCs (lane 1), myometrium (lane 2), human heart (lane 3), and amnion 
(lane 4), were subjected to western analysis. Blot A was probed with primary and secondary 
antibodies to detect CRTH2. Blot B was stained with methylene blue and the bands at 55kDa 
were cut out and underwent N-terminal sequencing. 
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3.4 Cloning CRTH2 
 
In order to provide a highly concentrated protein lysate of CRTH2 for a positive control 
CRTH2 was cloned. The 1.18kb CRTH2 transcript was amplified from white cell cDNA as 
described in section 2.7. The product was run out on a gel to confirm amplification and 
the correct product size (Figure 3.4A). The PCR was repeated in order to cut the band 
containing the cDNA under the UV light to purify ready for insertion into the 
intermediate vector pCR®-BluntII-TOPO®, figure 3.4B. The presence of CRTH2 was 
confirmed by digesting at the BAMH I and BGL II insertion site to produce two 
products: the sPG5 expression vector and the 1.18kb CRTH2 insert (Figure 3.4C). The 
transcript was also sequenced to confirm the presence of CRTH2 and to confirm that it 
was correctly orientated in the expression vector.   
 
The cell free in vitro transcription translation kit (TNT kit) was used with 35S 
Methionine to confirm the correct size of the protein product. Detection of the 34kDa 
CRTH2 product was by x-ray film (Figure 3.4D). The progesterone expression vector (a 
kind donation by Dr Yun Lee) was used as a positive control confirming the 
effectiveness of the TNT kit. The CRTH2 product roughly correlated with the Kozak rule 
[306], and was consistent with the CRTH2 transfect produced by Nagata et al [291]. 
The product size also matched the expected size of CRTH2 detected by the Santa Cruz 
antibody SC-23092 as published in the data sheet.   
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Figure 3.4 Cloning CRTH2 
A 1.18kb transcript was amplified from white cell cDNA (A). This transcript was purified for 
insertion into an intermediate vector (B). The expression vector containing CRTH2 was 
digested to confirm the presence of CRTH2 (n=2) (C). The in vitro transcription translation kit 
was used to produce CRTH2 with 35S Methionine and the product was detected by x-ray film, 
lane 2 (D). The progesterone (PRC 301) expression vector was used as a positive control, lane 1 
(D).  
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3.5 Western of cloned CRTH2  
 
Knowing that the pSG5 expression vector was functional I then sought to determine if 
the commercially available antibodies were able to detect CRTH2. Firstly, I used the 
protein lysate from the cell free system; both the exact lysate seen in Figure 3.4D as 
well as a non-radiolabelled lysate and performed western analysis with these 
products. As negative controls, the same volume from the kit and the progesterone 
lysate were used. The immunoblots were probed with three commercially available 
antibodies designed for western blotting. No band was detected at 34kDa, with non-
specific bands appearing also in the negative control of the TNT kit without plasmid 
DNA (Figure 3.5.1).  
 
Secondly, amniocytes were transfected with CRTH2 using GeneJuice and Fugene 
transfection reagents. Whole cell protein lysate was subjected to western analysis, 
using PBMC lysate as a positive control (Figure 3.5.2). No band was seen at the 
expected 34kDa size. A band was seen at 55 in blot A with the SC-23092 antibody, 
however, this corresponds with the band that was sequenced and found not to be 
CRTH2. A secondary antibody control blot was also included, which also showed a 
band at 55, consistent with this band being non-specific. Upon probing with the ProSci 
antibody, non-specific bands were also seen at 70 and 43kDA (Blot B). These bands 
were not detected in the positive control samples, and no difference in intensity was 
seen between non-transfected and transfected lysate.  
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Figure 3.5.1 Detection of CRTH2 produced in the cell free system by immunoblot 
The protein lysate from the TNT kit was subjected to western analysis; negative control: TNT 
kit with no plasmid DNA (lane 1), negative control: progesterone PSG5 expression vector (lane 
2), positive control: 35S Methionine labelled CRTH2 (Lane 3), cold Methionine CRTH2 protein 
product (lane 4). Membranes were probed with 3 commercially available antibodies; SC-23092 
(A), SC-21798 (B), ProSci 4027 (C). None of the antibodies detected CRTH2. 
 
 
 
 
 
 
 
 
 
Figure 3.5.2 Detection of CRTH2-transfected amniocytes by immunoblot 
The protein lysate from non transfected and transfected amniocytes was subjected to western 
analysis. Blot A was probed with the SC-23092 antibody and blot B was probed with the ProSci 
4027 antibody. Human peripheral blood cell protein lysate was used as a positive control. 
Protein lysates from myocytes (lane 1), amniocytes (lane 2), Genejuice-transfected amniocytes 
(Lane 3), Fugene-transfected amniocytes (lane 4), and PBMCs (lane 5) were examined. Blot A 
failed to show a band at the expected 34kDa. However, it did show the consistently seen band 
at 55. This band was confirmed to be non-specific with the secondary antibody control. The 
Proscience antibody failed to detect a band in the positive control.  
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3.6 FACS of endogenous CRTH2 
 
Flow cytometry is the most commonly reported technique used for the identification 
of CRTH2. Many papers have successfully demonstrated expression mainly in immune 
cells, but also in some non-immune cells. Having failed to demonstrate sensitivity of 
commercially available antibodies suitable for western analysis I used a flow cytometry 
antibody, as used by Chiba et al, firstly for demonstrating CRTH2 expression on 
peripheral blood lymphocytes, and secondly to examine endogenous and transfected 
expression of CRTH2 in amniocytes and myocytes.  
 
3.6.1 Detecting CRTH2 in human lymphocytes by flow cytometry 
 
Peripheral blood mononuclear cells were isolated as described in section 2.2.3 by Ficoll 
separation. Subjects were non-pregnant women without asthma or active infection, 
(n=6). Lymphocytes were determined on the basis of forward and side scatter profile 
as shown in Figure 3.6.1.1A. CRTH2 cell surface staining was performed as described in 
section 2.11. Example histograms are shown for cells with no staining, isotype control 
and CRTH2-PE (Figure 3.6.1.1B). Graphs are shown in Figure 3.6.1.2 summarising the 
percentage of lymphocytes labelled with the fluorophore phycoerythrin (PE), and the 
mean, geometric mean and median.  A mean of 2.15% of lymphocytes express CRTH2, 
with a background staining of 2.54% in the isotype control indicating non-specific 
background staining and a low level of expression. However, CRTH2 expression is 
clearly demonstrated by the high mean and median fluorescence intensity seen with 
CRTH2-PE compared with isotype control. The mean, geo mean and median 
fluorescence intensity of CRTH2 positive cells were 483.32, 218.09, and 342.13 
respectively compared with 61.60, 23.63 and 18.15 for isotype control (P< 0.0001 for 
each parameter), (Figures 3.6.1.2 A-D). 
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Figure 3.6.1.1 CRTH2 expression in human lymphocytes 
Lymphocytes were gated according to forward scatter and side scatter (n=6) A representative 
dot plot shows the lymphocyte population (A). Representative histograms of three subjects 
are shown for no staining, isotype controls and CRTH2 stained cells (B).  Cells expressing 
CRTH2 are shown towards the right of the histogram.  
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Figure 3.6.1.2 Graphs showing CRTH2 expression in human lymphocytes 
The mean percentage of CRTH2 positive lymphocytes is 2.15%. High background staining with 
the isotype is evident with 2.54% percent of cells binding to the isotype control (A). CRTH2 
expression is clearly seen as reflected by a higher mean (B), geo mean (C) and median (D) 
fluorescence compared with isotype control. For statistical analysis One way ANOVA was used 
with Bonferroni’s post hoc analysis; **** P<0.0001. 
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3.6.2 Exploring CRTH2 expression in amniocytes by flow cytometry 
 
Cultured primary amniocytes from amnion of pre-labour caesarean sections were 
prepared as described in section 2.2, (n=6). Cells were harvested on day 3 and labelled 
with CRTH2-PE. A representative dot blot shows the amniocyte population in Figure 
3.6.2.1A. The histograms of three representative subjects are shown in Figure 3.6.2.1B, 
showing cells with no stain, isotype control and CRTH2-PE. There was no significant 
difference between isotype controls and CRTH2 labelled samples with all parameters 
(percentage of labelled cells, mean and median fluorescence intensity), indicating no 
endogenous expression of CRTH2 on amniocytes (Figures 3.6.2.2A-D). 
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Figure 3.6.2.1 CRTH2 is not present on human amniocytes 
CRTH2 expression on amniocytes was examined by flow cytometry (n=6). A representative dot 
plot shows the amniocyte population (A). Representative histograms of three subjects are 
shown for no staining, isotype controls and CRTH2 stained cells (B). No difference is seen 
between the histograms of the isotype controls and CRTH2 stained samples reflecting no 
expression of CRTH2 on amniocytes.  
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Figure 3.6.2.2 Graphs showing no expression of CRTH2 expression in amniocytes 
CRTH2 expression on amniocytes was examined by flow cytometry (n=6). There was no 
significant difference in mean (B), geo mean (C) or median fluorescence intensity (D) between 
isotype control and CRTH2 labelled samples indicating no expression of CRTH2. There was a 
higher percentage of cells which stained with the isotype control compared with CRTH2-PE (A).  
For statistical analysis ANOVA of repeated measured was used with Bonferroni’s post hoc 
analysis. 
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3.6.3 Exploring CRTH2 expression in myocytes by flow cytometry 
 
Cultured myocytes from myometrium of pre-labour caesarean sections were prepared 
as described in section 2.2 (n=6). Cells were harvested at passage 1-3 and labelled with 
CRTH2-PE. A representative dot blot shows the myocyte population in Figure 3.6.3.1A. 
The histograms of three representative subjects are shown in Figure 3.6.3.1B, showing 
cells with no stain, isotype control and CRTH2-PE. There was no significant difference 
between cells with no staining and CRTH2 labelled samples with all parameters of 
(percentage of labelled cells, mean and median fluorescence intensity), indicating no 
expression of CRTH2 on myocytes, (Figures 3.6.3.2A-D). There was a higher mean, geo 
mean and median fluorescence intensity in the isotype control samples compared with 
the CRTH2-PE samples indicating a degree of background non-specific staining. 
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Figure 3.6.3.1 CRTH2 is not present on human myocytes 
CRTH2 expression on myocytes was examined by flow cytometry (n=6). A representative dot 
plot shows the myocyte population (A). Representative histograms of three subjects are 
shown for no staining, isotype controls and CRTH2 stained cells (B). No difference is seen 
between the histograms of the isotype controls and CRTH2 stained samples reflecting no 
expression of CRTH2 on myocytes.  
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Figure 3.6.3.2 Graphs showing no expression of CRTH2 expression in myocytes 
These graphs summarise the results of cultured myocytes (n=6). There was no significant 
difference in the percentage of cells labelled with CRTH2-PE (A), mean (B), geo mean (C) or 
median fluorescence intensity (D) and cells with no stain, or isotype control. There was a 
higher mean fluorescence intensity of cells which were stained with the isotype control 
compared with CRTH2-PE (B-D), indicating some background staining.  For statistical analysis 
ANOVA of repeated measured was used with Bonferroni’s post hoc analysis. * P<0.05. 
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3.7 Detection of transfected CRTH2 by flow cytometry  
 
Having found an antibody that detects CRTH2, amniocytes and myocytes were 
transfected with the CRTH2 pSG5 expression vector and analysed by flow cytometry.  
 
GeneJuice was used to transfect amniocytes which were harvested on day 1 post 
transfection as described in section 2.8. GFP was used as a control for transfection 
efficiency. Figure 3.7.1 shows the histograms for the cells with no staining, isotype-PE 
and CRTH2-PE.  
 
Myocytes were transfected with the CRTH2 pSG5 expression vector by electroporation 
as described in section 2.8. Cells were harvested on day 2 post transfection and 
analysed by flow cytometry. CRTH2 expression was seen, again at a low level. 
Histograms are shown in Figure 3.7.2. A representative image of GFP transfected cells 
is shown to demonstrate adequate transfection efficiency, Figure 3.7.3. 
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Figure 3.7.1 CRTH2 expression in transfected amniocytes  
A representative dot plot shows the transfected amniocyte population (A). Histograms of the 
transfected cells are shown for no staining, isotype controls and CRTH2 stained cells (B). The 
percentage of CRTH2 transfected cells is shown in (C), along with the mean fluorescence 
intensity (D). CRTH2 expression was very low, which is consistent with the cells not being able 
to express an endogenous stable CRTH2 protein.  
 
                                                                                                    Chapter 3: CRTH2 expression                                                                                                                                                                                                                                                                                                                    
 
120 
 
 
 
 
Figure 3.7.2 CRTH2 expression in transfected myocytes  
A representative dot plot shows the transfected myocyte population (A). Histograms of the 
transfected cells are shown for no staining, isotype controls and CRTH2 stained cells (B). The 
percentage of CRTH2 transfected cells is shown in (C), along with the mean fluorescence 
intensity (D). CRTH2 expression was low, which is consistent with the cells not being able to 
express an endogenous stable CRTH2 protein. 
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Figure 3.7.3 GFP transfected cells 
An example of the GFP transfected myocytes is shown. Myocytes were viewed under the 
microscope (A). The GFP (green fluorescent protein) in the myocytes was detected with the 
fluorescent microscope (B).  
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3.8 CRTH2 expression in peripheral blood mononuclear cells during 
pregnancy  
 
The expression of CRTH2 in peripheral blood T helper cells in pregnancy was next 
explored to determine if CRTH2 could be used as a marker of the hypothesised Th2 
bias of pregnancy. Blood was collected from women at 12 and 28 weeks of pregnancy, 
and at term pre-labour and in labour, with non-pregnant women serving as controls 
(n=8-10). T helper cells were identified firstly by gating lymphocytes based on forward 
and side scatter and secondly with CD4 cell surface staining. Cells were also stained 
with CRTH2-PE. Flow cytometry was used to detect CD4-APC and CRTH-2-PE. An 
example cytogram is shown in Figure 3.8A, with the upper right quadrant representing 
the CRTH2 positive CD4 cells. The percentage of CD4 positive cells expressing CRTH2 
was calculated (Figure 3.8B) and the geometric mean of the double positives was 
evaluated (Figure 3.8C). A trend was seen of an increase in the percentage of CRTH2 
expressing cells in the 3rd trimester, however this did not reach statistical significance. 
No difference in the mean fluorescence intensity was seen, implying no increase in 
CRTH2 receptor expression. The percentage of cells expressing CRTH2 in labour was 
not statistically different from non-labouring women. Although a decrease in mean 
fluorescence was seen in women in preterm labour, the error bar was large and this 
did not reach statistical significance.  
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Figure 3.8 CRTH2 expression in CD4 positive lymphocytes during pregnancy 
Lymphocytes were gated according to forward scatter and side scatter and T helper cells were 
identified using CD4 as a cell surface marker (n=8-10 for each group). A representative 
cytogram from lymphocytes taken at 28 weeks gestation is presented with the right upper 
quadrant showing CRTH2+/CD4+ lymphocytes (A). The percentage of CRTH2 positive T helper 
cells (presented as a percentage of CRTH2 positive CD4 positive cells) increased slightly in the 
third trimester although statistical significance was not seen (B). No significant difference was 
seen in the mean fluorescence intensity between non-pregnant controls and women at each 
gestational timepoint (C). For statistical analysis ANOVA with Bonferroni’s multiple comparison 
test was used. NP = non-pregnant, 12 w= 12 weeks, 28 w = 28 weeks, TNL = term not in labour, 
TL = term in labour, PTL=preterm labour.  
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Summary and discussion 
 
CRTH2 is a ligand for 15dPGJ2, a cyclopentenone prostaglandin that inhibits NF-κB in 
human amniocytes and myocytes [271], and delays preterm labour in inflammation 
induced preterm labour in the mouse [277]. CRTH2 is a receptor typically associated 
with immune cells, particularly Th2 cells. The function of CRTH2 on T helper cells 
appears to be important for the maintenance of the Th2 interleukin profile, whereas 
on eosinophils it appears to be important for chemotaxis in allergic conditions such as 
asthma [307]. Few studies have examined its expression in non-immune cells. In this 
chapter I explored the expression of CRTH2 in gestational tissues and myometrium as 
a basis for exploring the possibility that a) CRTH2 could be involved in 15dPGJ2-
mediated inhibition of NF-κB, and b) CRTH2 could play a functional role in contributing 
to a balance in the Th1:Th2 interleukin profile at the maternal fetal interface.  
 
CRTH2 is the second receptor to Prostaglandin D2, discovered over a decade after the 
DP1 receptor. The amnion, choriodecidua and placenta all show basal production of 
PGD2 in cultured explants at a concentration of 2.6, 2.5 and 95.8 pg/mg of tissue over 
24 hours respectively [279]. Low or undetectable mRNA levels of the DP1 receptor are 
seen in human myometrium [308, 309] and amnion [279]. It is plausible that the target 
of endogenous PGD2 is the second prostaglandin D2 receptor, CRTH2. There is limited 
data available on the mRNA expression and no data available on the protein 
expression of CRTH2 in these tissues. Nagata and colleagues have shown relatively 
high levels of mRNA expression in placenta and moderate levels in non-pregnant 
myometrium [287]. Helliwell and colleagues demonstrated mRNA expression present 
in 24/24 placentas, 7/12 choriodecidua samples and none of the 24 amnion samples 
examined [279].   
 
Detection of CRTH2 mRNA by PCR 
In this study all five pre-labour myometrial, amnion, choriodecidual and placental 
samples showed detectable levels of CRTH2 mRNA (Figure 3.1.3). Although standard 
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PCR was used for detection rather than quantitative PCR it was still possible to 
conclude that expression was weak in these tissue types, particularly in amnion and 
choriodecidua, since a cycle number of 35 was used to determine expression. In order 
to establish if the expression seen in amnion and myometrium was due to leukocyte 
infiltration, mRNA from cultured amniocytes and myocytes was determined. CRTH2 
mRNA was detected in 4/6 samples of amniocytes and 6/6 myocyte samples (figure 
3.1.4), again at a high cycle number of 35. This is consistent with the high cycle 
numbers required to demonstrate expression in monocytes and dendritic cells [290]. 
Increasing the cycle number is useful in order to analyse low copy number targets 
[310]. Rameckers et al reviewed the determinants of cycle numbers and demonstrated 
the requirement of cycles up to 45 for the detection of low target sequences [311]. 
However, with cycles above 40 there is an increased risk of introducing non-specific 
products. The consistent absence of a product in the non-template and reverse 
transcriptase negative controls in this study supports that neither random nor 
systematic contaminants such as genomic DNA are the sources of the products seen, 
but rather low target numbers of CRTH2.  
 
Detection of CRTH2 by western analysis 
 
Since mRNA expression was low in the cells and tissues examined, examination of 
CRTH2 at the protein level was explored to determine if the mRNA is translated. 
Western analysis was employed using two commercially available antibodies to detect 
CRTH2 in tissue samples (Figure 3.2.1). A single band at 55kDa was detected with the 
Sc-23092 antibody and a single band at 70kDa was detected with the Proscience 4027 
antibody in all tissue samples.  The band seen at 70kDa was deemed to be non-specific 
since it did not appear in the human heart and PBMC positive controls. The band seen 
at 55 was consistently seen in the positive controls human heart and PBMCs. Nagata 
et al have previously reported detection of CRTH2 in its glycosylated form at 55dKa 
and at 34 with oligosaccharide cleavage [291].  No band was detected at 34kDa or 
55kDa at the cellular level in amniocytes or myocytes (Figure 3.2.2), meaning that 
either CRTH2 is not expressed at the cellular level, or the bands detected in the 
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positive controls were non-specific. This led to sequencing of the band at 55kDa and 
cloning CRTH2 to provide a highly concentrated positive control.  
 
N-terminal sequencing of the band detected in amnion, myometrium, human heart 
and PBMCs failed to detect CRTH2. Immunoglobulin and keratin were detected; both 
are contaminants and a recognised limitation of the technique. This led to inconclusive 
results since proteins with low expression may be masked by the more highly 
expressed proteins of this size. By cloning CRTH2, a highly concentrated protein lysate 
was produced both in the cell free system and endogenously by transfecting 
amniocytes and myocytes. However, none of the three commercially available 
antibodies used for western analysis detected CRTH2 produced by the in vitro 
transcription translation kit (Figure 3.5.1). It is likely that the explanation for this is due 
to the reliance of the antibodies on the folded G-protein structure and/or the post-
translational modifications such as glycosylation. CRTH2 is known to have the classical 
7 transmembrane domains of a G-protein coupled receptor, and also has several 
potential sites for N-glycosylation and protein kinase C phosphorylation [291].  
 
To overcome the potential requirement for post-translational modifications for CRTH2 
detection, protein lysate from CRTH2-transfected amniocytes was probed with the Sc-
23092 and Proscience 4027 antibodies (Figure 3.5.2). The Santa cruz antibody again 
detected a band at 55 but no band in the transfected cells. With the persistence of the 
band at 55 in the positive control yet with no band seen in the transfected cells a 
secondary antibody control blot was examined. This band was shown to be non-
specific since it was still present in the absence of the primary antibody. The 
Proscience antibody detected the non-specific band at 70 again and a weak band at 
43. The band at 43 was considered non-specific since it was not present in the PBMC 
positive control and there was no increase in band intensity in the transfected cells 
compared with the non-transfected cells.  
 
Studies of the expression of CRTH2 on non-immune cells are limited, probably due to 
the lack of specific antibodies available for detection using techniques other than flow 
cytometry. There are only three publications using western analysis for the detection 
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of human CRTH2. Zayed et al detected bands at 41 and 55 for chondrocytes, using 
osteoblasts as a positive control [294]. However, they did not include blocking or 
secondary antibody controls to confirm specificity. Colombe et al detected a band for 
CRTH2 in keratinocytes and melanocytes at 45kDa with a Cayman Chemicals antibody 
(also suitable for immunohistochemistry) which has subsequently been taken of the 
market for lack of specificity [296]. The third group to publish on detection of CRTH2 
by western analysis is Nagata’s group who raised several antibodies to CRTH2, 
however, these antibodies are not available commercially. Together with data from 
these publications, the data presented in this chapter suggest there are no 
commercially available antibodies suitable for detecting CRTH2 by western analysis.  
 
Detection of CRTH2 by flow cytometry  
 
Flow cytometry is used successfully for the detection of CRTH2 on immune cells [291, 
312-316]. Flow cytometry detection of CRTH2 on non-immune cells has only been 
reported in human bronchial epithelial cells [317]. The antibody from this study was 
used to detect CRTH2 firstly in peripheral blood lymphocytes as a positive control, and 
then for the detection of CRTH2 in amniocytes and myocytes. CRTH2 was detected on 
a mean of 2.15% lymphocytes and 2.43% of CD4+ cells (Figures 3.6.1 and 3.8), 
consistent with published reports of between 0.4 and 6.5% of peripheral blood CD4+ 
cells expressing the receptor [291].  
 
Having established a way of demonstrating CRTH2 expression, flow cytometry was 
used to explore endogenous and transfected CRTH2 expression in amniocytes and 
myocytes. No CRTH2 was detected in any amniocyte and myocyte samples (Figures 
3.6.2 and 3.6.3), and low expression was seen in the transfected samples (Figure 3.7). 
Good transfection efficiency was seen with GFP, and thus the low expression of CRTH2 
in the transfected samples is potentially explained by the inability of amniocytes and 
myocytes to express a stable CRTH2 protein. This is consistent with the absence of 
endogenous CRTH2 protein expression in these cells.  
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The expression of CRTH2 in peripheral blood lymphocytes during pregnancy at 
different gestational time points was next examined. Since the immunology of 
pregnancy is characterised by a bias towards Th2, and that CRTH2 is a specific marker 
of T helper 2 cells [287], an increase in CRTH2 expression in CD4+ cells was expected 
during pregnancy. Although a small increase was seen in expression at 28 weeks and 
at term compared with non-pregnant controls, this did not reach statistical 
significance. Tsuda et al have previously reported an increase in CRTH2 expression in 
CD4+ cells of women at 7 weeks gestation (3.43%, P=0.02) compared with non-
pregnant women (2.08%) [312] but it is possible that this effect is diminished with 
advancing gestation.  
 
Expression levels of CRTH2 were also compared between women not in labour and in 
term and preterm labour. Since early preterm labour is associated with infection and 
inflammation, a Th1 bias is plausible leading to a diminished Th2 bias. For this reason, 
CRTH2 expression in women in preterm labour was anticipated to be reduced 
compared with women in term labour. No statistically significant reduction was seen 
in either the percentage of cells expressing CRTH2 or the mean expression levels of 
CRTH2 as determined by the mean fluorescence intensity.  Despite no significant 
increase being seen in CRTH2 expression in peripheral lymphocytes in pregnancy, this 
does not rule out a functional role for the receptor in the immunology of pregnancy. 
 
In summary, CRTH2 is not expressed at the protein level in amniocytes and myocytes, 
and can be used as a negative control for future CRTH2 expression studies. The most 
reliable technique for protein expression studies of CRTH2 is flow cytometry. It is likely 
that any detectable CRTH2 seen in gestational tissues and myometrium is from 
leukocyte infiltration. Although no significant increase is seen in CRTH2 expression in T 
helper cells in pregnancy, this does not rule out a functional role for the receptor in 
the maintenance of the balanced immunology of pregnancy. Since CRTH2 is not 
expressed on amniocytes and myocytes, it is not likely to contribute to 15dPGJ2 
mediated inhibition of NF-κB, however, it may still play a role in 15dPGJ2 mediated 
delay in inflammation induced preterm labour in the mouse.  
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CHAPTER 4 
 
The effect of CRTH2 agonists on NF-κB  
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Chapter summary 
 
Hypothesis:  
NF-κB controls the expression of many labour associated genes and its activity is 
increased in the amnion and myometrium at term and in labour. It may therefore play 
a key role in initiating preterm labour. The anti-inflammatory prostaglandin 15dPGJ2 
inhibits NF-κB in human amniocytes and myocytes [271]. The mechanism of 15dPGJ2 
mediated NF-κB inhibition remains to be elucidated. 15dPGJ2 is a CRTH2 agonist; 
however, since CRTH2 is not expressed on human myocytes and amniocytes it is 
unlikely that this receptor plays a role in 15dPGJ2-mediated inhibition of NF-κB. 
Nuclear phospho-p65 is suppressed in T helper cells during pregnancy [240]; but it is 
not known if NF-κB becomes activated in peripheral leukocytes during labour. If basal 
NF-κB activity is increased in peripheral leukocytes during labour and 15dPGJ2 has the 
same inhibitory effect on NF-κB in these cells, then 15dPGJ2 could provide a beneficial 
systemic anti-inflammatory effect, as well as the local anti-inflammatory effect seen 
on amniocytes and myocytes. 
 
Aims:  
The aims of the work described in this chapter are; first of all, to confirm that CRTH2 
plays no role in 15dPGJ2-mediated inhibition of NF-κB, secondly to determine if NF-κB 
activity is altered during pregnancy and in labour in peripheral blood mononuclear 
cells, and thirdly to determine if 15dPGJ2-mediated inhibition of NF-κB can be 
replicated in peripheral blood mononuclear cells (PBMCs).  
 
Methods:  
Prior to commencing experiments with the CRTH2 agonist Pyl A, its activity at the 
CRTH2 receptor was demonstrated by up regulation of CD11b expression. The effect of 
15dPGJ2 and Pyl A on IL-1β induced NF-κB activity in amniocytes and myocytes was 
determined by western analysis of nuclear p65 and phospho-p65. NF-κB activity in 
peripheral blood mononuclear cells from women at 28 weeks of pregnancy, term pre-
labour and in labour, and non-pregnant controls was determined by western analysis 
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of whole cell phospho-p65. To confirm that CRTH2 plays no role in 15dPGJ2-mediated 
inhibition of NF-κB, PBMCs were incubated with 15dPGJ2 with or without a CRTH2 
antagonist and analysed for phospho-p65 by western analysis. 
 
Results:  
15dPGJ2 inhibited NF-κB in amniocytes and myocytes. This effect was not reproduced 
by the CRTH2 agonist Pyl A. No change in PBMC phospho-p65 was seen during 
pregnancy compared to non-pregnant controls, or in labour compared with pre-
labour. 15dPGJ2 inhibited NF-κB activity in PBMCs, but this effect was not attenuated 
by the CRTH2 agonist.  
 
Conclusion:  
CRTH2 plays no role in 15dPGJ2-mediated inhibition of NF-κB. 15dPGJ2 was able to 
inhibit NF-κB in peripheral blood mononuclear cells. This inhibition is likely to lead to 
further anti-inflammatory effects such as the inhibition of pro-inflammatory cytokines, 
which may be of beneficial therapeutic effect in inflammation associated preterm 
labour. 
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Introduction 
15dPGJ2 inhibits NF-κB in cultured human amniocytes and myocytes in a mechanism 
that remains to be fully explained [271]. 15dPGJ2 is an agonist of the CRTH2 receptor 
and therefore the work in this thesis aims to explore the potential for the use of small 
molecule CRTH2 agonists to induce NF-κB inhibition. However, from the CRTH2 
expression studies of CRTH2 in amniocytes and myocytes, (presented in chapter 
three), it is evident that CRTH2 is not expressed in these cell types. This implies that 
CRTH2 is not involved in 15dPGJ2-mediated NF-κB inhibition. Data presented in this 
chapter aims to prove definitively that CRTH2 plays no role in 15dPGJ2-mediated 
inhibition of NF-κB. 
 
NF-κB activity is increased in both amnion [259] and myometrium at term [262], 
consistent with labour being considered a pro-inflammatory process. There is an 
increased production of pro-inflammatory cytokines in the amnion, amniotic fluid, 
choriodecidua, myometrium and cervix during labour, including IL-1β, TNF-α, IL-6 and 
IL-8 [25, 157, 158, 233]. Preterm labour is associated with infection and inflammation, 
and any trigger of NF-κB can lead to switching on a cascade of pro-inflammatory and 
labour associated genes such as IL-8, IL-1β, COX-2 and the MMPs [245]. The presence 
of inflammation is also associated with neonatal brain injury [318]. Systemic infection 
and inflammation even in term labour is associated with a poorer neonatal outcome 
[319]. Therefore, NF-κB is an attractive therapeutic target for both preventing preterm 
labour and neonatal brain injury. 
 
NF-κB activity is suppressed in T cells during pregnancy [240]. This suppression is 
thought to contribute to the suppression of Th1 interleukins which ultimately alter the 
Th1:Th2 ratio to favour the Th2 bias seen in pregnancy. It is not known whether this 
suppression in PBMCs is reversed towards term and during labour. The effect of 
15dPGJ2 on NF-κB in PBMCS has also not yet been reported on.  
 
Data presented in this chapter examines the effect of the CRTH2 agonists Pyl A on 
phospho-p65 amniocytes and myocytes to see if the effects of 15dPGJ2 can be 
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replicated. Secondly, the effect of these CRTH2 agonists on NF-κB activity in peripheral 
blood mononuclear cells was determined.  
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Results 
 
Prior to commencing experiments with the small molecule CRTH2 agonist Pyl A, its 
activity at the CRTH2 receptor was determined by demonstrating its ability to up-
regulate the expression of CD11b on eosinophils.  
 
4.1 Pyl A increases CD11b expression in eosinophils via CRTH2 
 
The small molecule CRTH2 agonist Pyl A was synthesised by Oxygen Healthcare 
(Cambridge, UK) based on the L-888,607 compound from Merck Frosst Centre for 
Therapeutic Research (Quebec, Canada) [320]. To prove the CRTH2 agonist activity of 
the compound, and based on the knowledge that the CRTH2 agonists PGD2 and 
15dPGJ2 increase CD11b expression on eosinophils and basophils via CRTH2, the effect 
of Pyl A on CD11b expression was examined [303, 321]. Granulocytes were isolated 
from non-pregnant women as described in section 2.2.3 and were treated with Pyl A. 
Flow cytometry was used to detect CD11b expression on eosinophils which were 
identified by high intensity CD49d expression and forward and side scatter 
characteristics (Figure 4.1). Up regulation of CD11b expression with Pyl A treatment 
was demonstrated by an increase in mean fluorescence intensity of CD11b-PE (P<0.5). 
This effect was attenuated with prior incubation of cells with the CRTH2 antagonist 
GSKCRTH2X, obtained from Glaxo Smith Kline, (London, UK) (P<0.5).    
 
An example dot blot is shown Figure 4.1A, with CD49d expression along the x-axis and 
CD11b along the y-axis. The double positive population is seen in the right upper 
quadrant. The cell population shows a subtle shift in the direction of the y-axis 
showing increased CD11b expression, which is reversed with pre-incubation with the 
CRTH2 antagonist GSKCRTH2.  The histogram in Figure 4.1B shows the shift to the right 
with Pyl A treatment (grey filled histogram), reflecting increased CD11b expression, 
which is reversed with the CRTH2 antagonist (black outlined histogram). The graph in C 
summarises the results of three biological replicates.  
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Figure 4.1 Pyl A increases CD11b expression on eosinophils 
32 µm of PYL A was used to increase CD11b expression on eosinophils. Pre-treatment with the 
CRTH2 antagonist GSKCRTH2X (100 µm) was used to confirm this effect was via CRTH2. 
Eosinophils were identified by labelling with anti-CD49d and on the basis of forward and side 
scatter. A representative cytogram is presented with the right upper quadrant showing 
CD11b+/CD49d+ cells (A). A representative histogram reveals a clear shift to the right with Pyl A 
treatment indicative of an increase in CD11b expression. This effect was attenuated with 
CRTH2 antagonist pre-treatment (B). A summary of CD11b expressed in eosinophils with each 
treatment is shown in the graph (n=3) (C). V= vehicle, PA =Pyl A, GSK X= GSKCRTH2X. For 
statistical analysis ANOVA of repeated measures with Bonferroni’s multiple comparison test 
was used; * P<0.05. 
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4.2 15dPGJ2 inhibits NF-κB in amniocytes and myocytes 
 
It has previously been shown that 15dPGJ2 inhibits IL-1β induced NF-κB activity in 
human amniocytes and myocytes in a mechanism independent of PPAR-γ [271]. For 
the purpose of this thesis these results were replicated showing a significant reduction 
in IL-1β induced NF-κB, as determined by nuclear p65, to below basal levels in 
amniocytes at 32 µm and in myocytes from 16 µm (Figure 4.2A and B).  
 
 
 
 
 
 
 
 
 
Figure 4.2 15dPGJ2 reduces NF-κB activity in amniocytes and myocytes  
Protein was extracted from IL-1β stimulated and 15dPGJ2 treated cells and levels of nuclear 
p65 were examined using immunoblotting. A dose response of 0.1-32 µm of 15dPGJ2 was 
performed (n=3). Representative immunoblots are shown for amniocytes, (A), myocytes (B). 
Immunoblots were re-probed for β-actin as an internal loading control.  
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4.3 Pyl A has no effect on NF-κB activity in amniocytes and myocytes 
 
The precise mechanism of 15dPGJ2-mediated inhibition of NF-κB is yet to be fully 
understood. In chapter three data was presented showing that CRTH2 is not expressed 
in amniocytes and myocytes. Therefore, this suggests that CRTH2 does not play a role 
in NF-κB inhibition. As anticipated, the small molecule CRTH2 agonist Pyl A did not 
reproduce the effects of 15dPGJ2; having no effect IL-1β induced NF-κB in amniocytes 
and myocytes. NF-κB activity was assessed by examining nuclear p65 and phospho-p65 
by immunoblot. Representative immunoblots for amniocytes and myocytes are shown 
in Figures 4.3A and B respectively.  Densitometric analysis, taking into account β-actin 
loading controls, was performed and a summary of n=3 experiments is shown in 
figures 4.3C-F.  Figures 4.3C and D represent p65 in amniocytes and myocytes 
respectively, and figures 4.3E and D represent phopsho-65 in amniocytes and 
myocytes respectively.   
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Figure 4.3 Pyl A has no effect on NF-κB activity in amniocytes and myocytes  
Protein was extracted from IL-1β stimulated and Pyl A treated cells and levels of nuclear p65 
and phosphorylated p65 (p-p65) were examined using immunoblotting. A dose response of 
0.1-32 µm of Pyl A was used (n=3). Representative immunoblots are shown for amniocytes, 
(A), myocytes (B). Immunoblots were re-probed for β-actin as an internal loading control. 
Densitometric analysis of the immunoblots was conducted revealing no effect of Pyl A on p65 
or p-p65 in amniocytes (C, E) or myocytes (D, F). Effect of treatment was examined for 
statistical significance using ANOVA of repeated measures with Bonferroni’s multiple 
comparison test; *P<0.05. 
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4.4 15dPGJ2 reduces NF-κB in peripheral blood mononuclear cells 
 
To determine if the inhibitory effect of 15dPGJ2 could be replicated in peripheral blood 
mononuclear cells, blood was collected and prepared as described in section 2.2.3. 
Cells were incubated with 1-32 µm of 15dPGJ2 or vehicle for 2 hours and whole cell 
lysate was analysed for phopsho-p65, the transcriptionally active form of NF-κB. A 
significant reduction in NF-κB activity was seen with 32 µm of 15dPGJ2 as shown by a 
representative blot (Figure 4.4A), and in the graph summarising results of three 
biological replicates (Figure 4.4B).  
 
 
 
 
 
Figure 4.4 15dPGJ2 reduces NF-κB activity in peripheral blood mononuclear cells  
Protein was extracted from peripheral blood mononuclear cells after a 2 hr incubation with 
15dPGJ2 and levels of whole cell phsopho-p65 were examined using immunoblotting. A dose 
response of 1-32 µm of 15dPGJ2 was used (n=3). Representative immunoblots are shown for 
phospho-p65 and β-actin (A). Immunoblots were re-probed for β-actin as an internal loading 
control and densitometric analysis of the immunoblots for all experiments was conducted and 
summarised in the graph (B). A reduction in NF-κB activity was seen from 16 µm 
concentration. Effect of treatment was examined for statistical significance using One-way 
ANOVA with Dunnett’s post-hoc analysis; *P<0.05. 
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4.5 Pyl A has no effect on NF-κB in peripheral blood mononuclear cells 
 
The CRTH2 agonist Pyl A was used to determine if the inhibitory effect of 15dPGJ2 
could be replicated. Cells were incubated with 0.1-32 µm of Pyl A or vehicle for 2 hrs 
and whole cell lysate was analysed for phopsho-p65. Four biological replicates were 
performed, with an example blot in Figure 4.5 A and a summary of all replicates in 
Figure 4.5 B. 
 
 
 
 
 
 
 
Figure 4.5 Pyl A has no effect on NF-κB activity in peripheral blood mononuclear cells  
Protein was extracted from peripheral blood mononuclear cells after a 2 hr incubation with Pyl 
A and levels of whole cell phsopho-p65 were examined using immunoblotting. A dose 
response of 0.1-32 µm of Pyl A was used (n=4). Representative immunoblots are shown for 
phospho-p65 and β-actin (A). Immunoblots were re-probed for β-actin as an internal loading 
control and densitometric analysis of the immunoblots for all experiments is summarised in 
the graph (B). No effect was seen on NF-κB activity at any concentration of Pyl A. Effect of 
treatment was examined for statistical significance using One-way ANOVA with Dunnett’s 
post-hoc analysis. 
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4.6 DK- PGD2 has no effect on NF-κB in peripheral blood mononuclear 
cells 
 
A second specific CRTH2 agonist was used to confirm that CRTH2 agonists have no 
effect on NF-κB activity. A dose response from 0.1-32 µm showed no effect on whole 
cell phospho-65 in peripheral blood mononuclear cells. A representative blot is shown 
in Figure 4.6A, and a graph summarising the absence of effect with three replicates is 
shown in Figure 4.6B.  
 
 
 
 
 
 
Figure 4.6 DK- PGD2 has no effect on NF-κB activity in peripheral blood mononuclear cells  
Protein was extracted from peripheral blood mononuclear cells after a 2 hr incubation with 
DK- PGD2 and levels of whole cell phsopho-p65 were examined using immunoblotting. A dose 
response of 0.1-32 µm of DK- PGD2 was used (n=3). Representative immunoblots are shown 
for phospho-p65 and β-actin (A). Immunoblots were re-probed for β-actin as an internal 
loading control and densitometric analysis of the immunoblots for all experiments is 
summarised in the graph (B). No effect was seen on NF-κB activity at any concentration of DK- 
PGD2. Effect of treatment was examined for statistical significance using One-way ANOVA with 
Dunnett’s post-hoc analysis. 
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4.7 15dPGJ2 inhibits basal on NF-κB in a mechanism independent of 
CRTH2 
 
Data presented so far supporting the hypothesis that CRTH2 is not involved in 
15dPGJ2-mediated inhibition of NF-κB includes the inability of Pyl A to replicate NF-κB 
inhibition in amniocytes, myocytes and peripheral blood mononuclear cells. The 
second CRTH2 agonist used (DK- PGD2) also did not replicate the effects of 15dPGJ2 in 
PBMCs. As a final confirmation that CRTH2 plays no role in 15dPGJ2 -mediated NF-κB 
inhibition, prior to treatment of PBMCs with 15dPGJ2 cells were pre-incubated with 
the CRTH2 antagonist (GSKCRTH2X). The CRTH2 antagonist could not attenuate the 
effects of 15dPGJ2, Figure 4.7. 
 
 
Figure 4.7 The effect of 15dPGJ2 on basal NF-κB p65 phosphorylation in peripheral blood 
mononuclear cells PBMCs were treated with 32 µm of 15dPGJ2 for 2 hrs with or without 
preincubation with 100 µm of GSKCRTH2X for 45 mins. Whole cell protein lysate was 
examined for levels of phosphorylated p65 (p-p65) using immunoblotting. A representative 
immunoblot from n=6 samples are shown (A). Immunoblots were reprobed for β-actin as an 
internal loading control. Densitometric analysis of the immunoblots was conducted revealing a 
complete inhibition of p-p65 levels with 15dPGJ2. Pre-incubation with the CRTH2 antagonist 
GSKCRTH2X had no effect on inhibition (B). Effect of treatment was examined for statistical 
significance using ANOVA of repeated measures with Bonferroni’s multiple comparison test; 
**** P<0.0001. 
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4.8 15dPGJ2 reduces PMA stimulated NF-κB in peripheral blood 
mononuclear cells  
 
PMA and ionomycin are stimulants used in vitro to represent in vivo T cell activation. 
To determine if 15dPGJ2 was able to inhibit PMA/ionomycin activated T cells, 
peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 
15dPGJ2 and stimulated with PMA/ionomycin for 10 mins. Whole cell protein lysate 
was extracted and assessed for levels of phosphorylated p65, the transcriptionally 
active subunit of NF-κB. PMA/ionomycin treatment stimulated NF-κB phosphorylation 
in all samples. Pre-treatment of cells with 15dPGJ2 reduced levels of p-p65 in all 
samples but narrowly missed out on statistical significance (n=4). A representative 
immunoblot is shown in Figure 4.8A and a summary of all experiments is expressed in 
the graph in Figure 4.8B. 
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Figure 4.8 15dPGJ2 reduces PMA stimulated NF-κB activity in peripheral blood mononuclear 
cells  
PBMCs were treated with 15dPGJ2 for 2 hrs then stimulated for 10 mins with PMA/ionomycin. 
Whole cell protein lysate was extracted and levels of phosphorylated p65 examined using 
immunoblotting. A representative immunoblots is shown (A). Immunoblots were reprobed for 
β-actin as an internal loading control. Densitometric analysis of the immunoblots was 
conducted revealing a significant increase in p-p65 levels upon stimulation and a decrease 
with the addition of 15dPGJ2 (B). Effect of treatment was examined for statistical significance 
at each gestational timepoint using ANOVA of repeated measures with Bonferroni’s multiple 
comparison test; *P<0.05. 
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4.9 NF-κB activity is unchanged during pregnancy and labour 
 
Previous studies have shown that NF-κB activity is suppressed in T cells in pregnancy. 
However, it is not known if this suppression is reversed at term and in labour. 
Peripheral blood mononuclear cell whole cell lysate from non-pregnant women, 
women at 28 weeks gestation and at term pre-labour and in labour was analysed for 
phospho-65 by western analysis. In this leukocyte population there was no difference 
in phosopho-p65 between non-pregnant women and pregnant women, or between 
labouring and non-labouring women.  Figure 4.9A shows a representative immunoblot 
and Figure 4.9B shows a summary of three to four replicates in the form of a graph.  
 
Figure 4.9 No difference in Phospho-p65 in peripheral blood mononuclear cells during 
pregnancy and in labour  
Whole cell lysate was extracted from peripheral blood mononuclear cells from non-pregnant 
women, women at 28 weeks and at term not in labour or in labour.  Levels of phosphorylated 
p65 (p-p65) were examined using immunoblotting. Representative immunoblots are shown 
for each gestational time point (A), n=3 or 4. Immunoblots were reprobed for β-actin as an 
internal loading control. Densitometric analysis of the immunoblots  showed no change in p-
p65 between gestational timepoints (B).  Effect of treatment was examined for statistical 
significance at each gestational timepoint using the Students t-test.  
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4.10 15dPGJ2 reduces PMA stimulated phospho p65 at all gestational 
time points  
 
Since 15dPGJ2 was shown to reduce PMA stimulated NF-κB in non-pregnant women, 
the effect on NF-κB during pregnancy and in labour was also determined. A reduction 
was seen at all gestational time points, with the most significant effect seen at 28 
weeks, (P<0.0001) and at term in labour (P<0.05), Figure 4.10. 
 
 
 
Figure 4.10 15dPGJ2 reduces PMA stimulated NF-κB p65 phosphorylation in peripheral blood 
mononuclear cells during pregnancy and in labour  
PBMCs were treated as previously described and whole cell lysate was extracted. Levels of 
phosphorylated p65 (p-p65) were examined using immunoblotting. Representative 
immunoblots are shown for each gestational time point (A) (n=3). Immunoblots were 
reprobed for β-actin as an internal loading control. Densitometric analysis of the immunoblots 
was conducted revealing a significant increase in p-p65 levels upon stimulation with 
PMA/ionomycin in all samples (B). A significant decrease in PMA/ionomycin stimulated p-p65 
was observed following 15dPGJ2 treatment in 28 week and term in labour samples. Effect of 
treatment was examined for statistical significance at each gestational timepoint using 2 way 
ANOVA with Bonferroni’s multiple comparison test; **** P<0.0001*** P<0.001, **P<0.01, 
*P<0.05. 
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Summary and discussion 
 
The discovery that the anti-inflammatory prostaglandin 15dPGJ2 inhibits NF-κB in 
human amniocytes and myocytes [271], and delays inflammation induced preterm 
labour in the mouse [277] by an unknown mechanism led us to investigate a potential 
role for the CRTH2 receptor and small molecule CRTH2 agonists. Data presented in 
chapter 3 concludes that CRTH2 is not expressed on human amniocytes and myocytes, 
thus implying there is no role for CRTH2 in 15dPGJ2-mediated inhibition of NF-κB in 
these cells. It is not known what effect CRTH2 agonists have on NF-κB signalling, and 
the effect of 15dPGJ2 on NF-κB in human peripheral mononuclear cells has not been 
examined before. Data presented in this chapter conclusively rules out any role for 
CRTH2 in 15dPGJ2-mediated inhibition of NF-κB, however it shows that 15dPGJ2 does 
have inhibitory effects on NF-κB in PBMCs, which is maximal in activated cells at 28 
weeks of gestation and in labour.  
 
The CRTH2 agonist Pyl A 
 
Pyl A is a stable synthetic, potent, and selective CRTH2 agonist which was made by 
Oxygen Healthcare based on the published compound L-888,607 synthesised by Merck 
[320]. The compound was shown to bind to DP1 and CRTH2 with affinity (Ki) of 2331 
and 0.8 nM (2.333 µM and 0.0008 µm) respectively. The structures of CRTH2 agonists 
are shown in Figure 4.11 (adapted from Gervais et al 2005). The CRTH2 agonist Pyl A 
(L-888,607) was developed from L-883,595 which generated two stereoisomers; L-
888,291 and L-888,607, with the latter being the most potent. The arrow (1) shows the 
point which reflects the stereoisomer structure. The cyclopentenone ring (2) 
contributes to the potency as does the presence of the sulphur molecule (3). 
Substituting a heavier molecule at the site of the fluoride molecule was found to 
reduce the potency (4). At higher concentrations, the compound is able to bind to 
other prostanoid receptors with the rank of order of affinity as follows: CRTH2> TP> 
EP3> DP> EP4> EP2> FP> IP> EP1. 
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Figure 4.11 The structure of CRTH2 agonists. Adapted from Gervais et al, 2005.  
The potent stereoisomer L-888,607 was developed from the L-883,595 compound by Gervais 
et al. The structure is shown alongside its stereoisomer L-888,291 with arrow 1 at the point 
which reflects the stereoisomeric structure. Arrow 2 points to the presence of the 
cyclopentenone ring which can be seen in all structures including 15dPGJ2. The presence of 
the sulphur molecule appears to be important for the affinity of the compound as shown by 
arrow 3. By substituting the fluoride molecule (arrow 4) the potency is reduced.  
 
 
 
The activity of L-888,607 at the CRTH2 receptor was demonstrated by its ability to 
cause eosinophil morphological shape change and maximal eosinophil chemotaxis at 
100 nM concentration [320]. For the purpose of this thesis, the activity at the CRTH2 
receptor was demonstrated by its ability to increase the expression of CD11b in 
eosinophils (Figure 4.1). PGD2, 15dPGJ2 and Indomethacin increase its expression via 
CRTH2, which is thought to contribute to eosinophil migration [303, 304, 321]. As 
added confirmation that Pyl A was acting through CRTH2, the CRTH2 antagonist 
GSKCRTH2X inhibited this response.  
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The CRTH2 agonist Pyl A has no effect on NF-κB in amniocytes, myocytes and PBMCs 
 
The agonist Pyl A had no effect on phospho-p65 in human amniocytes and myocytes 
(Figure 4.3). This was expected in view of the absence of detectable levels of the 
CRTH2 protein in amniocytes and myocytes. The effect of the CRTH2 agonists Pyl A and 
DK- PGD2 on NF-κB activity was explored in peripheral blood mononuclear cells, with 
known expression of CRTH2. However, no effect on phospho-65 was seen in PBMCs 
either, (Figures 4.5 and 4.6). The only other study to explore the effect of CRTH2 
agonists on NF-κB showed that an IKB inhibitor had no effect PGD2 induced cytokine 
production. Despite rocaglamide (an NF-κB inhibitor) causing a reduction in PGD2-
induced cytokine production by 30%, PGD2 did not lead to an increase phospho-IκB, 
suggesting a non-pathway specific effect of rocaglamide [302]. Together with this data 
reporting no direct effect on NF-κB signalling upon CRTH2 activation with PGD2, our 
data also supports no direct effect on NF-κB signalling via CRTH2. The main pathway 
activated with CRTH2 agonists appears to be the phosphatidylinositol 3-kinase (PI3K) 
pathway which is involved in indomethacin induced eosinophil morphological change, 
CD11b expression [304] and PGD2 induced production of IL-4, IL-5 and IL-13, and 
chemotaxis in Th2 cells [302].  
 
The CRTH2 agonist 15dPGJ2 inhibits NF-κB in amniocytes, myocytes and PBMCs 
independently of CRTH2 
 
As previously described, 15dPGJ2 is an endogenous prostaglandin which accumulates 
intracellularly [278], and can be measured endogenously in picomolar concentrations 
in body fluids [322].  As well as being a ligand for PPAR-γ, it is also an agonist of the 
CRTH2 receptor [287]. 15dPGJ2 has previously been shown to inhibit NF-κB in 
amniocytes and myocytes in vitro [271], the effect of which was replicated here as 
seen in Figure 4.2A and B. Since NF-κB controls the expression of many labour 
associated genes and pro-inflammatory cytokines; targeting its inhibition seems 
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attractive to prevent both inflammation induced preterm labour and the associated 
risk of brain injury associated with inflammation. As well as the potentially beneficial 
effect of 15dPGJ2 locally at the maternal fetal interface, a peripheral anti-inflammatory 
effect in women with systemic signs of chorioamnionitis could also be beneficial in 
preventing neonatal adverse outcome.  
 
The inhibitory effect of 15dPGJ2 on NF-κB activity was replicated in peripheral blood 
mononuclear cells at similar concentrations used with amniocytes and myocytes, 
(Figure 4.4). A reduction was also seen in PBMCs stimulated with the classical 
activators of T cells, PMA and ionomycin (Figure 4.8). To finally rule out a role of 
CRTH2 in 15dPGJ2 mediated inhibition of NF-κB activity, PBMCs were pre-incubated 
with the CRTH2 antagonist GSKCRTH2X (Figure 4.7). No attenuation of NF-κB inhibition 
was seen with the CRTH2 antagonist.  As demonstrated in chapter 3 CRTH2 is only 
present on a small subset of T cells, and the PBMCs population examined here will 
contain a significant proportion of non-CRTH2 expressing T and B cells. Since there was 
complete inhibition of NF-κB (Figure 4.7), whatever the mechanism of action, it must 
be a mechanism which is occurs in all subsets of leukocytes in the PBMC population 
examined.  
 
Although 15dPGJ2 is also a high affinity ligand to the nuclear PPAR-γ receptor, this is 
not the mechanism of  NF-ĸB inhibition in amniocytes and myocytes [271]. 15dPGJ2 
contains an electrophilic cyclopenteneone ring, a property which permits it to ligate 
nuclear receptors and modify intracellular signalling molecules. The highly reactive 
ring of 15dPGJ2 can form a covalent interaction with components of the NF-ĸB 
signalling pathway (IkB kinase complex B, p50, and p65 subunits) via the Michael 
reaction, resulting in impaired nuclear entry and DNA binding activity [323].  PGA1, 
which contains an electrophilic cyclopentenone ring mimics the effect of 15dPGJ2 in 
amniocytes and myocytes, whereas 9, 10-dihydro-15dPGJ2 (in which the ring is 
disrupted) does not [271]. Although Pyl A contains a cyclopentenone ring, it is not 
highly electrophilic like 15dPGJ2. It is highly likely that the electrophilic cyclopentenone 
ring of 15dPGJ2 is also essential for the inhibition of NF-ĸB seen in PBMCs. Although 
prostaglandin J2 has been shown to enter the cell by active transport [324], it is not 
                                                                                    Chapter 4: CRTH2 agonists and NF-κB 
 
151 
 
yet clear if this is the mechanism of entry into amniocytes, myocytes and PBMCs. Data 
presented in this chapter excludes a CRTH2-dependent receptor-mediated entry into 
the cell as a requirement for NF-ĸB inhibition, and excludes a CRTH2 dependent 
downstream signalling effect for the inhibition of NF-ĸB.  
 
NF-κB activity in PBMCs during pregnancy and in labour 
 
The immune system undergoes significant adaptation during pregnancy to 
accommodate the “foreign” fetus with a degree of immune-suppression whilst 
maintaining adequate immune function to ward off infection. The precise immuno-
regulatory mechanisms remain to be determined. There is significant evidence 
supporting the bias towards a favourable Th2 interleukin profile away from the pro-
inflammatory Th1 profile for successful pregnancy maintenance, which is discussed in 
more detail in chapter five. One proposed immuno-regulatory mechanism is that of  
suppressed NF-κB activity in T cells during pregnancy compared to non-pregnant 
controls which is thought to explain the suppressed Th1 response in pregnancy [240]. 
Peripheral blood mononuclear cells from women in the third trimester stimulated with 
pooled non-pregnant serum and LPS show reduced NF-κB DNA binding activity, 
reduced nuclear p65 and reduced cytosolic Iκ-Bα and Iκ-Bβ [257]. Isolated T cells of 
pregnant women in the third trimester also show a reduced response to 
PMA/ionomycin stimulation with absent nuclear and whole cell p65 and reduced 
whole cell and cytosolic Iκ-Bα and Iκ-Bβ [240].This group demonstrated that levels of 
PMA stimulated nuclear p65 returned to non-pregnant values by 72 hours post partum 
[256].   
 
Contrary to what was anticipated, basal NF-κB activity as determined by whole cell 
phospho-p65 was unchanged throughout pregnancy and in labour in peripheral blood 
mononuclear cells (Figure 4.9). PMA/ionomycin stimulation led to a significantly 
increased activity of NF-κB at all time points in pregnancy with no apparent difference 
compared to non-pregnant controls (Figure 4.10). Two of the studies above isolated T 
cells, and therefore the results from the PBMCs, which will include B cells are not 
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representative of the cell population in McCracken’s studies [240, 257]. In the one 
study in which they also used PBMCs, cells were stimulated with pooled serum and 
LPS, which again is not a comparable method to the one which was used in this thesis. 
Whilst all studies are valid and provide useful insights into potential in vivo leukocyte 
NF-κB activity, isolation of T cells provides more information on the potential immuno-
regulation specifically in these cells which may then alter the Th1/Th2 balance. 
However, the presence of B cells in vivo also serve a potentially important role, and 
the effect on peripheral blood cells as a whole with cell-cell interaction may be more 
relevant in reflecting the overall immune response which occurs in vivo.  
 
15dPGJ2 was able to reduce basal and PMA/ionomycin activated NF-κB, with the most 
significant effect seen at 28 weeks and at term in labour. The women at these time 
points would be the target populations of any proposed administration of 15dPGJ2 as 
an anti-inflammatory and anti-labour therapeutic agent.  
 
In summary, from the data presented in this chapter, a conclusion can be drawn that 
15dPGJ2 inhibits NF-κB in a mechanism independent of CRTH2. The discovery that 
15dPGJ2 also suppresses NF-κB activity in peripheral blood mononuclear cells raises 
the possibility that it may also be used to suppress systemic inflammation and reduce 
production of pro-inflammatory cytokines in circulating peripheral leukocytes.  
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CHAPTER 5 
 
CRTH2 agonist effect on the Th1/Th2 interleukins 
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Chapter summary  
Hypothesis:  
The CRTH2 agonist PGD2 induces the production of the Th2 interleukins in vitro. 
15dPGJ2 inhibits NF-κB in peripheral blood mononuclear cells (PBMCs). It is possible 
that the CRTH2 agonists 15dPGJ2 and Pyl A can modulate the systemic production of 
Th1/Th2 interleukins.  
 
Aims:  
The work presented in this chapter aims to determine if the Th1 interleukins are 
suppressed and if the Th2 interleukin IL-4 is increased in PBMCs during pregnancy. The 
Th1/Th2 interleukin profile during labour was also examined to determine if there is a 
shift towards the pro-inflammatory Th1 response, consistent with the pro-
inflammatory profile seen locally in amnion and myometrium. The potential 
immunomodulatory effect of the CRTH2 agonists 15dPGJ2 and Pyl A on the Th1/Th2 
profile in PBMCs was examined at different stages of pregnancy and in labour. 
 
Methods:  
Blood was collected from women at different gestational time points and during 
labour. PBMCs were treated with CRTH2 agonists or vehicle and stimulated with 
PMA/ionomycin. Expression of intracellular interleukins in CD4 or CRTH2 positive cells 
was determined by flow cytometry.  
 
Results:  
The Th1 interleukins IFN-γ and TNF-α were suppressed in pregnancy, with no increase 
in labour. There was no change in IL-4 production during pregnancy or in labour. 
15dPGJ2 suppressed PMA/ionomycin stimulated Th1 interleukin production; however 
neither 15dPGJ2 nor Pyl A increased IL-4 production. 
 
Conclusion:  
Unlike Pyl A, 15dPGJ2 is able to modulate the Th1:Th2 interleukin ratio, by suppressing 
the Th1 cytokines. This effect is not via CRTH2 and is likely to be via inhibition of NF-κB. 
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Introduction  
 
The hypothesis of Th2 predominance and downregulation of the Th1 response for the 
maintenance of successful pregnancy originated from Wegmann and colleagues [209] 
and was reinforced by evidence from both murine studies and the clinical course of 
Th2 and Th1 based conditions in pregnancy. Th1 and Th2 cell subsets originate from 
undifferentiated Th0 cells under the influence of IFN-γ and IL-4 respectively. Type 1 
CD4+ T cells produce an array of inflammatory cytokines including IFN-γ [190], IL-2 
[191], and Tumor necrosis factor-alpha (TNF-α) [192], whereas the type 2 CD4+ T cells 
(Th2) produce IL-4, IL-5, IL-13, IL-10 [190]. 
 
Term labour is often seen as a pro-inflammatory state and therefore it is plausible that 
labour is associated with a reversal in the bias back towards Th1 rather than Th2 in the 
peripheral blood cells. There is substantial evidence that the Th1 cytokines play a role 
in the initiation of labour at term locally at the maternal fetal interface [192]. Fetal 
membranes [166, 171] and myometrium [325] produce IL-1β at term, and TNF-α and 
IL-1β are both increased in amnion, amniotic fluid and decidua at term [233]. TNF-α 
and IL-1β are potent inducers of the transcription factor NF-κB [271]. NF-κB regulates 
the expression of several labour-associated genes including COX-2, the oxytocin 
receptor, IL-8 and matrix metalloproteinase-9 (MMP-9) [245]. 
 
Preterm labour is often associated with infection and inflammation, particularly early 
preterm labour [63]. Activation of the Th1 cytokines occurs as a specific response to 
infection caused by intracellular bacteria, parasites and viruses [239]. During infection  
IL-12 is produced by macrophages and dendritic cells [326, 327], which leads to 
polarisation from Th0 to Th1 type cells [194]. The Th1:Th2 ratio is further altered by 
IFN-γ up-regulating the IL-12 receptor leading to further Th1 development, and by the 
inhibition of Th2 cells [328]. As part of the fetal response to infection and PROM, there 
is also evidence of a fetal Th1 polarised response with an increase IFN-γ production in 
cord blood [101]. Pro-inflammatory cytokines, such as TNF-α and IL-1β can ultimately 
result in the production of prostaglandins and MMPs [236], via NF-κB.  The production 
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of pro-inflammatory Th1 interleukins therefore has the potential for triggering a 
cascade of pro-labour events including uterine contractility and fetal membrane 
rupture leading to preterm labour. The presence of infection and inflammation is now 
considered an independent risk factor for the neonatal brain injury in neonates born 
preterm [319], and at term [329]. For example, amniotic fluid and cord blood pro-
inflammatory cytokines IL-1β, IL-6, and TNF-α are associated with radiological 
evidence of cerebral damage [330, 331].  
PGD2 promotes the production of the Th2 interleukins IL-4, IL-13, IL-5 and IL-10 in T 
helper 2 cells in vitro via the second PGD2 receptor, CRTH2 [217]. PGD2 is produced by 
the placenta and may play a role in the chemo-attraction of Th2 cells, via the CRTH2 
receptor, to the maternal fetal interface to produce a localised Th2 bias [198]. The 
non-immune cells of the maternal fetal interface; trophoblast, decidua and amnion 
can contribute to the Th2 cytokine environment by production of IL-13 [222], IL-10 
[223], IL-4 and IL-6 [224, 225]. There is substantial evidence for the importance of a 
Th2 bias during pregnancy, mainly at the maternal fetal interface [192, 208, 332]. 
Consistent with this, decidual CD4+ cells from women undergoing unexplained 
recurrent pregnancy loss typically exhibit  reduced IL-4 and IL-10 production [149]. 
In this chapter, the potential for CRTH2 agonists as immunomodulatory therapeutic 
agents was explored. The expression profile of the Th1 interleukins IFN-γ and TNF-α, 
and the Th2 interleukin IL-4 in T helper cells were examined to identify if; firstly a Th2 
bias exists during pregnancy, and secondly if this is altered during term labour. The 
effect of 15dPGJ2 on the Th1 and Th2 interleukins was examined to determine if a Th1 
response could be suppressed via its ability to inhibit NF-κB in PBMCs, and if a Th2 
response could be induced via its agonist effect on the CRTH2 receptor. The small 
molecule agonist Pyl A was also used to determine if a Th2 response could be induced, 
and if a Th1 response could be indirectly suppressed by the production of Th2 
interleukins.  
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Results 
 
5.1 The Th1/Th2 interleukin profile during pregnancy and labour 
  
Many groups have reported on a bias in the Th1:Th2 interleukin ratio in favour of Th2 
interleukins during pregnancy at a local level, however there is limited data on the 
Th1:Th2 profile in peripheral blood mononuclear cells in labour. This chapter reports 
on the Th1:Th2 profile in T helper cells during pregnancy and in labour, and the effects 
of the CRTH2 agonists 15dPGJ2 and Pyl A on the interleukins. PBMCs were examined 
from women at 28 weeks gestation, at term pre labour and in labour, and from non-
pregnant women serving as controls. Cells were stimulated with PMA/ionomycin (or 
vehicle control). For examining the effects of the CRTH2 agonists cells were incubated 
for 2 hrs with the agonist prior to PMA/ionomycin stimulation. Intracellular production 
of the Th1 interleukins IFN-γ and TNF-α, and the Th2 interleukin IL-4 were examined by 
flow cytometry. The percentage of cells producing the interleukins, as well as the 
mean fluorescence intensity of expression was analysed. Four biological replicates 
were used in all experiments presented in this chapter.  
 
5.1.1 IFN-γ production in CD4+ (T helper cells) at different gestational time points  
 
PMA /ionomycin stimulated cells from women at 28 weeks, term pre labour, term in 
labour and non-pregnant women were examined for IFN-γ production. Cells were 
labelled with CD4-APC to identify T helper cells. The percentage of IFN-γ+/CD4+ cells 
and the geometric mean fluorescence intensity of IFN-γ in these cells were 
determined. Figure 5.1.1A shows a representative dot blot of non-stimulated cells, 
non-pregnant and 28 week PMA/ionomycin treated lymphocytes. The right upper 
quadrant shows the IFN-γ+/CD4+ cells. A clear increase in the percentage of cells 
producing IFN-γ is seen with PMA/Ionomycin treatment. A lower percentage of cells 
produced IFN-γ during pregnancy, as shown by the representative non-pregnant and 
28 week dot blots.  
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Panel B summarises the results for n=4. The mean percentage of IFN-γ-producing CD4+ 
lymphocytes in response to stimulation reduced from 10.74%  in non pregnant women 
to 6.57% at 28weeks, 5.065% at term pre-labour and 5.55% at term in labour 
respectively (P < 0.05, P <0.001 and P <0.01 respectively). There was also a reduction 
in the percentage of cells secreting IFN-γ in the non-stimulated state, however this did 
not reach statistical significance. PMA/ionomycin significantly increased the 
production of IFN-γ at all time points, however the mean fluorescence intensity of 
production was not significantly different between gestational time points in 
stimulated cells; with a mean fluorescence intensity of 101.92, 115.7, 110.14 and 
88.28 in non pregnant, 28 weeks, term pre-labour and term in labour samples 
respectively (Figure 5.1.1C). No significant increase in either the percentage of cells 
producing IFN-γ or the expression of IFN-γ was seen in labour compared to the pre-
labour samples in stimulated and non-stimulated cells (Figure 5.1.1B). There was 
nevertheless a small but clear increasing trend in the basal percentage of cells 
producing IFN-γ from 28 weeks to term, with a further increase in labour (Figure 
5.1.1B – seen more clearly with different axis range later in Figure 5.2.1A panel B). 
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Figure 5.1.1 IFN-γ production in CD4+ T helper cells at different gestational time points 
Peripheral blood mononuclear cells were isolated and stimulated with PMA/ionomycin. The 
percentage of IFN-γ+/CD4+ positive cells and the geometric mean fluorescence intensity of  
IFN-γ+ were detected by flow cytometry in samples derived from non-pregnant (NP), 28 week 
pregnant, term pre-labour (TL-) and term in labour (TL+) samples. A representative dot blot 
shows the effect of stimulation on IFN-γ production in CD4 positive cells in non-pregnant and 
28 week lymphocyte samples, (seen in the right upper quadrants in panel A).  A significant 
reduction in the percentage IFN-γ secreting CD4+ lymphocytes was seen at all gestational time 
points compared to non-pregnant controls (B). Geometric mean fluorescence intensity (M.F.I.) 
was also assessed as a measure of total cytokine production (C). PMA/ionomycin stimulation 
significantly increased IFN-γ production in all sample groups, however no differences in 
gestation-dependent responses were detected. For statistical analysis Two-way ANOVA with 
Bonferroni’s multiple comparison test using NP or non-stimulated  samples as a control was 
used; ****P<0.0001, ***P< 0.001, **P<0.01, *P<0.05.  
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5.1.2 TNF-α production in CD4+ (T helper cells) at different gestational time points  
 
The second Th1 interleukin to be examined in PMA /ionomycin stimulated cells at the 
different gestational time points was TNF-α. The percentage of TNF-α+/CD4+ cells and 
the geometric mean fluorescence intensity of TNF-α in these cells were determined. 
Figure 5.1.2A shows a representative dot blot of non-stimulated cells, non-pregnant 
and 28 week PMA/ionomycin treated lymphocytes. The right upper quadrant shows 
the TNF-α+/CD4+ cells. An increase in the percentage of cells producing TNF-α is seen 
with PMA/ionomycin treatment. A lower percentage of cells produced TNF-α during 
pregnancy, as shown by the representative non-pregnant and 28 week dot blots, 
although the effect was more subtle than in the IFN-γ dot blots. 
 
Panel B of figure 5.1.2 summarises the results for n=4. The mean percentage of TNF-α -
producing CD4+ lymphocytes in response to stimulation reduced from 20.6% in non-
pregnant women to 14.53% at 28 weeks, 15.78% at term pre-labour and 13.26% at 
term in labour respectively, however this effect did not reach statistical significance. 
There was also a non-significant reduction in the percentage of cells secreting TNF-α in 
the non-stimulated cells. PMA/ionomycin significantly increased the percentage of 
cells producing TNF-α and the expression within the positive cells at all time points, 
however the mean fluorescence intensity of production was not significantly different 
between gestational time points in stimulated cells; with a mean fluorescence 
intensity of 63.28, 72.62, 64.44 and 55.96 in non pregnant, 28 weeks, term pre-labour 
and term in labour samples respectively (Figure 5.1.2C). No significant increase in 
either the percentage of cells producing TNF-α or the expression of TNF-α was seen in 
labour compared to the pre-labour samples in PMA/ionomycin or non-stimulated cells 
(Figures 5.1.2B). There was nevertheless a small but clear increasing trend in the basal 
percentage of cells producing TNF-α from 28 weeks to term, with a further increase in 
labour (Figure 5.1.2B – seen more clearly with different axis scale later in Figure 5.2.2A 
panel B). 
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Figure 5.1.2 TNF-α production in CD4+ T helper cells at different gestational time points 
Peripheral blood mononuclear cells were isolated and stimulated with PMA/ionomycin. The 
percentage of TNF-α+/CD4+ positive cells and the geometric mean fluorescence intensity of  
TNF-α were determined by flow cytometry in samples derived from non-pregnant (NP), 28 
week pregnant, term pre-labour (TL-) and term in labour (TL+) samples. A representative dot 
blot shows the effect of stimulation on TNF-α production in CD4 positive cells in non-pregnant 
and 28 week lymphocyte samples, (seen in the right upper quadrants in panel A).  
PMA/ionomycin significantly increased the percentage of cells producing TNF-α and mean 
expression (B). Although a reduction was seen in the percentage of TNF-α/CD4+ cells during 
pregnancy in both non-stimulated and stimulated cells, this narrowly missed out on statistical 
significance. Geometric mean fluorescence intensity (M.F.I.) was also assessed as a measure of 
total cytokine production (C). PMA/ionomycin stimulation significantly increased TNF-α 
production in all sample groups, however no differences in gestation-dependent responses 
were detected. For statistical analysis Two-way ANOVA with Bonferroni’s multiple comparison 
test using NP or non-stimulated  samples as a control was used; ****P<0.0001, ***P< 0.001, 
**P<0.01.  
 
                                                     Chapter 5: CRTH2 agonist effect on Th1/Th2 interleukins 
 
162 
 
5.1.3 IL-4 production in CRTH2+ cells at different gestational time points  
 
The classic Th2 interleukin is IL-4. CRTH2 cells produce IL-4 upon stimulation. The 
effect of PMA/ionomycin stimulation at the different gestational time points was 
examined. The percentage of IL-4+/CRTH2+ cells and the geometric mean fluorescence 
intensity of IL-4 in these cells were determined. Figure 5.1.3A shows a representative 
dot blot of non-stimulated cells, and non-pregnant and 28 week PMA/ionomycin 
stimulated lymphocytes. The right upper quadrant shows the IL-4+/CRTH2+ cells.  
 
A very small increase in the percentage of CRTH2 positive cells producing IL-4 is seen 
with PMA/ionomycin treatment during pregnancy, although this does not reach 
statistical significance; see Figure 5.1.3 panel B. PMA/ionomycin significantly increased 
the mean production of IL-4 in PMA/ionomycin stimulated cells at 28 weeks and at 
term pre-labour from 33.07 to 39.35 and 31.5 to 39.4 respectively.  However the mean 
fluorescence intensity of production was not significantly different between 
gestational time points in stimulated cells. Despite there being an increase in the 
percentage of cells producing IL-4 at 28 weeks compared to non –pregnant samples, 
with a subsequent reduction pre labour at term, this narrowly missed out on statistical 
significance with the use of the Bonferroni’s multiple comparisons test. No significant 
difference in either the percentage of cells producing IL-4 or the expression of IL-4 was 
seen in labour compared to the pre-labour samples.  
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Figure 5.1.3 IL-4 production in CRTH2+ T helper cells at different gestational time points 
Peripheral blood mononuclear cells were isolated and stimulated with PMA/ionomycin. The 
percentage of CRTH2+/ IL-4 positive cells and the geometric mean fluorescence intensity of  IL-
4 were determined by flow cytometry in samples derived from non-pregnant (NP), 28 week 
pregnant, term pre-labour (TL-) and term in labour (TL+) samples. A representative dot blot 
shows the effect of stimulation on IL-4 production in CRTH2 positive cells in non-pregnant and 
28 week lymphocyte samples, (seen in the right upper quadrants in panel A).  PMA/ionomycin 
increased the percentage of cells producing IL-4 (B) and mean expression during pregnancy 
(C). No statistically significant difference was seen in the percentage of IL-4/CRTH2+ cells or IL-
4 production during pregnancy compared to non-pregnant controls in both non-stimulated 
and stimulated cells. For statistical analysis two-way ANOVA with Bonferroni’s multiple 
comparison test using NP or non-stimulated samples as a control was used; **P<0.01, 
*P<0.05. 
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5.2 The effect of the CRTH2 agonist 15dPGJ2 on the Th1 and Th2 
interleukins  
 
15dPGJ2 is an anti-inflammatory prostaglandin and a ligand for CRTH2. We therefore 
explored the effect of 15dPGJ2 on the Th1 cytokines; IFN-γ and TNF-α. To do this, cells 
were pre incubated with 32 µM of 15dPGJ2 or vehicle control prior to the addition of 
PMA/ionomycin or vehicle before intracellular cytokines were detected by flow 
cytometry.  
 
5.2.1 Effect of 15dPGJ2 on IFN-γ production in CD4
+ (T helper cells) 
 
5.2.1A Non PMA/Ionomycin stimulated cells 
The effect of 15dPGJ2 on basal IFN-γ production was examined. 15dPGJ2 appeared to 
create a CD4+/IFN-γ+ population as demonstrated in the representative dot plot in 
panel A of figure 5.2.1A. This led to an increase in the percentage of IFN-γ+/CD4+ cells 
(panel B) and an increase in IFN-γ production, (panel C). The percentage of IFN-γ+/CD4+ 
lymphocytes increased from 1.3% to 2.2% in non-pregnant women (non-significant), 
0.35% to 2.36% at 28 weeks (P<0.001), 0.57% to 1.84% at term (P<0.05), and 0.87% to 
1.78% (non- significant) at term in labour. 15dPGJ2  also led to a small increase in the 
production of IFN-γ (measured as the geometric mean fluorescence intensity) in T 
helper cells from 24.36 to 28.08 (non-significant) in non-pregnant controls, 37.29-
45.59 (P<0.05) in 28 week samples and from 29.26 to 34.35 in term pre-labour (non-
significant), and 38.85 to 45.34 in term in labour (non significant) samples. An example 
histogram shows the mean intensity of IFN-γ+/CD4+ cells under the different 
conditions, panel D. 
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5.2.1B PMA/Ionomycin stimulated cells 
The effect of 15dPGJ2 on PMA/ionomycin IFN-γ production was examined, with a 
representative dot plot shown in panel A of figure 5.2.1B. 15dPGJ2 reduced the 
percentage of PMA/ionomycin stimulated IFN-γ+/CD4+ cells and the mean production 
of IFN-γ at all gestational time points, see panel B and C Figure 5.2.1B. The percentage 
of IFN-γ+/CD4+ lymphocytes reduced from 10.7% to 5.13% in non-pregnant women 
(P<0.001), 6.6% to 3.4% at 28 weeks (P<0.05), 5.1% to 2.5% at term L- and 5.6 % to 
2.9% at term L+. The reduction in PMA/ionomycin stimulated IFN-γ (measured as the 
geometric mean fluorescence intensity) was from 101.9 to 52.96 (P<0.01) in non-
pregnant controls, 115.7 to 52.35 (P<0.001) in 28 week samples and from 110.1 to 
60.73 in term pre-labour (P<0.01), and 88.28 to 66.30 in term in labour (P>0.05) 
samples. An example histogram shows the mean intensity of IFN-γ+/CD4+ cells under 
the different conditions, panel D. 
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Figure 5.2.1A Effect of 15dPGJ2 on IFN-γ production in non-stimulated CD4
+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
before being gated on the lymphocyte population according to forward and side scatter. 
15dPGJ2 induced a population of IFN-γ
+/CD4+ cells as shown in a representative 28 week 
patient sample, with IFN-γ+/CD4+ cells shown in the right upper quadrant (A). The percentage 
of IFN-γ+/CD4+ cells increased with 15dPGJ2 treatment (B), as did the mean production of IFN-
γ+ as summarised in the graphs (C). A representative histogram reveals a small shift to the right 
upon treatment indicative of an increase in IFN-γ (D). For statistical analysis a two-way ANOVA 
with Bonferroni’s multiple comparison test was used with non-treated cells as controls; 
***P<0.001, *P<0.05. 
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Figure 5.2.1B Effect of 15dPGJ2 on IFN-γ production in PMA stimulated CD4
+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
and stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. 15dPGJ2 reduced the percentage of IFN-γ
+/CD4+ cells  as 
shown in a representative 28 week patient sample, with IFN-γ+/CD4+ cells shown in the right 
upper quadrant (A). The percentage of IFN-γ+/CD4+ cells reduced with 15dPGJ2 treatment at all 
gestational time points (B), as did the mean production of IFN-γ+ as summarised in the graphs 
(C). A representative histogram reveals a clear shift to the left upon treatment with 15dPGJ2 
indicative of a decrease in IFN-γ (D). For statistical analysis a two-way ANOVA with 
Bonferroni’s multiple comparison test was used with non-treated cells as controls; 
***P<0.001, **P<0.01, *P<0.05. 
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5.2.2 Effect of 15dPGJ2 on TNF-α production in CD4+ (T helper cells) 
 
5.2.2A Non PMA/Ionomycin stimulated cells 
The effect of 15dPGJ2 on basal TNF-α production was examined to determine if the 
same effect was seen as with IFN-γ. 15dPGJ2 also appeared to create a TNF-
α+/CD4+population as demonstrated in the representative dot plot in panel A of Figure 
5.2.2A. This led to an increase in the percentage of TNF-α+/CD4+ cells (panel B) and a 
small increase in TNF-α production, (panel C). The percentage of TNF-
α+/CD4+lymphocytes increased from 1.57% to 3.28% in non-pregnant women (non-
significant), 0.31% to 4.36% at 28 weeks (P<0.001), 0.72% to 3.08% at term (P<0.05), 
and 1.12% to 3.13% (non-significant) at term in labour. 15dPGJ2 also led to a small 
increase in the production of TNF-α (measured as the geometric mean fluorescence 
intensity) in T helper cells from 19.85 to 24.75 (non-significant) in non-pregnant 
controls, 33.4-34.54 (non-significant) in 28 week samples and from 13.73 to 23.96 in 
term pre-labour (P<0.05), and 22.65 to 26.67 in term in labour (non-significant) 
samples. An example histogram shows the mean intensity of TNF-α+/CD4+ cells under 
the different conditions, panel D. 
 
5.2.2B PMA/Ionomycin stimulated cells 
The effect of 15dPGJ2 on PMA/ionomycin TNF-α production was also examined, with a 
representative dot plot shown in panel A of figure 5.2.2B. 15dPGJ2 reduced the 
percentage of PMA/ionomycin stimulated TNF-α+/CD4+ cells (panel B) and the mean 
production of TNF-α at all gestational time points, see panel C Figure 5.2.2B. The 
percentage of TNF-α+/CD4+ lymphocytes reduced from 20.6% to 16.75% in non-
pregnant women (P<0.05), 14.53% to 8.99% at 28 weeks (P<0.001), 15.79% to 12.92% 
at term (non-significant) and 13.96% to 8.93% (P<0.05). 15dPGJ2 also reduced the 
production of PMA/ionomycin stimulated TNF-α (measured as the geometric mean 
fluorescence intensity) in T helper cells from 63.29 to 45.65 (P<0.05) in non-pregnant 
controls, 72.62 to 53.14 (P<0.01) in 28 week samples and from 64.44 to 46.05 in term 
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pre-labour (P<0.01), and 55.96 to 45.97 in term in labour (non-significant) samples. An 
example histogram shows the mean intensity of TNF-α+/CD4+ cells under the different 
conditions, panel D. 
 
Figure 5.2.2A Effect of 15dPGJ2 on TNF-α
+ production in non-stimulated CD4+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
before being gated on the lymphocyte population according to forward and side scatter. 
15dPGJ2 induced a population of TNF-α
+/CD4+ cells  as shown in a representative 28 week 
patient sample, with TNF-α+/CD4+ cells shown in the right upper quadrant (A). The percentage 
of TNF-α+/CD4+ cells increased with 15dPGJ2 treatment (B), as did the mean production of TNF-
α as summarised in the graphs (C). A representative histogram reveals a small shift to the right 
upon treatment indicative of an increase in TNF-α (D). For statistical analysis a two-way 
ANOVA with Bonferroni’s multiple comparison test was used with non-treated cells as 
controls; ***P<0.001, **P<0.01 *P<0.05. 
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Figure 5.2.2B Effect of 15dPGJ2 on TNF-α production in PMA stimulated CD4
+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
and stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. 15dPGJ2 reduced the percentage of TNF-α
+/CD4+ cells  
as shown in a representative 28 week patient sample, with TNF-α+/CD4+ cells shown in the 
right upper quadrant (A). The percentage of TNF-α+/CD4+ cells reduced with 15dPGJ2 
treatment at all gestational time points (B), as did the mean production of TNF-α as 
summarised in the graphs (C). A representative histogram reveals a clear shift to the left upon 
treatment with 15dPGJ2 indicative of a decrease in TNF-α (D). For statistical analysis a two-way 
ANOVA with Bonferroni’s multiple comparison test was used with non-treated cells as 
controls; **P<0.01, *P<0.05. 
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5.2.3 Effect of 15dPGJ2 on IL-4 production in CRTH2
+ cells 
 
Since the CRTH2 agonists indomethacin and PGD2 induce IL-4 production in T helper 
cells via CRTH2, it was hypothesized that 15dPGJ2 would induce an increase in IL-4 
production via its action on the CRTH2 receptor.  
 
5.2.3A Non PMA/Ionomycin stimulated cells 
The effect of 15dPGJ2 on basal IL-4 production was examined. 15dPGJ2 had no effect 
on the percentage of IL-4 producing CRTH2 cells and did not increase the mean 
production of IL-4, (Figure 5.2.3A, panels A and B).  
 
5.2.3B PMA/Ionomycin stimulated cells 
PMA/ionomycin stimulation induced a population of IL-4 producing CRTH2+ cells. 
These cells were pre-treated with 32 µm of 15dPGJ2 for 2 hours. As with non-
stimulated cells, pre-treatment with 15dPGJ2 in the PMA/ionomycin stimulated cells 
had no effect on the percentage CRTH2 cells producing IL-4, neither did it increase the 
mean production of IL-4 in these cells, (Figure 5.2.3B, panels A and B)  
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Figure 5.2.3A Effect of 15dPGJ2 on IL-4 production in non-stimulated CRTH2
+ cells 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
before being gated on the lymphocyte population according to forward and side scatter. No 
significant change in the percentage of IL-4 producing CRTH2+ cells was detected (A). 
Treatment with 15dPGJ2 also had no effect in the mean production of IL-4 production (B). For 
statistical analysis a two-way ANOVA with Bonferroni’s multiple comparison test was used 
with non-treated cells as controls. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.3B Effect of 15dPGJ2 on IL-4 production in PMA-stimulated CRTH2
+ cells 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of 15dPGJ2 
and stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. No significant change in the percentage of IL-4 
producing CRTH2+ cells was detected (A). Treatment with 15dPGJ2 also had no effect in the 
mean production of IL-4 production (B). For statistical analysis a Two-way ANOVA with 
Bonferroni’s multiple comparison test was used with non-treated cells as controls. 
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5.3 The effect of the CRTH2 agonist Pyl A on the Th1/Th2 interleukins  
The effect of the in-house CRTH2 agonist Pyl A on the Th1/Th2 interleukins was next 
examined. No direct effect on the Th1 response should be seen, since CRTH2 is not 
expressed on the Th1 cells. However, an indirect reduction in the Th1 interleukins is 
possible secondary to a possible CRTH2 mediated induction of IL-4 or IL-10 production 
in Th2 cells. The effect of Pyl A on the Th1 interleukins IFN-γ and TNF-α, along with the 
Th2 interleukin IL-4 was examined by flow cytometry.  
 
5.3.1 Effect of Pyl A on IFN-γ production in CD4+ (T helper cells) 
 
5.3.1A Non PMA/Ionomycin stimulated cells 
The effect of 32 µm of Pyl A on basal IFN-γ production was examined. Unlike 15dPGJ2, 
Pyl A did not create a CD4+/IFN-γ+ population as demonstrated in the representative 
dot plot in figure 5.3.1A (A). Pyl A had no effect on the percentage of IFN-γ+/CD4+ cells 
at all gestational time points examined (Figure 5.3.1A, panel B). There was also no 
effect seen on the production of IFN-γ (measured as the geometric mean fluorescence 
intensity) (Figure 5.3.1A, panel C). An example histogram shows the mean intensity of 
IFN-γ+/CD4+ cells under the different conditions, with no shift in either direction with 
Pyl A treatment (Figure 5.3.1A, panel D). 
 
5.3.1B PMA/Ionomycin stimulated cells 
The effect of 32 µm of Pyl A on PMA/ionomycin induced IFN-γ production was 
examined, with a representative dot plot shown in Figure 5.3.1B (A). Pyl A had no 
effect on the percentage of PMA/ionomycin stimulated IFN-γ+/CD4+ cells or the mean 
production of IFN-γ at all gestational time points, (Figure 5.3.1B, panel B and C). An 
example histogram shows the mean intensity of IFN-γ+/CD4+ cells under the different 
conditions, with no shift in either direction with Pyl A treatment (Figure 5.3.1B, panel 
D). 
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Figure 5.3.1A Effect of Pyl A on IFN-γ production in non-stimulated CD4+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of Pyl A 
before being gated on the lymphocyte population according to forward and side scatter. Pyl A 
did not have any effect on IFN-γ production in CD4+ cells. A representative dot blot shows the 
absence of IFN-γ+/CD4+ cells in the right upper quadrant in this Pyl A treated 28 week sample 
(A). The percentage of IFN-γ+/CD4+ cells and the mean production of IFN-γ+ are summarised in 
the graphs, showing no difference between non-treated and Pyl A treated samples at all 
gestational time points (B and C). A representative histogram reveals no shift indicating no 
effect on IFN-γ (D). For statistical analysis a two-way ANOVA with Bonferroni’s multiple 
comparison test was used with non-treated cells as controls.  
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Figure 5.3.1B Effect of Pyl A on IFN-γ production in PMA-stimulated CD4+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of Pyl A, 
then stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. Pyl A did not have any effect on IFN-γ production in 
PMA stimulated CD4+ cells. A representative dot blot shows no difference in the percentage of 
IFN-γ+/CD4+ cells in the right upper quadrant in this 28 week sample with Pyl A treatment (A). 
The percentage of IFN-γ+/CD4+ cells and the mean production of IFN-γ+ are summarised in the 
graphs, showing no effect with Pyl A (B and C). A representative histogram reveals no shift 
indicating no effect on IFN-γ (D). For statistical analysis a two-way ANOVA with Bonferroni’s 
multiple comparison test was used with non-treated cells as controls.  
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5.3.2 Effect of Pyl A on TNF-α production in CD4+ (T helper cells) 
 
5.3.2A Non PMA/Ionomycin stimulated cells 
The effect of 32 µm of Pyl A on basal TNF-α production was examined. Unlike 15dPGJ2, 
Pyl A did not create a TNF-α+/CD4+ population as demonstrated in the representative 
dot plot in figure 5.3.2A, panel A. Pyl A had no effect on the percentage of TNF-
α+/CD4+ cells at all gestational time points examined (Figure 5.3.2A, panel B). There 
was also no effect seen in the production of TNF-α (measured as the geometric mean 
fluorescence intensity) (Figure 5.3.2A, panel C). An example histogram shows the 
mean intensity of TNF-α +/CD4+ cells under the different conditions, with no shift in 
either direction with Pyl A treatment (Figure 5.3.2A, panel D). 
 
5.3.2B PMA/Ionomycin stimulated cells 
The effect of 32 µm of Pyl A on PMA/ionomycin induced TNF-α production was 
examined, with a representative dot plot shown in figure 5.3.2B, panel A. Pyl A had no 
effect on the percentage of PMA/ionomycin stimulated TNF-α +/CD4+ cells or the mean 
production of TNF-α at all gestational time points, figure 5.3.2B, panel B and C. An 
example histogram shows the mean intensity of TNF-α +/CD4+ cells under the different 
conditions, with no shift in either direction with Pyl A treatment (Figure 5.3.2B, panel 
D). 
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Figure 5.3.2A Effect of Pyl A on TNF-α production in non-stimulated CD4+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of Pyl A 
before being gated on the lymphocyte population according to forward and side scatter. Pyl A 
did not have any effect on TNF-α production in CD4+ cells. A representative dot blot shows the 
absence of TNF-α +/CD4+ cells in the right upper quadrant in this Pyl A treated 28 week sample 
(A). The percentage of TNF-α +/CD4+ cells and the mean production of TNF-α + are summarised 
in the graphs, showing no difference between non-treated and Pyl A treated samples at all 
gestational time points (B and C). A representative histogram reveals no shift indicating no 
effect on TNF-α (D). For statistical analysis a two-way ANOVA with Bonferroni’s multiple 
comparison test was used with non-treated cells as controls.  
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Figure 5.3.2B Effect of Pyl A on TNF-α production in PMA-stimulated CD4+ (T helper cells) 
Peripheral blood mononuclear cells were incubated with vehicle control or 32 µM of Pyl A, 
then stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. Pyl A did not have any effect on TNF-α production in 
PMA stimulated CD4+ cells. A representative dot blot shows no difference in the percentage of 
TNF-α +/CD4+ cells in the right upper quadrant in this 28 week sample with Pyl A treatment (A). 
The percentage of TNF-α +/CD4+ cells and the mean production of TNF-α + are summarised in 
the graphs, showing no difference effect of Pyl A (B and C). A representative histogram reveals 
no shift indicating no effect on TNF-α (D). For statistical analysis a two-way ANOVA with 
Bonferroni’s multiple comparison test was used with non-treated cells as controls.  
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5.3.3 Effect of Pyl A on IL-4 production in CRTH2+ cells 
 
The effect of the specific small molecule agonist Pyl A on IL-4 production was also 
examined. Two concentrations were used; 32 µm and 1 µm. 32 µm was used to serve 
as a direct comparison with 15dPGJ2. 1 µm was also used since activity at the CRTH2 
receptor should be seen at this concentration [320] with minimal non-specific effects 
that may be seen with a higher concentration of 32 µm.  
 
5.3.3A Non PMA/Ionomycin stimulated cells 
Firstly the effect of Pyl A on basal IL-4 production was examined. A representative dot 
plot is shown of cells labelled with CRTH2-PE and IL-4-PECy7 in a 28 week sample 
(Figure 5.3.3A, panel A). Pyl A had no significant effect on the percentage of IL-4 
producing CRTH2 cells or the mean production of IL-4 (Figure 5.3.3A, panel B). The 
example histogram shows no effect on IL-4 production with Pyl A in non-PMA treated 
cells from a 28 week sample (Figure 5.3.3A, panel CD. 
 
5.3.3B PMA/Ionomycin stimulated cells 
PMA/ionomycin stimulation induced a population of IL-4 producing CRTH2+ cells. Cells 
were pre-treated with 1 or 32 µm of Pyl A for 2 hrs. A representative dot plot is shown 
of cells labelled with CRTH2-PE and IL-4-PECy7 in a 28 week sample (Figure 5.3.3B, 
panel A). Pre-treatment with Pyl A in the PMA/Ionomycin stimulated cells had no 
significant effect on the percentage CRTH2 cells producing IL-4, or mean production of 
IL-4 during pregnancy (panel B and C). There was a statistically significant increase in 
the mean production of IL-4 from 37.08 to 43.6 in non-pregnant samples (P<0.01), 
with no significant increase in the percentage of cells producing of IL-4 (Figure 5.3.3B, 
panel B and C). An example histogram shows the effect of Pyl A on IL-4 production in a 
28 week sample (Figure 5.3.3B, panel D).  
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Figure 5.3.3A Effect of Pyl A on IL-4 production in non-stimulated CRTH2+ cells 
Peripheral blood mononuclear cells were incubated with vehicle control, 1 µM or 32 µM of Pyl 
A before being gated on the lymphocyte population according to forward and side scatter. Pyl 
A did not have any effect on IL-4 production in CRTH2+ cells. A representative dot blot shows 
the absence of IL-4+/CRTH2+ cells in the right upper quadrant in this Pyl A treated 28 week 
sample (A). The percentage of IL-4 +/CRTH2+ cells and the mean production of IL-4 are 
summarised in the graphs, showing no difference with Pyl A (B and C). A representative 
histogram reveals no shift indicating no effect on IL-4 (D). For statistical analysis a two-way 
ANOVA with Bonferroni’s multiple comparison test was used with non-treated cells as 
controls.  
                                                     Chapter 5: CRTH2 agonist effect on Th1/Th2 interleukins 
 
181 
 
 
 
 
 
Figure 5.3.3B Effect of Pyl A on IL-4 production in PMA stimulated CRTH2+ cells 
Peripheral blood mononuclear cells were incubated with vehicle, 1 µM or 32 µM of Pyl A and 
then stimulated with PMA/ionomycin before being gated on the lymphocyte population 
according to forward and side scatter. Pyl A did not have a significant effect on IL-4 production 
in CRTH2+ cells. A representative dot blot shows the IL-4+/CRTH2+ cells in the right upper 
quadrant with no difference between treatment groups (A). The percentage of IL-4+/CRTH2+ 
cells and the mean production of IL-4 are summarised in the graphs, showing no difference 
with Pyl A (B and C). A small increase in the mean was seen in non-pregnant women (B). A 
representative histogram reveals no shift indicating no effect on IL-4 (D). For statistical analysis 
a two-way ANOVA with Bonferroni’s multiple comparison test was used with non-treated cells 
as controls. 
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Summary and discussion 
 
A balance of immune suppression and immune tolerance during pregnancy to 
facilitate the growing fetus was first hypothesised by Medawar and colleagues in the 
1950’s through his work on transplant rejection [140]. Wegmann and colleagues 
further developed this hypothesis and specifically introduced the notion of a shift from 
the Th1 response towards a Th2 bias during pregnancy [209]. Compelling evidence 
particularly from murine studies suggests an important role in this altered ratio for the 
maintenance of successful pregnancy [210, 333, 334]. Although many studies have 
explored the Th1:Th2 interleukin profile at the maternal fetal interface [149, 223, 335]  
and in peripheral blood during human pregnancy [147, 218, 336], data is lacking on the 
profile in peripheral blood during labour. Endogenous pro-pregnancy hormones such 
as progesterone and leukaemia inhibitory factor have the ability to modulate the 
Th1:Th2 profile [149, 337], and therefore developing immunomodulating therapeutic 
agents could form and adjunct to maintaining the Th1:Th2 profile. Here I examine the 
production of the Th1 cytokines IFN-γ and TNF-α, and the Th2 cytokine IL-4 throughout 
pregnancy and in labour, and the potential of the CRTH2 agonists 15dPGJ2 and Pyl A, 
to act as therapeutic agents to modulate the Th1:Th2 response.  
 
The Th1/ Th2 interleukins in pregnancy and in labour 
Consistent with the notion of suppressed Th1 cytokine response throughout gestation 
[146, 147, 218, 338], the results presented here revealed a reduction in the 
percentage of IFN-γ and TNF-α-secreting T helper cells during pregnancy in response 
to PMA/ionomycin stimulation (Figure 5.1.1B and 5.1.2B respectively). Interestingly, 
the mean production of IFN-γ and TNF-α remained constant within the CD4+/IFN-γ+ 
and CD4+/TNF-α+ cell populations (Figure 5.1.1C and 5.1.2C respectively). This 
indicates that while fewer cells maintain the capacity to initiate a Th1 response to 
inflammatory stimuli with advancing gestation, the cells which maintain the ability to 
produce these cytokines do no show reduced production.  
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Since normal human labour reflects a pro-inflammatory state, an increase in the 
percentage of IFN-γ and TNF-α producing T helper cells with the onset of labour was 
anticipated. However, no statistically significant difference in the percentage of T 
helper cells producing IFN-γ and TNF-α, or the mean production of interleukins was 
seen between term non-labouring and term labouring samples in non-stimulated or 
PMA/ionomycin stimulated cells. However, a trend of a small increase in the basal 
percentage of cells producing IFN-γ and TNF-α was seen from 28 weeks to term with a 
further increase in labour. It is likely that the extent of  localized pro-inflammatory 
response in the uterus and fetal membranes seen in labour does not occur 
systemically, which indeed would lead to adverse neonatal outcome by the transfer of 
maternal cytokines across the placenta. However, the evidence presented here of a 
degree of inflammation may suggest a biological requirement for some systemic 
inflammation. Examination of these cytokines in women with suspected 
chorioamnionitis and who are pyrexial during labour may however have shown a more 
exaggerated inflammatory response. 
Several studies have shown an increase in intrinsic [146, 221] and mitogen stimulated 
IL-4 production in PBMCs during pregnancy [147, 218, 220]. An increase in basal and 
PMA/ionomycin induced IL-4 production in CRTH2 positive cells during pregnancy was 
anticipated, with a reduction in the labouring samples.  CRTH2 is a classic marker of 
Th2 cells and thus should reflect their functional role in pregnancy. However, no 
significant difference in the percentage of CRTH2+/IL-4+ secreting cells, or the mean 
production of IL-4 was seen during pregnancy and in labour compared to non-
pregnant controls, (figure 5.1.3B and 5.1.3C respectively). Although an increase in the 
percentage of IL-4 secreting cells was observed in both non-stimulated and stimulated 
28 week samples, which returned to non-pregnant levels at term, this narrowly missed 
out on statistical significance when the Bonferroni’s multiple comparisons test was 
applied.  The fact that the percentage of CRTH2 expressing CD4+ cells is low in the 
peripheral blood, and the numbers in this experiment were small, it is not possible to 
rule out a modest yet biologically significant change in IL-4 production in these cells. 
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The effect of 15dPGJ2 on the Th1/Th2 interleukins 
To examine the potential of further modulating the Th1:Th2 bias in pregnancy the 
effect of the CRTH2 agonist and anti-inflammatory cyclopentenone prostaglandin on 
the Th1 and Th2 interleukins was determined by flow cytometry. 15dPGJ2 is an 
endogenous product of PGD2. PGD2 is readily converted to 15dPGJ2 by a series of 
dehydration reactions in the presence of albumin and is found in amniotic fluid [279] 
and the placenta [280]. PGD2 has been shown to promote the Th2 bias through IL-4, IL-
10 and IL-5 production in Th2 cells in vitro via CRTH2 [217]. Therefore, the combined 
properties of being both an anti-inflammatory prostaglandin and a CRTH2 agonist led 
to the hypothesis that it could both suppress the Th1 interleukins whilst promoting the 
Th2 response.   
 
15dPGJ2 pre-treatment significantly reduced the PMA-stimulated production of both 
Th1 cytokines; IFN-γ and TNF-α, in non-pregnant and all pregnant samples (Figure 
5.2.1B and 5.2.2B respectively). The anti-inflammatory properties of 15dPGJ2 are 
thought to be at least partly via the inhibition of the transcription factor NF-κB [339]. 
NF-κB is known to play a key regulatory role in controlling the Th1 immune response 
by modulating the expression of Th1 cytokines [256]. Data is presented in chapter four 
showing the ability of 15dPGJ2 to inhibit basal NF-κB (Figure 4.4) and significantly 
reduce PMA stimulated NF-κB in PBMCS of women at 28 weeks of pregnancy and at 
term in labour, as determined by western analysis of the transcriptionally active NF-κB 
subunit p-p65 (Figure 4.10). A non-significant reduction was also observed in non-
pregnant controls and samples acquired at term pre-labour. This data provides 
evidence that the Th1 inhibitory properties of 15dPGJ2 are likely to be regulated 
through NF-κB. 
 
The effect of 15dPGJ2 on basal production of IFN-γ and TNF-α was surprising. A small 
population of CD4+/IFN-γ+ and CD4+/TNF-α+ appeared upon treatment with 32µm of 
15dPGJ2 (Figure 5.2.1A and 5.2.2A). This led to a statistically significant increase in the 
percentage of cells producing IFN-γ and TNF-α at 28 weeks and at term pre-labour. 
However, the percentage of IFN-γ and TNF-α producing cells was still low, 2.3% and 
                                                     Chapter 5: CRTH2 agonist effect on Th1/Th2 interleukins 
 
185 
 
4.3% at 28 weeks and 1.7% and 3.1% at term in labour respectively, and therefore the 
potential in vivo biological relevance of this is uncertain. 15dPGJ2 significantly 
improves pup survival with intrauterine injection in LPS treated mice [277], and 
therefore this suggests an overall in vivo neuroprotective effect rather than causing 
adverse effects. In other cell types 15dPGJ2 has been shown to suppress both IFN-γ 
[340] and LPS and PMA induced TNF-α [341].  
 
The relevance of 15dPGJ2-mediated inhibition of IFN-γ and TNF-α seen in the 
PMA/ionomycin treated cells is nevertheless still significant, since PMA and ionomycin 
are standard in vitro stimulants used to most closely mimic the degree potential of in 
vivo activation of T cells in an in vitro setting. T cell activation involves several steps 
including activation of protein tyrosine kinases, plasma membrane inositol 
phospholipid hydrolysis and an increase in intracellular Ca2+ to activate calcineurin 
[342]. PMA activates protein kinase C and ionomycin artificially increases intracellular 
Ca2+ [343], and therefore mimics the in vivo mechanism of T cell activation.  
 
Interestingly, no increase was seen on the production of the Th2 cytokine, IL-4, in 
response to 15dPGJ2 treatment. An increase may have been counteracted by an 
overriding effect of a non-CRTH2 mediated mechanism such as the inhibition of other 
signalling proteins involved the transcriptional regulation of IL-4 expression. Evidence 
for this has been previously reported in a PMA/ionomycin activated T cell line where 
15dPGJ2 inhibited IL-4 production in a dose dependent manner through the down-
regulation of Nuclear factor of activated T-cells (NF-AT) activation [286].  
 
The effect of the CRTH2 agonist Pyl A on the Th1/Th2 interleukins 
Pyl A had no effect on the Th1 interleukins. Th1 cells do not express the CRTH2 
receptor, however, an indirect inhibition of the Th1 cytokines could have been 
possible if CRTH2 mediated IL-4 and IL-10 production occurred in the T helper cells. Pyl 
A alone did not induce IL-4 production (Figure 5.3.3A). With the addition of 
PMA/ionomycin, Pyl A led to a statistically significant increase in IL-4 production in 
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non-pregnant samples at 1 µm concentration (Figure 5.3.3B). No significant response 
was seen during pregnancy and in labour. Two studies have shown a CRTH2-mediated 
increase in the Th2 interleukins in T helper cells in vitro, including IL-4. Tanaka et al 
used treated purified CRTH2+ cells with PGD2, Indomethacin and DK- PGD2 for 6 hours 
which resulted in an increase in the percentage of cells producing IL-4, IL-5 and IL-13 
[299]. Xue et al also treated purified CRTH2+ cells with PGD2 and demonstrated a dose 
dependent increase in the production of IL-4, IL-5, IL-13 and IL-10 [217]. Both of these 
studies differ in design to this study in that they used a purified CRTH2 population for 
determining the effects of the CRTH2 agonists. Only approximately 13% of the CRTH2+ 
cells in Tanaka’s study produced IL-4, and therefore, with only roughly 2% of 
lymphocytes expressing CRTH2 in our study any CRTH2 agonist effect could be difficult 
to detect without using purified CRTH2+ cells. 
 
 
Summary 
While 15dPGJ2 appears to have no effect on the peripheral Th2 response, the 
demonstrated inhibition of the Th1 response represents a collective shift towards a 
Th2 bias, or in other words, an increase in the Th2:Th1 ratio. The lack of a 
demonstrable effect on the Th2 profile by Pyl A could be explained by the design of 
the experiment by not isolating a purified CRTH2+ population. Nevertheless, this data 
presents evidence that the Th1:Th2 balance is naturally altered during pregnancy 
through Th1 suppression rather than Th2 promotion. It also provides further evidence 
of the potential anti-inflammatory effects of 15dPGJ2; through the suppression of NF-
κB, and the Th1 pro-inflammatory cytokines IFN-γ and TNF-α. These properties may be 
of therapeutic benefit for the prevention of inflammation associated preterm labour 
and the reduction of inflammation induced neonatal morbidity where an aberrant 
profile favouring the Th1 response is seen.  
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CHAPTER 6 
 
The effect of CRTH2 agonists on myometrial contractility 
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Chapter summary 
 
 
Hypothesis:  
15dPGJ2 inhibits NF-κB in human myocytes [271]. NF-κB controls the expression of 
many genes required for uterine contractility. It is possible the 15dPGJ2 could inhibit 
myometrial contractility via NF-κB. Although CRTH2 is not expressed on human 
myocytes, the CRTH2 agonist indomethacin inhibits myometrial contractility in a 
mechanism independent of CRTH2. Indomethacin has a similar structure to Pyl A and 
therefore it is possible that Pyl A could replicate the inhibitory effects of indomethacin 
on myometrial contractility.  
 
Aims:  
To determine if the CRTH2 agonists 15dPGJ2 and Pyl A inhibit human myometrial 
contractility.  
 
Methods:  
Myometrial biopsies were collected from women undergoing pre-labour caesarean 
section, dissected into strips and mounted on the DMT myograph. A cumulative dose 
response was performed with 1-100 µm of 15dPGJ2, Pyl A, PGD2 and indomethacin. 
Vehicle control strips were also used. The total and average area under the curve, 
peak amplitude and rate of contractions were analysed as markers of myometrial 
contractility.  
 
Results:  
15dPGJ2 and PGD2 had no effect on myometrial contractility. Pyl A mimicked the 
effects of indomethacin and inhibited myometrial contractility.  
 
Conclusion:  
Although 15dPGJ2 did not inhibit myometrial contractility, the CRTH2 agonist Pyl A did 
so in a mechanism independent of CRTH2.  
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Introduction 
 
Throughout pregnancy and parturition the uterus undergoes changes which can be 
separated into four phases, as described by Challis et al [53]. During pregnancy the 
uterus remains quiescent, but as labour approaches an activation phase occurs with 
up-regulation of contraction-associated proteins, and is followed by a stimulation 
phase when the uterus becomes responsive to prostaglandins and oxytocin. Finally, 
post-partum the uterus involutes. Throughout pregnancy, uterine quiescence is 
thought to be attributed in part to the effects of progesterone. It is likely that 
progesterone represses NF-κB activity [344] until term, when NF-κB activity is 
increased in the myometrium in association with an increase in PR-A:PR-B ratio and 
possibly the expression of  truncated forms of the inhibitory progesterone receptors 
PR-C [263] . 
NF-κB controls the expression of several genes required for uterine contractions. 
Prostaglandins are essential for stimulating myometrial contractions [55]. 
Prostaglandins are synthesised in a 2-step reaction, firstly from the generation of 
arachidonic acid from glycerophospholipids via PLA2 isozymes, and then from the 
conversion of arachidonic acid via COX-2 which is the rate limiting step [345]. The 
cPLA2 and sPLA2 isozymes are expressed in gestational tissues and appear to play 
significant roles in parturition [346]. cPLA2 and sPLA2 have response elements for NF-
κB in their promoter regions [247], suggesting a regulatory role for NF-κB in their 
activity. In support of this, NF-κB inhibition with sulphalazine [275] and NAC [347] 
results in the inhibition of LPS induced production of these isozymes in placenta 
amnion and choriodecidua. The COX-2 gene also contains two NF-κB response 
elements, and site directed mutation of either of these elements leads to suppression 
of COX-2 promoter activity [259]. The promoter region of the oxytocin receptor 
contains three NF-κB binding sites, suggesting a role for NF-κB in the regulation of the 
oxytocin receptor [54]. The oxytocin receptor can also be activated by a synergistic 
interaction between NF-κB and the C/EBP transcription factor, forming a complex 
which binds with the receptor  [266].  
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NF-κB appears to play a key role in regulating proteins that are central to the 
mechanism of uterine contractility. Since inhibition of NF-κB is seen in myocytes 
treated with 15dPGJ2, it is plausible that 15dPGJ2 can also lead to the inhibition of 
myometrial contractility.  
Indomethacin can be used as a tocolytic [348]; however, due to the potential adverse 
effects on the fetus and the advent of other safer tocolytics, it is now less commonly 
used. Indomethacin is a non-selective COX inhibitor and an agonist of the CRTH2 
receptor. Many of the adverse effects of indomethacin are thought to be due to COX-1 
inhibition since it is mainly COX-1 that contributes to prostaglandin synthesis in the 
fetus [348, 349]. Myometrial contractility is inhibited ex vivo by indomethacin in a 
relatively rapid response [349, 350]. It is likely that inhibition is due to inhibition of 
calcium channels rather than the inhibition of COX-2 and prostaglandin synthesis. 
Since CRTH2 is not expressed in myocytes, the inhibitory mechanism is also 
independent of CRTH2. The structure of Pyl A is similar to indomethacin; therefore it is 
plausible that Pyl A may reproduce the effects of indomethacin and inhibit myometrial 
contractility. This chapter explores the effects of the CRTH2 agonists 15dPGJ2, 
indomethacin, Pyl A and PGD2 on human myometrial contractility. 
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Results 
 
To determine if the CRTH2 agonists 15dPGJ2, Pyl A and PGD2 have a direct effect on 
uterine contractility, myometrial biopsies were collected from women undergoing pre-
labour caesarean section. Strips were dissected and mounted on a myograph. A 
cumulative dose response from 1 µm to 100 µm was performed. Effect of treatment 
was compared to spontaneous contractions at the beginning of the experiment and 
divided by the equivalent timepoint for vehicle control. The total area under the curve 
per time point of the experiment, the average area under the curve, average peak 
amplitude and the rate of contractions were analysed.  
 
6.1 15dPGJ2 does not inhibit human myometrial contractility  
 
No inhibition of myometrial contractility was seen with cumulative doses of 15dPGJ2, 
(Figure 6.1). There was a small non-significant decrease in the area under the curve, 
peak amplitude and rate of contractility, but this did not follow a dose response. There 
was also variability within subjects and between subjects which is reflected in the large 
error bars seen at some time points. Figure 6.1A shows a representative experiment 
with 15dPGJ2 and vehicle control strips. Overall, no effect on myometrial contractility 
was seen with 15dPGJ2.  
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Figure 6.1 The effect of 15dPGJ2 on myometrial contractility  
Non-labouring myometrial biopsies were dissected and mounted on the myograph (n=3 
subjects with 2-3 strips each). A representative trace is shown for 15dPGJ2 treated strips and 
vehicle control (A). A cumulative dose response with 15dPGJ2 or vehicle was performed and 
the effect on total and average area under the curve (B and C), peak amplitude (D) and rate of 
contractility (E) was determined. 15dPGJ2 had no significant effect on myometrial contractility. 
V=vehicle.  For statistical analysis ANOVA of repeated measures was used with Dunnett’s 
multiple comparison test. 
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6.2 Indomethacin inhibits human myometrial contractility  
 
Indomethacin has previously been shown to inhibit myometrial contractility ex vivo. 
Indomethacin has several known actions. For example, it is a CRTH2 agonist, a COX-2 
inhibitor, and is likely to inhibit contractility via modulation of intracellular calcium.   A 
cumulative dose response from 1 µm to 100 µm was performed. Figure 6.2A shows 
contracting strips from a representative experiment. Total area under the curve was 
significantly reduced from 10 µm (Figure 6.2B) and the peak amplitude and rate of 
contractions was significantly reduced from 100 µm p<0.01 (Figure 6.2 D and E).  
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Figure 6.2 The effect of Indomethacin on myometrial contractility  
Non-labouring myometrial biopsies were dissected and mounted on the myograph (n=3 
subjects with 2-3 strips each). A representative trace is shown for indomethacin treated strips 
and vehicle control (A). A cumulative dose response with indomethacin or vehicle was 
performed and the effect on total and average area under the curve (B and C), peak amplitude 
(D) and rate of contractility (E) was determined. Indomethacin significantly reduced 
myometrial contractility with maximal response seen at 100 µm. V=vehicle.  For statistical 
analysis ANOVA of repeated measures was used with Dunnett’s multiple comparison test; (* 
P<0.05, ** P<0.01, *** P<0.001). 
 
 
                                        Chapter 6: CRTH2 agonists and human myometrial contractility 
195 
 
6.3 Pyl A inhibits human myometrial contractility  
 
Although CRTH2 is not expressed on human myometrium, Pyl A has a similar chemical 
structure to indomethacin and therefore its effect on myometrial contractility was 
examined. A cumulative dose response from 1 µm to 100 µm was performed. Figure 
6.3A shows contracting strips from a representative experiment. Total area under the 
curve was significantly reduced from 1 µm (Figure 6.3B) and the rate of contractions 
was significantly reduced from 20 µm (p<0.001) (Figure 6.3 D and E). Complete 
inhibition was seen with 100 µm.  
 
 
 
 
                                        Chapter 6: CRTH2 agonists and human myometrial contractility 
196 
 
 
 
 
Figure 6.3 The effect of Pyl A on myometrial contractility  
Non-labouring myometrial biopsies were dissected and mounted on the myograph (n=4 
subjects with 2-3 strips each). A representative trace is shown for Pyl A treated strips and 
vehicle control (A). A cumulative dose response with Pyl A or vehicle was performed and the 
effect on total and average area under the curve (B and C), peak amplitude (D) and rate of 
contractility (E) was determined. Pyl A significantly reduced myometrial contractility with 
maximal response seen at 100 µm. V=vehicle.  For statistical analysis ANOVA of repeated 
measures was used with Dunnett’s multiple comparison test; (* P<0.05, ** P<0.01, *** 
P<0.001). 
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6.4 PGD2 does not inhibit human myometrial contractility  
 
PGD2 has two receptors: DP1 and DP2. The effect of PGD2 on myometrial contractility 
was determined in order to establish if Pyl A was acting in a non-CRTH2 mediated 
mechanism by inhibiting the DP1 receptor at the high concentrations used. However, 
no inhibition of myometrial contractility was seen with the cumulative dose response 
(Figure 6.4). There was a non-statistically significant trend in increased myometrial 
contractility as seen in all parameters examined. There was significant variability 
within subjects and between subjects which is reflected in the large error bars seen at 
some most time points. Overall, no inhibition of myometrial contractility was seen 
with PGD2, which excludes the DP1 receptor as a target for Pyl A mediated inhibition of 
contractility.  
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Figure 6.4 The effect of PGD2 on myometrial contractility  
Non-labouring myometrial biopsies were dissected and mounted on the myograph (n=3 
subjects with 2 strips each). A representative trace is shown for PGD2 treated strips and 
vehicle control (A). A cumulative dose response with PGD2 or vehicle was performed and the 
effect on total and average area under the curve (B and C), peak amplitude (D) and rate of 
contractility (E) was determined. PGD2 had no significant effect on myometrial contractility. 
V=vehicle.  For statistical analysis ANOVA of repeated measures was used with Dunnett’s 
multiple comparison test. 
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Summary and Discussion 
 
For the uterus to become activated for labour to ensue, there is an increase in the 
expression of contraction-associated proteins. These proteins enhance the interaction 
between actin and myosin, increase the excitability of myometrial cells and promote 
intercellular connectivity which aids the development of synchronous contractions 
[41]. The contractile force of the myometrium is due to cyclical attachments and 
detachments of cross bridges between myosin and actin microfilaments which is 
triggered by the activation of the regulatory 20 kDa chain of myosin molecules [351]. 
Myosin light chain activation occurs by phosphorylation by myosin light chain kinase 
(MLK), which is in turn activated by calmodulin [40]. An increase in intracellular 
calcium and calmodulin activate MLK [43]. After depolarization of the myocyte there is 
an influx of extracellular calcium and a release of intracellular calcium stores [44], 
which then promotes myosin actin interaction and further promoting contractions.  
The major contractile pathways activate phospholipase C (PLC), the release of 
intracellular calcium and the stimulation of calcium entry [54]. PGE2 and PGF2α activate 
ligand-regulated channels leading to the release of calcium from intracellular stores 
[352, 353]. Oxytocin activates the Gαq OTR, which is linked to PLC, leading to the 
release of inositol triphosphate and in turn the release of calcium from intracellular 
stores [43, 354, 355]. Relaxant pathways often target G protein coupled receptors 
which upon activation increase cAMP or cGMP [54], such as the B adrenergics, or 
target the inhibition of calcium entry such as nifedipine and oxytocin antagonists 
[356].  
The major disadvantage with the currently available tocolytics is their lack of anti-
inflammatory effects. Therefore, delaying preterm labour with tocolytics to provide 
steroid treatment for lung maturation, may lead to a detrimental increase in duration 
of exposure of the fetus to a hostile inflammatory environment. For this reason, the 
effects of the anti-inflammatory prostaglandin 15dPGJ2 were explored to determine if, 
by inhibition of NF-κB and thus COX-2 and prostaglandins, inhibition of myometrial 
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contractility could be elicited. Acute administration of 15dPGJ2 in a cumulative dose 
response failed to inhibit myometrial contractility. It is possible that the duration of 
the experiment was not long enough to assess for inhibition of protein expression, via 
NF-κB. A reduction in NF-κB and cPLA2 can be demonstrated in vivo in the murine 
model by 1 hr after administration of 15dPGJ2, with COX-2 inhibition at the protein 
level seen at 6 hrs [277]. Unfortunately the control strips failed to contract for long 
enough to demonstrate meaningful results at time points long enough to reliably 
assess for inhibition of prostaglandin synthesis. However, pre-incubation with 15dPGJ2 
for 2 hours prior to mounting strips on the contractility machine led to a reduction in 
contractility [357]. 
Mechanical stretch activates NF-κB in cultured myocytes [183], increases the 
expression of the oxytocin receptor [84] and the gap junction proteins: Connexin-43 
and Connexin-26 in the rat [358], and thus stretch may contribute to triggering uterine 
contractility and labour. In support of this, women with multiple pregnancies and 
polyhydramnios are at a higher risk of delivering preterm [359, 360]. The stretch on 
the uterus at term is estimated to correlate with a resting tone of 0.5g per 1mm 
diameter of myometrial strips ex vivo on a myograph [361]. The stretch of 3-4g which 
is applied to the individual 5-10 mm strips in this study correlates with the resting tone 
of the uterus. It was anticipated that 15dPGJ2 would inhibit contractility via NF-κB 
inhibition in the stretched myometrium. The assumption was made however, that 
15dPGJ2 was able to penetrate the myometrial tissue to act at the cellular level on NF-
κB. To allow for this, higher concentrations of up to 100 µm was used compared to 32 
µm used in the in vitro studies, yet despite this, no inhibition of contractility was seen, 
(Figure 6.1). 
Indomethacin did however cause inhibition of myometrial contractility (Figure 6.2) 
consistent with previous experiments performed by this research group [349, 350].  
Although 10 µm of indomethacin reduces PGE2 production by 90% in fetal membranes 
[362], the rapid inhibitory effect on myometrial contractility seen with indomethacin 
suggests that its mechanism is not via the inhibition of COX-2 and prostaglandin 
synthesis. The effect of indomethacin on calcium influx has therefore been explored in 
myocytes, which revealed an inhibition in the Ca2+ channel current, although with a 
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smaller inhibitory effect than the effect seen on actual contractility [349]. This could 
be explained by an alternative and as yet unidentified mechanism for indomethacin-
induced inhibition of contractility.  By demonstrating the absence of CRTH2 on human 
myocytes, the role of CRTH2 in indomethacin-induced inhibition of myometrial 
contractility has been excluded in this study. 
Despite this, the effect of the CRTH2 agonist Pyl A on human myometrial contractility 
was examined, since it shares a similar chemical structure to indomethacin. Pyl A also 
inhibited myometrial contractility (figure 6.3), but more potently than indomethacin. 
The mechanism of inhibition, which is independent of CRTH2, may be via the 
alteration of the Ca2+ channel current, as with indomethacin.  However, at higher 
concentrations, Pyl A also reacts with other prostanoid receptors at a potency of TP> 
EP3> DP> EP4> EP2> FP> IP> EP1 [320]. The prostaglandin receptors can be grouped 
into two categories; EP1, EP3 FP, and TP which stimulate contraction, and DP1, EP2, EP4, 
and IP which are considered to be relaxatory receptors [363]. It is likely that the effect 
of Pyl A is due to non-specific binding with either the EP2 or EP4 receptors, or the DP1 
receptor.  
 
Upon activation of the stimulatory receptors EP1, EP3 and FP, an increase in 
intracellular calcium leads to increased uterine contractility [352, 364]. The relaxatory 
receptors EP2 and EP4 are expressed in the myometrium, but the quiescence 
associated with pregnancy is more likely to be due to EP2 rather than the EP4 receptor, 
[308]  by  increasing cAMP thereby inducing smooth muscle relaxation [352]. Our 
group have shown inhibition of myometrial contractility with EP2 receptor but not with 
EP4 agonists [365]. Typically the DP1 receptor is considered to be relaxatory. 
Expression studies of the prostanoid receptors in the human myometrium reveal 
higher mRNA expression of DP1 than EP2, with no difference in either between non-
pregnant or pre-labour and in-labour myometrial samples [366]. The effect of PGD2 on 
human myometrial contractility was therefore explored to see if myometrial 
contractility could be inhibited via the DP1 receptor. However no inhibition was seen. 
Previous studies of human non-pregnant and pregnant myometrium have shown 
initial excitatory responses [308, 367], consistent with the slight increase in 
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contractility seen in Figure 6.4. However both studies then showed the excitatory 
response was followed by a subsequent inhibitory effect with PGD2. The excitatory 
effects of PGD2 are likely to be due to cross-reactivity with the EP3, FP or TP receptor.  
In conclusion, Pyl A inhibited myometrial contractility in a mechanism independent of 
CRTH2. It is likely that the inhibitory effect of Pyl A is through non-specific binding with 
the EP2 receptor or via alteration of calcium channel current. Contrary to anticipated 
15dPGJ2 failed to inhibit human myometrial contractility. The use of Pyl A as a tocolytic 
may therefore be considered.   
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CHAPTER 7 
 
CRTH2 agonist effect on murine myometrial contractility and 
inflammation induced preterm labour 
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Chapter summary  
 
Hypothesis:  
15dPGJ2 delays inflammation induced preterm labour and significantly reduces pup 
mortality. The mechanism behind this effect is not fully understood. 15dPGJ2 is a 
ligand for the CRTH2 receptor; therefore it is plausible that a small molecule agonist 
could replicate some of the effects of 15dPGJ2.  
 
Aims:  
CRTH2 expression in murine myometrium was determined, and the direct effects of 
the CRTH2 agonists 15dPGJ2 and Pyl A on murine myometrial contractility was 
investigated. The effects of Pyl A on both LPS induced preterm labour and fetal 
viability were explored, together with the effects on the inflammatory proteins; NF-κB, 
COX-2 and the Th1:Th2 interleukins in the myometrium.  
 
Methods:  
CRTH2 mRNA expression was determined by PCR, and the direct effect of the CRTH2 
agonists on myometrial contractility was examined ex-vivo using a myograph. Intra-
uterine LPS was administered on E16 to CD1 mice with vehicle or Pyl A. Dams were 
sacrificed at 4.5 hours post injection and myometrium and pup brain was harvested 
for mRNA and protein analysis by PCR, western analysis or ELISA. Fetal viability was 
also assessed. In a subsequent experiment mice were allowed to deliver 
spontaneously, and delivery time and pup survival was recorded.  
 
Results:  
CRTH2 mRNA was detected by PCR. Pyl A inhibited circular myometrial contractility in 
a mechanism independent of CRTH2. Pyl A augmented an inflammatory response in 
murine myometrium leading to an increase in NF-κB, TNF-α, IFN-γ and IL-1β. Despite 
this an increase in fetal viability was seen which was associated with an increase in 
myometrial IL-10. In contrast to the anticipated delay in preterm labour, but in 
                                                 Chapter 7: CRTH2 agonists and murine preterm labour 
 
205 
 
keeping with the pro-inflammatory effect seen with Pyl A, preterm labour was 
augmented rather than delayed.  
 
Conclusion:  
15dPGJ2-mediated delay in inflammation induced preterm labour is not mediated via 
CRTH2. CRTH2 agonist activity is associated with augmentation of inflammation 
induced preterm birth, therefore CRTH2 should not be considered as potential 
therapeutic target for the prevention of preterm labour and neonatal morbidity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 Chapter 7: CRTH2 agonists and murine preterm labour 
 
206 
 
Introduction  
 
In a murine model of inflammation induced preterm labour, 15dPGJ2 delays preterm 
labour. More importantly 15dPGJ2 improves pup survival from 30% with LPS, to 95% 
with co-injection of 15dPGJ2 [277]. The mechanisms by which 15dPGJ2 exert these 
effects are not fully understood, but it is likely that the inhibition of NF-κB in the 
myometrium and the brain is important. Alternative mechanisms such as the direct 
inhibition of uterine contractility or an alteration Th1:Th2 interleukin profile via 
CRTH2, are also plausible. 
Murine CRTH2 expression at the protein level is hampered by the lack of specific 
antibodies [368]. Prior to this thesis, mRNA expression of CRTH2 in murine 
myometrium had not been explored. Although CRTH2 was not detected at the protein 
level in human myometrium, the distribution of CRTH2 differs in the mouse compared 
to the human. For example, CRTH2 is detected on both Th1 and Th2 cells in the mouse 
[369].  
Murine CRTH2 shares 77% homology with the human CRTH2 receptor amnio acid 
sequence [369], and shares 90% homology within the transmembrane domains which 
explains the virtually identical pharmacology between receptors [370]. The CRTH2 
agonists Pyl A, 15dPGJ2, DK- PGD2, PGD2, and indomethacin all show activity at the 
mouse CRTH2 receptor [290, 320, 371-373]. Human contractility studies with the 
CRTH2 agonists (presented in chapter six) revealed an inhibitory effect with Pyl A 
which was not mediated via the CRTH2 receptor. It is plausible that this inhibitory 
effect could be demonstrated in murine myometrium. 
15dPGJ2 inhibits NF-κB in human amniocytes, myocytes and PBMCS, as shown in 
chapter four [271, 374]. Upon intrauterine injection in the mouse it also reduces basal 
and LPS induced NF-κB in both the myometrium and the pup brain [277]. Pyl A failed 
to replicate this effect in human amniocytes, myocytes and PBMCs (see chapter four) 
and therefore is also unlikely to replicate the effects of 15dPGJ2 in the murine 
myometrium and pup brain. The effects of Pyl A on both NF-κB and COX-2 in the 
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murine myometrium were nevertheless explored in this chapter to confirm that 
15dPGJ2 inhibits NF-κB in the mouse independently of CRTH2.  
The importance of the balance between the Th1:Th2 profile at the maternal fetal 
interface in the mouse for successful pregnancy maintenance is well established. In 
the deciduas/placental compartment IL-4, IL-5 and IL-10 are present in all three 
trimesters with IFN-γ present at low levels only in first trimester. Interestingly, all are 
undetectable in the spleen indicating local production of the interleukin [334]. IL-10 
protects the fetus by reducing fetal loss as a result of pro-inflammatory cytokines and 
LPS administration [210, 375]. In the human, PGD2 stimulates the production of the 
Th2 cytokines IL-4, IL-5, IL-13 and IL-10 in cultured Th2 cells in vitro [217]. IL-4 is able to 
inhibit the Th1 response directly, with IL-10 inhibiting the production of inflammatory 
mediators indirectly [194]. Although 15dPGJ2 was able to modulate the Th1:Th2 bias in 
human PBMCs in vitro by suppressing the Th1 response , Pyl A could not mimic the 
effects of 15dPGJ2 or the increase in Th2 cytokine profile seen with PGD2 (data shown 
in chapter five). It is possible that the lack of effect seen may represent a limitation of 
in vitro models.  
The data presented in this chapter focuses on the in vivo effects of the CRTH2 agonist 
Pyl A in the mouse. CRTH2 expression at the mRNA level in murine myometrium was 
examined. The direct effects of the CRTH2 agonists 15dPGJ2, Pyl A and DK- PGD2 on 
murine myometrial contractility were examined to determine if this is an additional 
mechanism of action of 15dPGJ2-mediated delay in murine preterm labour. Finally, the 
in vivo effects of Pyl A on NF-κB and the Th1:Th2 interleukin profiles were examined to 
conclude if there is any potential for in vivo administration of CRTH2 agonists in the 
prevention of preterm labour.  
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Results 
 
7.1 CRTH2 mRNA expression in murine myometrium 
  
Murine myometrium was harvested from mice treated with intrauterine 
administration of vehicle, LPS +/- Pyl A. mRNA was extracted and a CRTH2 transcript 
was amplified using RT-PCR, along with the housekeeping gene L-19, (Figure 7.1). 
Amplification of CRTH2 was seen by cycle 33 (four-fold higher than the human) and L-
19 by cycle 19. 
 
 
 
 
 
 
 
Figure 7.1 Murine myometrial CRTH2 mRNA  
mRNA was isolated from murine uterus and converted to cDNA (n=3 per treatment group).  A 
CRTH2 transcript of product size of 344bp and L-19 transcript of product size 72bp were 
amplified by RT-PCR. No difference in CRTH2 expression was seen between the treatment 
groups. Non-template control (lane 1), vehicle treated mouse (lane 2), Pyl A treated (lane 3), 
LPS treated (lane 4), LPS/Pyl A treated (lane 5).  
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7.2 The effects of the CRTH2 agonists on murine myometrial contractility 
  
To determine if the CRTH2 agonists 15dPGJ2, Pyl A and DK- PGD2 have a direct effect 
on uterine contractility, uteri were harvested from mice on E15-16, dissected, and 
mounted on the myograph in the circular orientation. A cumulative dose response 
from 1 µm to 100 µm was performed, with vehicle control strips. 
 
7.2.1 The effect of 15dPGJ2 on murine myometrial contractility 
No inhibition of myometrial contractility was seen with the cumulative dose response 
of 15dPGJ2, (Figure 7.2.1). This indicates that the delay in inflammation induced 
preterm labour seen with 15dPGJ2 is not due to a direct effect on myometrial 
contractility.  
 
7.2.2 The effect of Pyl A on murine myometrial contractility 
Pyl A reduced myometrial contractility from 10 µm concentration (P<0.01), with 
complete inhibition seen with 100 µm (P<0.001) (Figure 7.2.2). The effect of Pyl A on 
longitudinal muscle was also examined by mounting the strips along the longitudinal 
orientation. Contractility was not maintained in the longitudinal orientation for the 
whole duration of the experiment in control strips to robustly examine the effect of Pyl 
A on longitudinal muscle contractility. Despite this, the clear inhibition seen in the 
circular muscle was not evident in the longitudinal strips.  
 
7.2.3 The effect of DK- PGD2 on murine myometrial contractility 
No inhibition of myometrial contractility was seen with the cumulative dose response 
of DK- PGD2 (Figure 7.2.3), indicating no role for CRTH2 in Pyl A mediated inhibition of 
circular myometrial contractility. 
 
                                                 Chapter 7: CRTH2 agonists and murine preterm labour 
 
210 
 
 
 
 
Figure 7.2.1 The effect of 15dPGJ2 on circular muscle contractility  
CD1 mice were sacrificed on E15-16 and myometrial tissue was harvested and mounted on the 
myograph in the circular orientation (n=3). A cumulative dose response with 15dPGJ2 or 
vehicle was performed and the effect on average area under the curve, peak amplitude and 
rate of contractility was determined. 15dPGJ2 had no effect on myometrial contractility. A 
representative trace is shown in (A), with graphs summarising parameters of n=3 experiments 
(B,C,D). V=vehicle.  For statistical analysis ANOVA of repeated measures was used with 
Dunnett’s multiple comparison test. 
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Figure 7.2.2 The effect of Pyl A on circular muscle contractility  
CD1 mice were sacrificed on E15-16 and myometrial tissue was harvested and mounted on the 
myograph in the circular orientation (n=3). A cumulative dose response with Pyl A or vehicle 
was performed and the effect on average area under the curve, peak amplitude and rate of 
contractility was determined. Pyl A inhibited myometrial contractility. A representative trace is 
shown in (A), with graphs summarising parameters of n=3 experiments (B,C,D). V=vehicle, PA = 
Pyl A.  For statistical analysis ANOVA of repeated measures was used with Dunnett’s multiple 
comparison test; (* P<0.05, ** P<0.01, *** P<0.001) 
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Figure 7.2.3 The effect of DK- PGD2 on circular muscle contractility  
CD1 mice were sacrificed on E15-16 and myometrial tissue was harvested and mounted on the 
myograph in the circular orientation (n=3). A cumulative dose response with DK- PGD2 or 
vehicle was performed and the effect on average area under the curve, peak amplitude and 
rate of contractility was determined. DK- PGD2 had no effect on myometrial contractility. A 
representative trace is shown in (A), with graphs summarising parameters of n=3 experiments 
(B,C,D). V=vehicle.  For statistical analysis ANOVA of repeated measures was used with 
Dunnett’s multiple comparison test. 
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7.3 LPS induced murine preterm labour  
 
Prior to commencing experiments exploring the effect of the CRTH2 agonist on 
inflammation induced preterm labour, a dose response with the LPS serotype 0111:B4 
was performed to find the optimal concentration for reliably inducing preterm labour. 
CD1 mice were time-mated and an intrauterine infection of LPS or vehicle was 
performed by mini laparotomy and mice were allowed to delivery spontaneously. 
Mice were monitored by infrared CCTV, allowing continuous monitoring without 
physical intrusion, in order not to disrupt labour. The optimal concentration with the 
minimal variation was found to be 20 µg which induced preterm labour at a mean 
12.45 hrs (SEM +/- 1.33). No pups survived labour with >10 µg of LPS.  
 
 
 
 
 
 
 
 
Figure 7.3 Dose response of LPS induced preterm labour 
CD1 mice received an intrauterine injection of vehicle or LPS at E16 and were allowed to 
deliver, (n=3-10 per treatment group). No vehicle control mice delivered preterm and LPS 
induced preterm labour in a dose response effect, (A). No surviving pups were seen at an LPS 
dose of >10 µg (B). For statistical analysis one-way ANOVA with Dunnett’s post hoc test 
comparing all groups to the vehicle control; **P<0.01, *** P<0.001. 
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7.4 The effect of the CRTH2 agonist Pyl A on LPS induced murine preterm 
labour  
 
We sought to determine if the CRTH2 agonist Pyl A had the same feto-protective effect 
as 15dPGJ2 in delaying preterm labour in LPS treated mice. 20 µg of LPS with vehicle or 
250 µg of Pyl A was introduced by intrauterine injection and mice were allowed to 
labour spontaneously. Vehicle control mice delivered 64.5 hrs post injection and LPS 
treated mice delivered 7.7 hrs post injection (P<0.001).  Co-injection of LPS and Pyl A 
augmented delivery to 5.8 hrs (mean) post injection (Figure 7.4A). This effect was 
more pronounced with a higher dose of Pyl A of 500 µg and lower dose of LPS of 10 
µg, shortening delivery time from 14.7 to 8.7 hrs post injection (P<0.01) (Figure 7.4B).  
Although at 250 µg Pyl A alone did not induce labour earlier than control mice, at 500 
µg labour was induced earlier with a mean of 44.8 hrs post injection compared to 64.6 
in the vehicle control group (Figure 7.4C). None of the vehicle control treated mice 
delivered preterm.  
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Figure 7.4 The effect of Pyl A on LPS induced preterm labour 
CD1 mice received an intrauterine injection of vehicle, LPS or Pyl A at E16 and were allowed to 
deliver, (n=3 per treatment group). No vehicle control mice delivered preterm, and at 250 µg 
Pyl A alone did not induce preterm labour (A). LPS induced preterm labour in a dose response 
effect, and this effect was augmented with the addition of Pyl A (B). 250 µg of Pyl A alone did 
not induce preterm labour, however at 500 µg Pyl A augmented labour (C).   V= vehicle, PA= 
Pyl A. For statistical analysis one-way ANOVA with Bonferroni’s multiple comparison’s test or 
Dunnett’s post hoc test was used; **P<0.01, *** P<0.001. 
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7.5 The effect of the CRTH2 agonist Pyl A on the inflammatory cascade 
 
7.5.1 Effect of Pyl A on NF-κB and COX-2 in the myometrium and pup brain 
 
To explore the mechanisms behind Pyl A-augmented LPS-induced preterm labour, key 
mediators of inflammation in the myometrium were investigated. Myometrium and 
pup brain were harvested at 4.5 hrs post intrauterine injection and western analysis 
was used to detect whole cell phospho-p65 and COX-2.  LPS did not lead to an increase 
in NF-κB in the myometrium; however an increase was seen with co-administration of 
LPS and Pyl A (P<0.05) (Figure 7.5.1 A). A reduction was seen in NF-κB in pup brain 
with LPS compared to vehicle control, with no increase with co-administration with Pyl 
A (Figure 7.5.1 B). No difference in COX-2 expression was seen between treatment 
groups in the myometrium or pup brain at this timepoint (Figure 7.5.1 C and D).  
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Figure 7.5.1 The effect of LPS and Pyl A on myometrial and pup brain NF-κB and COX 2 
Dams were sacrificed at 4.5 hrs post intrauterine injection and tissue was harvested for 
protein for detection of phospho-p65 and COX-2 by western analysis (n=3). Co-injection of LPS 
and Pyl A increased myometrial phospho-p65 (A), with no effect on pup brain phospho-p65. 
Phospho-p65 was decreased in pup brain of dams treated with LPS alone (B). Representative 
phospho-p65 immunoblots are shown for each treatment group, and β-actin was used as a 
loading control. No significant changes in COX-2 were seen in any treatment group in either 
the myometrium or pup brain (C,D). For statistical analysis one-way ANOVA and Bonferroni’s 
multiple comparison test was used; * P< 0.05. 
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7.5.2 Effect of Pyl A on inflammatory cytokines in the myometrium and pup brain 
 
With the activation of NF-κB upon co-administration of Pyl A and LPS, the effect on 
downstream activation of pro-inflammatory cytokines was next examined. Since the 
CRTH2 agonist PGD2 induces the production of the Th2 cytokines IL-10 and IL-4 in 
human T cells [217], the anticipated effect of Pyl A was to see an increase in these 
anti-inflammatory cytokines and an inhibition of the pro-inflammatory cytokines. 
However, contrary to anticipated but yet consistent with NF-κB activation, Pyl A and 
LPS led to an increase in the pro-inflammatory cytokines (Figure 7.5.2). mRNA of the 
Th1 interleukins IFN-γ and TNF-α was significantly increased at 4.5 hrs post injection (P 
<0.05 and P< 0.01 respectively) (Figure 7.5.2 A), but the increase in protein expression 
missed out on statistical significance. A significant increase in protein expression of 
other pro-inflammatory cytokines was seen including IL-1β, KC/GRO (the murine 
chemokine equivalent of human IL-8 [376]), and IL-12 (P<0.05) (Figure 7.5.2 B).  
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Figure 7.5.2 Effect of LPS and Pyl A on the pro-inflammatory cytokines in the myometrium 
Dams were sacrificed at 4.5 hrs post intrauterine injection of 20 µg of LPS/250 µg of Pyl A for 
harvesting myometrium. mRNA and protein was extracted and analysed by PCR and ELISA 
respectively (n=3). With co-injection of LPS and Pyl A, IFN-γ and TNF-α mRNA were significantly 
increased (A) as well as protein levels of IL-12, IL-1β and KC-GRO (IL-8) (B).  V= vehicle, PA = Pyl 
A. For statistical analysis one-way ANOVA with Bonferroni’s multiple comparison test was 
used; * P<0.05, ** P<0.01. 
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7.5.3 Effect of Pyl A on inflammatory cytokines in the pup brain 
 
The effect of Pyl A on the pro-inflammatory cytokines in the pup brain was examined 
by ELISA. Only KC-GRO (the murine equivalent of IL-8) was found at detectable levels. 
KC-GRO was slightly elevated in LPS treated mice with a further increase with co-
administration of Pyl A, although this was not statistically significant (Figure 7.5.3). 
Overall, no statistically significant difference was seen between treatment groups.  
 
 
 
 
 
 
Figure 7.5.3 Effect of LPS and Pyl A on the pro-inflammatory cytokines in the brain 
Dams were sacrificed at 4.5 hrs post intrauterine injection of 20 µg of LPS/250 µg of Pyl A and 
protein was extracted from the pup brain (n=3). The Th1:Th2 profile was determined by ELISA, 
with only KC-GRO (IL-8) expressed at detectable levels. No statistically significant difference 
was seen between groups.  V= vehicle, PA = Pyl A. For statistical analysis one-way ANOVA with 
Bonferroni’s multiple comparison test was used.  
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7.6 The effect of the CRTH2 agonists on in utero viability in LPS treated 
mice 
 
To determine if the CRTH2 agonist Pyl A maintained the same feto-protective effect as 
15dPGJ2, fetal wellbeing was examined at 4.5 hrs post intrauterine injection of LPS 
with vehicle or Pyl A. Mice were anaesthetised and a mini laparotomy was performed, 
and uteri were incised. Fetuses were assessed for viability by assessment of movement 
with or without physical stimulus. Contrary to expected, in view of the findings of the 
effect of Pyl A and LPS on the pro-inflammatory cascade, a significant improvement in 
fetal viability was observed when LPS treated mice were injected with Pyl A compared 
to LPS and vehicle control. Fetal survival was increased from 20% in LPS treated mice 
to 100% in LPS/Pyl A treated mice, (P<0.0001) (Figure 7.6A). However, this benefit was 
not seen post spontaneous labour (Figure 7.6B), due to the adverse effects of preterm 
labour.  
 
 
 
 
Figure 7.6 Effect of Pyl A on intrauterine fetal viability at 4.5 hours post intrauterine 
injection and post spontaneous labour 
Dams were sacrificed at 4.5 hrs post intrauterine injection of 20 µg of LPS/ 250 µg of Pyl A and 
pup viability was assessed (n=3 dams). There was an average of 11-14 pups per dam in all 
treatment groups. Pyl A significantly reduced fetal death at 4.5 hrs post injection from 100% 
with LPS alone to 20% with Pyl A (A). However, post labour, no surviving pups were seen, 
which is likely to be attributed to the effects of prematurity (B).  V= vehicle, PA = Pyl A. For 
statistical analysis one-way ANOVA with Bonferroni’s multiple comparison test was used; 
****p<0.0001. 
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7.7 The effect of the CRTH2 agonist Pyl A on the anti-inflammatory Th2 
interleukins 
 
The mechanism of increased in utero fetal survival seen with Pyl A was explored by 
analysing the mRNA and protein expression of Th2 anti-inflammatory cytokines in the 
myometrium and pup brains. There was no difference in IL-4 mRNA between 
treatment groups, and protein concentrations were below the detection level of the 
assay. There was a slight increase in the production of IL-5, and an increase in both 
mRNA (Figure 7.7A) and protein expression (Figure 7.7B) of IL-10, which also did not 
achieve statistical significance. These interleukins were not detectable in fetal brain 
samples. 
 
Figure 7.7 Effect of LPS and Pyl A on the anti-inflammatory cytokines in the myometrium  
Dams were sacrificed at 4.5 hrs post intrauterine injection of 20 µg of LPS/ 250 µg of Pyl A. 
mRNA and protein was extracted from the myometrium and analysed by PCR or ELISA 
respectively. No change in IL-4 mRNA expression was seen, and a non-significant increase in IL-
10 was seen with co-administration of Pyl A and LPS (A). Although there was an increase in 
protein levels of IL-10 and IL-5 with co-injection of LPS and Pyl A, this did not reach statistical 
significance (B). V=Vehicle, PA= Pyl A.  
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Summary and Discussion 
 
The search for preventative therapies for both preterm birth and related neurological 
damage has recently focused upon anti-inflammatory in addition to tocolytic 
strategies. It is generally accepted that parturition is a pro-inflammatory event, with 
preterm labour being associated with an exaggerated inflammatory response and/or 
infection. With the discovery that the CRTH2 agonist 15dPGJ2 delays inflammation 
induced preterm labour in the mouse and increases pup survival [277], this led to the 
hypothesis that this effect could be replicated with stable small molecule CRTH2 
agonists. This chapter explored the potential for the small molecule agonist Pyl A to 
both delay preterm labour and improve fetal outcomes in a model of inflammation 
induced preterm labour in the mice.  
 
CRTH2 expression in murine myometrium 
 
Murine CRTH2 mRNA was detected in the mouse myometrium using the primers as 
described by Abe et al [369], (Figure 7.1). Detection at the protein level was hampered 
by the lack of available antibodies [368]. However, mRNA expression of CRTH2 has 
been shown in murine Th1 and Th2 cells, and in various tissues including the lung, 
kidney, brain heart thymus and spleen [369]. It is possible that detection of CRTH2 in 
tissue samples is through contamination of leukocytes. However, it is unlikely that the 
CRTH2 detected in the murine myometrium in this study can be explained by this since 
there was no difference in mRNA expression between vehicle, Pyl A, LPS or LPS/Pyl A 
treated mice, and one would anticipate leukocyte infiltration particularly in the LPS 
treated group. Although we cannot definitively conclude that CRTH2 is expressed at 
the protein level in murine myometrium on the basis of mRNA expression alone, 
amplification at a cycle number of 33, (four fold higher than the human), is suggestive 
that the mRNA is expressed and thus is likely to be translated. This may imply a 
biological relevance for CRTH2 in the myometrium of the mouse.  
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The effects of the CRTH2 agonists on murine myometrial contractility 
 
15dPGJ2 inhibits the pro-labour transcription factor NF-κB at both the basal level and 
in LPS treated mice [277]. NF-κB controls the expression of labour associated genes 
such as prostaglandins, connexin 43 and the oxytocin receptor [245] and therefore 
15dPGJ2 may indirectly inhibit myometrial contractility via NF-κB. The effect of 
15dPGJ2 on murine myometrial contractility was examined ex vivo with a myograph. 
As with human myometrial contractility, no effect was seen with acute administration 
of 15dPGJ2 in a cumulative dose response of 1-100 µm over a two and a half hour time 
frame (Figure 7.2.1). Arguably this may not be long enough to assess a downstream 
inhibitory effect at the level of control of gene expression.  
 
A non-CRTH2 mediated inhibition of human contractility was seen with Pyl A (see 
chapter six) which indeed was replicated in murine circular muscle (Figure 7.2.2). 
Again this was shown to be independent of CRTH2 since neither 15dPGJ2 nor DK- PGD2 
had the same effects (Figures 7.2.1 and 7.2.3). The robust inhibitory effect was clearly 
demonstrated in circular muscle, however, was not demonstrated in longitudinal 
muscle in part since the control strips did not contract for long enough to carry out the 
cumulative dose response. At high doses Pyl A cross-reacts with other prostanoid 
receptors including the EP2 and EP4 receptors [320].  Previously we have shown that 
the EP2 agonist, but not EP4 agonist inhibits human myometrial contractility [365]. 
Stimulation of the EP2 and EP4 receptors leads to cAMP production via the G protein Gs 
leading to smooth muscle relaxation [377].  Thus the effect seen with Pyl A study could 
be due to non-specific binding with the EP2 receptor.  
 
The effect of the CRTH2 agonist Pyl A on LPS induced murine preterm labour  
 
Pyl A does not replicate the inhibitory effects of 15dPGJ2 on NF-κB in human cultured 
amniocytes and myocytes (chapter four), and therefore it is unlikely to inhibit NF-κB in 
the murine myometrium. However, in view of the discovery that Pyl A inhibits murine 
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circular myometrial contractility, it is still possible that a delay in LPS induced preterm 
labour could be demonstrated. Contrary to anticipated, co-injection of LPS treated 
mice with Pyl A was found to augment the time to preterm labour in a dose dependant 
response (Figure 7.4B). At a high dose of Pyl A alone, labour was augmented to a mean 
of 44 hrs post delivery compared to 65 hrs in the vehicle control (Figure 7.4C). Several 
mechanisms were explored in order to explain these findings.  
 
Firstly, current understanding of the functional role of the individual muscle layers of 
the mouse uterus in pregnancy and parturition suggests that inhibition of the circular 
myometrial muscle is unlikely to prevent labour. Although there is limited knowledge 
of the role of the individual muscle layers in the mouse, it has been suggested that the 
function of the longitudinal muscle myometrium in other species such as the pig and 
rat is to move luminal contents by contraction [378], and that tonic contraction of the 
circular muscle may be required for spacing and retention of the  embryos/fetuses 
[379]. Circular muscle cells have a higher spontaneous electrical activity than 
longitudinal muscle cells during rat pregnancy [380], supporting its potential role in 
the maintenance of pregnancy. If circular muscle contraction is necessary for retention 
of uterine contents, this could explain how inhibition of circular muscle contraction by 
Pyl A leads to preterm expulsion of the fetuses seen in this study. In the human a 
relatively new, although controversial, concept has emerged relating to the 
importance of relaxation of uterine tone during human labour [381]. It is proposed 
that relaxation of the lower segment of the uterus, in conjunction with contractions of 
the fundal region, is required for the passage of the fetus through the birth canal. 
Secondly, the effect of Pyl A on the pro-labour transcription factor NF-κB in the 
myometrium was examined, and thirdly its effect on the anti and pro-inflammatory 
cytokines was determined. 
 
The effect of the CRTH2 agonist Pyl A on the inflammatory cascade 
 
Treatment of animals with Pyl A alone increased NF-κB activity in the myometrium 
which was enhanced with co-administration of LPS (Figure 7.5.1 A). Surprisingly, 
                                                 Chapter 7: CRTH2 agonists and murine preterm labour 
 
226 
 
myometrial COX-2 levels remained unchanged 4.5 hrs post treatment in all groups 
(Figure 7.5.1 C). As preterm labour was induced following LPS/Pyl A treatment at 5.8 
hrs (SEM + 0.7) it was expected that any COX-2 up-regulation in the myometrium 
should have already been apparent by 4.5 hrs post treatment. It is possible that COX-2 
was already up-regulated prior to intrauterine injection in preparation for term labour. 
In support of this COX-2 is suppressed in pregnancy and by E16 it is already up-
regulated in preparation for term labour and cannot be further increased [382]. 
Analysis of pup brain extracts collected from LPS treated dams revealed a decrease in 
levels of phospho-p65. This may reflect protein degradation induced by the pre-
terminal state of the live pups (Figure 7.5.1 B).  
 
Co-injection of Pyl A and LPS also led to an increase in the production of the pro-
inflammatory cytokines TNF-α, IFN-γ, IL-12, IL-1β and KC-GRO (Figure 7.5.2). Pro-
inflammatory stimuli such as LPS [383] and the cytokines TNF-α [384] and IL-1 [385] 
have been shown to activate NF-κB via the canonical pathway by phosphorylating 
serines leading to IKB degradation and translocation of the NF-κB complex into the 
nucleus, activating gene expression of pro-inflammatory cytokines which further 
augments the pro-inflammatory response in a positive feed-forward loop [245]. The 
assessed cytokines were also increased (but to a lesser degree) in the absence of NF-
κB activation with LPS treatment alone (Figure 7.5.2 A and B).  It is therefore plausible 
that LPS and Pyl A co-administration activates a strong cytokine response which then 
further induces NF-κB activation via a feed forward mechanism. 
 
The pro-labour and pro-inflammatory effect seen with the CRTH2 agonist Pyl A was 
disappointing. However, consistent with the effect seen here, several murine studies 
with CRTH2 agonists/antagonists and/or the use of CRTH2 knock-out mice have shown 
a pro-inflammatory role for the CRTH2 receptor [371, 372, 386-390]. The CRTH2 
agonist DK- PGD2 causes eosinophilia in mouse lung [390] and intra-peritoneal 
administration of DK- PGD2 causes a 2-fold induction of MCP-1 and a 25-fold induction 
of MIP-2 (the functional equivalent of the IL-8 receptor in the mouse) [371]. 
Furthermore, in a murine study of FITC induced inflammation of the skin (a model of 
contact hypersensitivity), a CRTH2 antagonist was found to significantly reduce the 
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production of the pro- inflammatory cytokines TNF-α, IL-1β and the chemokines MIP-2 
and GRO-α [391]. Similarly reduced levels of lung IFN-γ, IL-4 and IL-5 have been 
observed in a mouse model of airways inflammation upon administration of a CRTH2 
antagonist [389].  
 
The Pyl A and LPS induced pro-inflammatory effects on both NF-κB and the Th1 type 
cytokines, along with the inhibition of circular muscle contractility are the likely 
mechanisms explaining augmented preterm labour.  
 
The effect of Pyl A on in-utero viability in LPS treated mice and the anti-inflammatory 
Th2 interleukins  
 
With the overwhelming pro-inflammatory response seen in the myometrium, it was 
surprising to discover the significant increase in fetal viability seen with co-injection of 
Pyl A compared to LPS alone (Figure 7.6). The mechanism behind the increase in fetal 
viability seen with administration of Pyl A and LPS at 4.5 hours post injection was 
explored by analysing the effect on the anti-inflammatory Th2 type cytokines. While 
no changes in the levels of IL-4 were detected, an increase (non-significant) in IL-5 was 
observed (Figure 7.7).  Moreover, a non-significant increase in IL-10 mRNA and protein 
with LPS and Pyl A treatment was also detected. Although the increase did not reach 
statistical significance with an n=3, the biological relevance of a small increase is not 
always necessarily reflected by statistical analyses. IL-10 is a potent protective 
interleukin against fetal loss in the mouse, including loss associated with LPS 
administration [375]. 
 
In summary, this chapter reveals that the CRTH2 agonist Pyl A augments a pro-
inflammatory response in LPS induced preterm labour in the mouse. Pyl A shortened 
the time interval from intrauterine injection to preterm delivery via increased NF-κB 
activity and increased production of pro-inflammatory cytokines. Pyl A also led to an 
inhibition of circular myometrial contractility ex vivo which was likely to contribute to 
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the rapid expulsion of the fetuses. Despite increased fetal viability seen with Pyl A in 
LPS treated dams, which was likely to be secondary to an increase in IL-10, an 
overwhelming pro-inflammatory response was seen with the CRTH2 agonist in the 
mouse. This may be secondary to a functional CRTH2 receptor on murine Th1 cells, 
unlike in humans. Therefore, in conclusion, 15dPGJ2-mediated delay in murine 
preterm labour is not mediated via CRTH2. Finally, since the CRTH2 agonist seems to 
augment inflammation induced preterm birth, CRTH2 should not be considered as a 
potential therapeutic target for the prevention of preterm labour and neonatal 
morbidity.  
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8.1 Summary of hypotheses  
 
Prior to the work presented in this thesis, 15dPGJ2 was found to be a promising agent 
for the prevention of inflammation associated preterm labour and the neurological 
sequale associated with inflammation. 15dPGJ2 was shown to inhibit the pro-labour 
and pro-inflammatory transcription factor NF-κB in human amniocytes and myocytes 
[271] and delay inflammation induced preterm labour in the mouse where it offered 
neuroprotection and increased pup survival [277]. However, the mechanism of action 
by which 15dPGJ2 operates in these systems was not fully understood. 
 
Since 15dPGJ2 is a CRTH2 agonist, the key hypotheses of this work were that CRTH2 
plays a role in the following effects of 15dPGJ2; 
 
a) NF-κB inhibition 
b) Delay in inflammation induced preterm labour 
c) Increased pup survival 
 
Secondly, it was hypothesised that the CRTH2 agonist effects could be exploited, to 
create a Th2 cytokine bias and promote positive pregnancy outcomes.  
 
Thirdly, it was hypothesised that if CRTH2 was involved in the mechanism of action of 
15dPGJ2, then a stable small molecule agonist could be used as a future therapeutic 
agent for both the prevention of inflammation associated preterm labour and the 
reduction of inflammation induced brain injury.  
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8.2 Summary of results and discussion 
 
CRTH2 expression 
 
The potential expression of CRTH2 on amniocytes and myocytes was first explored as 
part of the investigations to determine if CRTH2 plays a role in 15dPGJ2 mediated 
inhibition of NF-κB. There are limited studies examining CRTH2 expression in fetal 
membranes and the uterus. One study failed to demonstrate mRNA expression in 
amnion [279], and another study examining non-pregnant uterus detected moderate 
levels [287]. As presented in chapter three, CRTH2 mRNA was detected at low levels in 
both amniocytes and myocytes. However, this mRNA was not translated since CRTH2 
could not be detected at the protein level using a variety of approaches. The work 
presented in this thesis demonstrates the lack of sensitive and specific commercially 
available antibodies hampering the use of western blotting for detecting CRTH2. By 
using peripheral blood leukocytes and CRTH2-transfected amniocytes and myocytes as 
positive controls, flow cytometry was successful in detecting both endogenous PBMC 
CRTH2 and transfected amniocyte and myocyte CRTH2. Flow cytometry failed to 
detect endogenous CRTH2 on amniocytes and myocytes, thus providing conclusive 
evidence that these cells do not express CRTH2.  
 
CRTH2 and NF-κB 
 
In view of the absence of the CRTH2 receptor on amniocytes and myocytes, it seemed 
unlikely that CRTH2 had a functional role in 15dPGJ2-mediated inhibition of NF-κB. 
However, to fully conclude this, a series of experiments were performed with 15dPGJ2, 
a specific CRTH2 agonist (Pyl A), and the CRTH2 antagonist GSKCRTH2 on amniocytes, 
myocytes and peripheral blood mononuclear cells (PBMCs), results of which are 
presented in chapter four. Pyl A failed to replicate 15dPGJ2-mediated inhibition of IL-
1β-stimulated NF-κB in amniocytes and myocytes. Although 15dPGJ2 was found to 
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inhibit NF-κB in peripheral blood mononuclear cells, this effect was not replicated by 
the specific CRTH2 agonists DK-PGD2 or Pyl A, and its effect was not attenuated by pre-
incubation with the CRTH2 antagonist. These experiments provide compelling 
evidence that CRTH2 is not involved in 15dPGJ2-mediated NF-κB inhibition.  
 
Although 15dPGJ2 is also a ligand for PPAR-γ, inhibition of NF-κB in amniocytes and 
myocytes is independent of this receptor [271]. The electrophilic cyclopentenone ring 
of 15dPGJ2 appears to contribute to its actions. The cyclopentenone prostaglandin 
PGA1 (which contains one reactive electrophilic carbon as opposed to two) also 
inhibits NF-κB activity, although at markedly higher concentrations. 15dPGJ2 is able to 
inhibit multiple steps in the IKK/NF-κB signalling pathway. It inhibits nuclear 
translocation by preventing the IL-1β induced phosphorylation of IKKα and IKKβ, and 
also by preventing IKBα degradation and thus the release of the NF-κB subunits [271]. 
Endogenous 15dPGJ2 can accumulate intracellularly and can bind to components of 
the NF-κB signalling pathway directly. For example, direct modification of cysteine 179 
of IKKβ by covalent interaction with 15dPGJ2 has been demonstrated in HeLa cells 
[392]. Furthermore, the formation of covalent adducts between 15dPGJ2 and the p50 
subunit has been demonstrated [323]. Despite these mechanisms having been 
described, it is still not known how 15dPGJ2 enters the cell, or if a receptor dependent 
factor is required for the inhibition of NF-κB. However, work presented in this thesis 
has at least excluded the possibility that the effects of 15dPGJ2 are via the G protein 
coupled receptor CRTH2.  
 
Effect of pregnancy, labour and CRTH2 agonists on the Th1/Th2 profile 
 
A bias exists in pregnancy to favour the Th2 interleukin profile, especially at the 
maternal fetal interface [193]. The suppression of Th1 interleukins peripherally is 
thought to be at least in part due to suppression of NF-κB in T helper cells in pregnancy 
[240]. Several groups have demonstrated this bias in PBMCs during pregnancy which 
returns to the non-pregnant state post-partum [146, 147, 218]. However, during 
labour it is unclear if cells are activated or if the bias has already reversed consistent 
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with the post-partum state [393, 394] . PBMCs of women in labour were examined to 
see if a systemic pro-inflammatory state was reflected, consistent with local activation 
of NF-κB and pro-inflammatory cytokines seen at the maternal fetal interface and in 
the uterus at term and in labour.  
 
Confirmation of the reduction in both IFN-γ and TNF-α production in PMA/ionomycin 
and non-stimulated cells during pregnancy is reported in chapter five. Although the 
mean production per cell of IFN-γ and TNF-α was generally unchanged, the percentage 
of cells secreting the interleukins was reduced. This potentially reflects regulation at 
the levels of differentiation or development of the cells rather than at an individual 
cellular level. However, no significant increase in the production of Th1 interleukins 
was seen in PMA/ionomycin treated PBMCs of women in labour. A moderate increase 
in the basal percentage of cells producing IFN-γ and TNF-α was seen from 28 weeks to 
term with a further increase with the onset of labour. However, this increase was not 
statistically significant. The biological relevance of this increase is not known and 
indeed the physiological implications of a systemic inflammatory response could 
potentially be detrimental to both mother and fetus. Studies to explore both NF-κB 
and the Th1 profile in women with clinical evidence of chorioamnionitis are required 
to determine if this basal inflammatory response is more pronounced, and therefore 
amenable to immuno-modulation.  
 
Several groups have demonstrated an increase in IL-4 production systemically during 
pregnancy [146, 147, 218], however the contrary has been reported by one group 
where a reduction in IL-4 during pregnancy was observed [219]. Since CRTH2 is a 
marker of Th2 cells, the production of IL-4 in this population was examined during 
pregnancy and in labour. An increase in the percentage of cells secreting IL-4 was seen 
at 28 weeks compared to non-pregnant women, with return to non-pregnant values at 
term, however this did not reach statistical significance when the multiple 
comparisons test was applied. Had more subjects have been examined, or if the 
CRTH2+ cells producing IL-4 had been purified, a more marked response may have 
been demonstrated. The increase in IL-4 producing cells, together with the absence of 
any change in the mean production is consistent with a potential regulation at the 
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levels of differentiation or development of the CRTH2 positive cells rather than at an 
individual cellular level, as seen with the Th1 interleukin profile.  
 
The CRTH2 agonists PGD2 and Indomethacin both induce the production of the Th2 
interleukins IL-4, IL-5 and IL-10 in Th2 cells in vitro [217, 299]. As part of a negative 
feedback regulatory system, IL-4 can directly inhibit the development of Th1 cells, 
whereas IL-10 achieves this indirectly [194]. This leads to the inhibition of the 
production of pro-inflammatory cytokines. Having demonstrated a bias towards Th2 
with suppression of the percentage of cells producing Th1 interleukins as well as a 
moderate increase in the CRTH2 positive cells secreting IL-4 during pregnancy, the 
immunomodulatory effects of CRTH2 agonists were examined. It was anticipated that 
the agonists would be able to further modulate interleukin production at the cellular 
level by modifying mean interleukin production. 
 
Only 1 µM of Pyl A had any effect on CRTH2 positive cells. A small, yet non-significant, 
increase was seen in the percentage and mean production of IL-4 at 28 weeks in non-
PMA/ionomycin treated cells. A statistically significant increase in the mean 
production in PMA/ionomycin treated cells in non-pregnant samples was also found. 
The subtle response may be due to the experimental design in view of the small 
amount of non-purified CRTH2+ cells being analysed, but also the PMA/ionomycin may 
be maximally stimulating IL-4 preventing further stimulation with Pyl A. No change was 
seen in IFN-γ or TNF-α production with either concentration used, probably due to 
only a minor effect on IL-4 production. Overall, no significant immuno-modulation 
could be demonstrated with Pyl A. 
 
In contrast, significant modulation of the Th1 cytokines was seen with 15dPGJ2, with 
substantial downregulation of PMA/ionomycin stimulated IFN-γ and TNF-α at all 
gestational time points. Data presented in chapter four reveals the inhibitory effect of 
15dPGJ2 on NF-κB in peripheral blood mononuclear cells. Since NF-κB is known to play 
a key regulatory role in controlling the Th1 immune response by modulating the 
expression of Th1 cytokines [256], it is likely that the Th1 inhibitory properties of 
15dPGJ2 are regulated through NF-κB. Conversely, no effect was seen on IL-4 
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production. This may be due to an overriding effect of a non-CRTH2 mediated 
mechanism such as the inhibition of other signalling proteins involved the 
transcriptional regulation of IL-4 expression. For example, 15dPGJ2 inhibits nuclear 
factor of activated T-cells (NF-AT), which transcriptionally regulates IL-4 production, in 
a PMA/ionomycin activated T cell line in a dose dependent manner [286]. Overall, Th1 
suppression is seen with 15dPGJ2, thereby leading to a Th2 bias indirectly. Preterm 
labour, particularly in the presence of chorioamnionitis, is associated with a shift 
towards the Th1 cytokine response [192]. Specifically PMA stimulated PBMCs of 
women in threatened preterm labour who deliver preterm have significantly higher 
IFN-γ compared to women who go on to deliver at term [238]. Data presented in this 
thesis demonstrates that the anti-inflammatory properties of 15dPGJ2, previously 
demonstrated in the amnion and myometrium [271], can also be applied systemically  
resulting in the inhibition of NF-κB and the Th1 interleukins in PBMCs. 
 
Effect of CRTH2 agonists on myometrial contractility  
 
An ideal therapeutic agent for the prevention of preterm labour would have both anti-
inflammatory and tocolytic properties. The inhibitory effect of 15dPGJ2 on NF-κB and 
COX-2 in myocytes [271], together with stretch mediating an increase in NF-κB activity 
[183], led to the hypothesis that 15dPGJ2 could also have tocolytic properties. This was 
investigated ex vivo by mounting myometrial strips collected from women at term 
(pre-labour) and treating them with 15dPGJ2 in a cumulative dose response, as 
presented in chapter six. No effect on contractility was seen with acute administration. 
This may be because activation of NF-κB may not be required for uterine contractions 
induced ex vivo by the myograph. Surprisingly, treatment of myometrial strips with Pyl 
A led to a dose dependent inhibition of myometrial contractility, although in a CRTH2 
independent mechanism. Possible mechanisms of inhibition include wither via non-
specific interaction with the EP2 receptor, or via its structural similarity to 
Indomethacin.  
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Effect of the CRTH2 agonist Pyl A on a murine model of inflammation induced preterm 
labour 
 
Despite not being able to replicate the anti-inflammatory effect of 15dPGJ2 on NF-κB, 
or showing immunomodulatory effects on the human Th1/Th2 profile in vitro, the 
considerable tocolytic effect of Pyl A led us to investigate if the same effect could be 
achieved in vivo. Whilst it is appreciated that tocolysis in the presence of clinically 
apparent inflammation is not advisable, it was also important to establish if CRTH2 
plays a role in 15dPGJ2-mediated delay in inflammation induced preterm labour and 
increased pup survival. Results of the effect of Pyl A on murine myometrial 
contractility and inflammation induced preterm labour were presented in chapter 
seven. 
 
Pyl A showed significant tocolytic effects on murine circular myometrium ex vivo, 
consistent with the effects seen in the human, and again in a CRTH2 independent 
mechanism. However, in vivo administration of Pyl A led to augmentation of labour, 
which was amplified with co-injection of LPS. Controversy remains with regards to the 
function of the circular muscle in the mouse. Tonic contraction of the circular muscle 
in the rat may be required for spacing and retention of embryos/fetuses [379], and 
weak high frequency contractions in the circular muscle layer are thought to prevent 
movement of fetuses towards the cervix during pregnancy [395], supporting the 
potential role of tonic contraction in the maintenance of pregnancy. Also, in support of 
this, uterine relaxation of the lower segment during human labour in the human is 
thought to aid passage of the fetus through the birth canal [381].  
 
Alternatively the tocolytic effect of Pyl A may not have contributed to the 
augmentation of labour. This may have been purely due to the overwhelming 
inflammatory response induced by the co-administration of Pyl A and LPS. Activation 
of NF-κB was demonstrated which also lead to downstream activation of several pro-
inflammatory cytokines including IL-1β, IFN-γ, TNF-α and KC-Gro (the murine 
equivalent of IL-8). Although this pro-inflammatory effect was not induced by Pyl A 
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alone, and only a small effect with LPS alone, there is a clear synergistic effect with 
both LPS and Pyl A together. It is plausible that a subtle trigger in NF-κB activation with 
LPS together with a subtle trigger from Pyl A is enough to lead to an amplified 
response and a continued feed forward loop. Despite the significant pro-inflammatory 
response caused by Pyl A, a surprising increase in fetal viability was seen at the 4.5 hr 
sacrificial timepoint, likely to be due to the increase in IL-10 production. This 
protective effect however was not maintained post delivery, with zero pup survival 
since all delivered at a pre-viable gestation. In conclusion, data presented here 
provides conclusive evidence that CRTH2 does not play a role in 15dPGJ2 mediated 
delay in preterm labour or increased pup survival.  
 
The differences in effect seen with Pyl A between the human and the mouse highlight 
the limitations of in vivo work in species other than humans. The mouse is commonly 
used for models of preterm labour, due to its relatively short gestation and low cost of 
experiments and maintenance, however, there are clear differences in pregnancy and 
parturition compared to that of the human. For example, the human myometrium is 
not composed of such a discrete longitudinal/circular muscle arrangement, nor is the 
uterus bicornuate. A biochemical withdrawal of progesterone occurs in the mouse at 
term [396] rather than a functional progesterone withdrawal that is seen in the human 
[397]. Specifically with regards to CRTH2, unlike in the humans, its expression is 
detected on murine Th1 cells [369]. Although it is not known if the CRTH2 receptor is 
functional in murine Th1 cells, this could account for the significant production of Th1 
cytokines induced by Pyl A. Finally, although protein expression of CRTH2 in murine 
myocytes was hampered by the lack of commercially available antibodies, the 
comparable mRNA expression in the myometrium of vehicle vs LPS vs LPS Pyl A 
suggests that CRTH2 expression in the myometrium is not solely due to infiltrating 
leukocytes.  
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8.3 Conclusion 
 
In conclusion, the CRTH2 agonist Pyl A does not replicate the anti-inflammatory effects 
of 15dPGJ2 in the human or the mouse. It can be deduced that CRTH2 does not play a 
functional role in NF-κB inhibition; delay in inflammation induced murine preterm 
labour or increased pup survival. Finally, Pyl A and 15dPGJ2 do not modulate the Th2 
interleukin profile in peripheral blood mononuclear cells via CRTH2. However, it was 
found that the anti-inflammatory effects of 15dPGJ2 can be extended to activated 
peripheral blood mononuclear cells resulting in both the inhibition of NF-κB and Th1 
interleukins, thereby indirectly modulating the peripheral Th1/Th2 interleukin profile 
to favour the Th2 response.  
 
8.4 Clinical relevance 
 
Preterm labour remains a common challenge to obstetrics. The incidence has not 
reduced, despite increased efforts in understanding the mechanisms controlling its 
onset. The management of women with preterm rupture of membranes, particularly 
pre-viability or at the margin of viability, remains variable amongst obstetricians. The 
use of tocolytics also remains variable worldwide in terms of the type of tocolytic 
used, the indication and the duration. Economically, the neonatal sequale of preterm 
labour and indeed the long-term health issues that follow account for a significant 
portion of NHS resources. It is therefore imperative that preventive strategies are 
developed to target those at risk of preterm labour.  
 
Controversy still remains with regards to aiming to prevent preterm labour in those 
presenting with threatened preterm labour. This is mainly due to the risk of delaying 
preterm labour in the presence of subclinical infection/inflammation, thereby 
potentially increasing neonatal morbidity and mortality. The focus of this thesis was on 
the potential use of 15dPGJ2 or a specific CRTH2 agonist with a view to targeting the 
inhibition of the biochemical pathways associated with both inflammation and labour. 
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The ultimate aim is to prophylactically administer such an agent to prevent the initial 
biochemical triggers of both inflammation and labour that precede the onset of clinical 
symptoms.  Although specific small molecule CRTH2 agonists should not be considered 
as future therapeutic agents, the anti-inflammatory prostaglandin 15dPGJ2 shows 
considerable promise for the future.  
 
8.5 Future work 
 
Future work with 15dPGJ2 will include exploring its role in the inhibition of NF-κB and 
pro-inflammatory cytokines both locally at the maternal fetal interface and 
systemically in maternal peripheral blood mononuclear cells in women in preterm 
labour and term labour associated with clinically evident chorioamnionitis. Effects of 
the anti-inflammatory compound will also be explored in cord blood obtained from 
matched samples to ascertain if it has potential for preventing the fetal inflammatory 
response syndrome. If these results are consistent with the anti-inflammatory effects 
seen so far, as presented in this thesis, then it will be proposed that 15dPGJ2 should be 
used in a primate model of inflammation induced preterm labour.   
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